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Studying tumor evolution in mouse models of lung cancer
Tyler Jacks. Massachusetts Institute of Technology, Cambridge, MA
Like other solid tumors, lung adenocarcinoma progresses through multiple
stages including tumor initiation, expansion in the lung, and metastasis of the
primary tumor to distant organs. Dissection of this process requires quanti-
tative and tractable models that recapitulate the human disease at the genetic
and histological level. We have employed autochthonous mouse models of
lung adenocarcinoma that recapitulate tumor initiation, progression and
metastasis in the human disease both genetically, and pathologically. We
have established oncogenic Kras as the initiating event in lung adenoma and
amplification of the oncogenic signaling is associated with progression to
adenocarcinoma. The p53 tumor suppressor limits tumor progression in this
model. Restoration of the Trp53 locus has pinpointed the adenoma-adeno-
carcinoma transition as the stage in which p53 function is critical for tumor
suppression. Expression of oncogenic Kras in the absence of p53 leads to the
development of distant metastases after long latency. This suggests that
unknown cooperating genetic events are required for metastatic spread and
we are utilizing multiple tools to identify these changes. Use of lentiviral
vectors that drive stable GFP expression in tumors allows for identification
and purification of tumor cells. Additionally, identification of the lentiviral
integration site in each tumor allows the clonal relationship between metas-
tases and the primary tumors to be unequivocally established. Gene expres-
sion and DNA copy number analyses of metastasis-derived cell lines and
primary lung tumors have uncovered a metastasis associated gene expression
signature and recurrent genomic alterations. Integration of these datasets,
other genome-wide analyses and human tumor data are providing insights
into the molecular mechanism and biology of lung cancer progression and
metastasis.
Plenary Session 1: Tyrosine Kinase Signaling
and Targeted Therapy
Discovery and clinical application of a novel oncogene,
EML4-ALK, in lung cancer
Hiroyuki Mano. Jichi Medical University, Tochigi, Japan
In order to discover novel transforming genes in non-small cell lung cancer
(NSCLC), we have developed a sensitive retroviral expression library system
for full-length cDNAs, and applied this technology to an NSCLC specimen
without EGFR mutations. A focus formation assay with the library led to the
discovery of a novel fusion gene between the echinoderm microtubule-
associated protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK)
genes, both of which are closely mapped to the same short arm of human
chromosome 2 [1,2]. Fusion to EML4 induces a constitutive dimerization of
the ALK kinase domain, and thereby its marked activation.
Transgenic mice expressing EML4-ALK in lung epithelial cells generate
hundreds of adenocarcinoma nodules only at a few weeks after birth,
demonstrating the pivotal role of this fusion kinase in the transformation of
NSCLC [3]. Further, oral administration of a specific inhibitor to ALK
successfully cleared such nodules from the mice. Knowing the high efficacy
of such compounds for EML4-ALK–positive NSCLC, we have tried to
develop a multiplex RT-PCR system for EML4-ALK messages and a sensi-
tive immunohistochemical detection system for the encoded protein. By
utilizing such technologies, we have constructed a nation-wide diagnostic
network for EML4-ALK–positive NSCLC in Japan, and have unexpectedly
discovered another fusion of ALK, KIF5B-ALK, in a subset of NSCLC [4, 5].
Several pharmaceutical companies are currently known to develop ALK-
specific inhibitors to treat EML4-ALK–positive individuals, and one of such
companies has recently reported the outcome of a phase I clinical trial with
an ALK inhibitor in the annual meetings of ASCO and ECCO/ESMO,
demonstrating a significant reduction of the tumor burden among 50% of
the patients with EML4-ALK.
These data demonstrate that a subset of lung cancer express previously
unidentified fusion kinases that are promising candidates for a therapeutic target
as well as for a diagnostic molecular marker for this intractable disorder.
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Concurrent Session 2: Other Thoracic Cancers
(Mesothelioma, Thymic, Neuroendocrine)
Personalizing novel mesothelioma treatments for conventional
and novel therapies
Steven M. Albelda, Steven Wang, Vassiliki Saloura. University of Pennsyl-
vania, Philadelphia, PA
Unlike lung cancer, personalized medicine for malignant mesothelioma is in
its infancy. In this presentation, I will highlight potential advances with
regard to conventional and experimental therapies.
The standard chemotherapy used to treat mesothelioma is cisplatin com-
bined with pemetrexed based on a study showing that this combination led
a 3-month increase in median survival compared to cisplatin alone. However,
recent large phase 2 trials have suggested that cisplatin combined with
gemcitabine has similar efficacy. It would thus be highly desirable to have
biomarkers suggesting response or lack of response to pemetrexed. A
potential predictor of response to the multitargeted folate drug pemetrexed is
the level of the enzyme thymidylate synthase (TS); the hypothesis being that
high levels of expression would induce resistance. One preliminary report
from the Scagliotti group (ASCO 2009, abstract 7508) suggests that higher
mRNA or protein levels of TS predict poorer response to pemetrexed. We
have therefore studied expression levels of TS using semi-quantitative
immunohistochemistry (12-point scale) in 46 mesothelioma patients. We
found a broad array of expression levels: 12% of tumors had very low levels
of expression (scores of 0–3), 38% had moderate expression levels (scores of
3–7), and 29% had very high levels of expression (scores of 8–12). No
relationship with histology type was noted. Correlation of clinical response
to pemetrexed and TS levels is ongoing, but these data, combined with the
aforementioned abstract and data in lung cancer, suggest that determination
of TS expression levels may be an important determinant in “personalizing”
the choice between pemetrexed and other agents (i.e. gemicitabine) in
patients with mesothelioma.
Given the poor outcomes of any type of standard chemotherapy, novel
approaches are needed. One area that has shown some promise in the past is
the use of the interferon-alpha (a type 1 interferon). Another area that is
receiving increasing attention is the use of oncolytic viral vectors. These are
naturally occurring or modified viruses that selectively replicate within
mesothelioma cells and directly cause cell death and/or deliver a therapeutic
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payload. Such viruses include herpes virus, Reo virus, Newcastle disease
virus, measles virus, vaccinia virus, or vesicular stomatitis virus (VSV). The
basis of selectivity of these viruses is thought to largely be due defects in the
normal type 1 inteferon (IFN) response to viral infection that occur com-
monly in malignant cells. We studied a novel replicating VSV virus that
expressed interferon-beta as a safety feature. To our surprise, only 4 of 12
human Meso lines were sensitive to lysis by this vector. We determined that
this was due to a functional INF-response pathway that existed in the other
8 cell lines. We were able to predict response to oncolytic viruses by
screening the lines for key INF-response proteins. Specifically, we found that
baseline loss of type 1 interferon receptors or the STAT-binding protein p48
(ISFG3) could accurately predict sensitivity to viral lysis. We extended this
observation to pleural fluid samples from our pleural adenovirus-interferon-ß
clinical trial and showed that the presence of p48 in 3 tumor samples
predicted responsiveness to interferon (as measured by the upregulation of
the INF-dependent gene OAS1. Our data indicate that many mesothelioma
tumors have partially intact IFN pathways that may affect the efficacy of
oncolytic virotherapy or predict response to treatment with interferons. p48
could thus be a potential biomarker that could be used to guide therapies
based on response to interferons.
Concurrent Session 3: JAK/STAT Pathways as
Therapeutic Targets
Targeting STATs for the molecular therapy of lung cancer:
Translation from the lab to the clinic
David A. Frank. Dana-Farber Cancer Institute, Harvard Medical School,
Boston, MA
Over 150,000 people die of lung cancer each year in the United States, and this
number shows little sign of decreasing. Thus, it is abundantly clear that new
therapeutic strategies are required to treat this disease, and these therapies should
be based on our increased understanding of the molecular underpinnings of lung
cancer. Recent evidence has suggested that the transcription factor STAT3 plays
a major role in driving the malignant behavior of a majority of non-small cell
lung cancers. STAT3, which regulates genes controlling proliferation, survival,
self-renewal, and invasion, is normally activated rapidly and transiently in
response to cytokines and growth factors. In non-small cell lung cancer, by
contrast, STAT3 is activated constitutively, continuously driving expression of
genes that underlie the malignant behavior of these cells. Inhibiting STAT3 leads
to a loss of viability and proliferation of non-small cell lung cancer cells. Normal
cells, however, can tolerate a loss of STAT3 function due to redundancies in
signaling pathways. Consequently, STAT3 appears to be an excellent target for
the molecular therapy of non-small cell lung cancer.
To identify drugs to target STAT3, we developed a cell-based screening
system. We generated a cell line in which a luciferase reporter gene
responsive to STAT3 was stably integrated. We also generated parallel cell
lines in which luciferase expression was regulated by other STAT family
members, or the unrelated transcription factor NF-KB. We used these cell
lines to interrogate chemical libraries to identify compounds that could
specifically inhibit STAT3. We have employed both large diverse chemical
libraries as well as smaller libraries biased toward drugs already known to be
safe in humans. From this approach, we have identified a number of
compounds that specifically inhibit STAT3 function.
This “chemical biology” approach to drug discovery has had several
notable benefits. For targets such as transcription factors, which have
generally been thought to be difficult to modulate pharmacologically, it has
provided proof-of-concept that small molecules can alter their function
specifically. In addition, active compounds identified through this approach
have helped to identify multiple cellular targets and mechanisms by which
transcription factors can be modulated. Finally, these agents have proven to
be useful biological probes, and may serve as prototypes for cancer therapy.
The STAT3 inhibitors we have identified show little toxicity to normal cells.
However, in cancer cells driven by activated STAT3, they decrease expression
of STAT3 target genes, and decrease cellular survival and proliferation. Further-
more, by decreasing the apoptotic potential of tumor cells, these STAT3
inhibitors show synergy with conventional anti-cancer therapies. The current
focus is to translate these findings into clinical trials in patients with advanced
non-small cell lung cancer who have progressed on, or are not suitable for,
cytotoxic chemotherapy. The goal of such a trial would be two-fold. Of primary
importance is to assess the clinical response of the tumor in patients. However,
the second key goal concerns pharmacodynamics, determining if STAT3 is
being inhibited in the tumor. Without this information it would be impossible to
interpret the clinical findings in a way in which subsequent studies could
logically be designed. Through this type of rational approach, continual advances
in the molecular therapy of lung cancer may be achieved.
Plenary Session 3: Cancer Stem Cells
Lung cancer stem cells: Identification and translation to the
clinic
John D. Minna1,3,4, James P. Sullivan1, Monica Spinola1, Jill Larsen1,
Boning Gao1,2, Robin Frink1, Chunxian Huang1, Oliver Delgado3, Michael
Dodge3, Katja Schuster4, Pier P. Scaglioni4, Ping Yuan6, Gabriela Raso6, Fei
Yang6, Sophie Sun7, Joan Schiller4, Adi F. Gazdar1,3,5, Jerry Shay3, Ignacio
I. Wistuba6. 1Hamon Center for Therapeutic Oncology Research - Simmons
Cancer Center and Departments of 2Pharmacology, 3Cell Biology, 4Internal
Medicine, and 5Pathology, UT Southwestern Medical Center, Dallas, TX;
6UT M. D. Anderson Cancer Center, Houston, TX; 7Division of Medical
Oncology, British Columbia Cancer Agency, Vancouver, Canada
Lung Cancer Stem Cell Importance and Identification. The emergence of the
cancer stem cell (CSC) hypothesis and initial studies identifying a subpopu-
lation of cells within lung cancers with “stem cell like” (“cancer initiating”)
properties indicates they are important new targets for early detection,
prevention and therapeutic targeting (1–5). The primary tenant of this
hypothesis is that a subset of cells within the tumor behave like stem cells
including using stem cell signaling pathways and that it is this subset of cells
(rather than the remainder of the cells in the tumor – “progenitor cells” )
which initiate tumor formation and drive tumor progression and metastatic
disease through aberrant self-renewal and differentiation (5). In essence,
cancers have hijacked stem cell physiology to maintain tumor growth beyond
normal developmental boundaries. In conjunction with their enhanced tumor
initiating capacity, it is believed that CSCs are responsible for generating
distant metastases, and are more resistant than the “progenitors” to radio and
chemotherapy. Another important aspect is that the microenvironment (re-
ferred to as “stem cell niche”) can play an important role in regulating not
only normal but also cancer stem cell growth. Taken together these attributes
highlight the CSC population and their “niche” as prime cellular components
that drives tumor progression. From a clinical perspective, monitoring and
managing the lung CSC population presents new opportunities and chal-
lenges. Because CSCs are thought to be derived from transformed stem cells,
it is possible that the prevalence of lung epithelial stem cells that have
acquired genetic and epigenetic changes may be the most important “field
defect” linked with increased lung cancer risk. Furthermore, there could be
both inherited and acquired genetic/epigenetic changes that elevate stem cell
numbers in the lung that may also lead to and be predictors for increased
cancer risk (5). These same pathways and factors may be targets for both
chemoprevention of lung cancer and for targeting therapy to clinical evident
lung cancers. To this end, a better understanding of the stem cell pathways
expressed in normal, premalignant, and clinically evident lung cancers may
yield valuable information on lung cancer risk, the prognosis of individual
cancers, and what would be the best pathways to target in individual patient’s
tumors. Managing and eliminating lung CSCs hinges on our ability to
identify lung CSCs and dissect the molecular characteristics of lung CSCs.
Currently few lung CSC specific markers have been described. Recently the
stem cell marker, ALDH1 leading to increased ALDH activity, was found to
identify CSCs and provide prognostic information for breast and lung
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cancers (6–7). Our studies of a large number of non-small cell lung cancers
(NSCLCs) have found ALDH() cells in 0.1–20% of cells while small cell
lung cancers (SCLCs) show significantly higher levels of 50% and prior
studies have shown SHH as a potential therapeutic target in SCLC (8). Thus,
SCLCs appear to be greatly enriched in an ALDH() population. We have
found that lung cancer ALDH() populations are more tumorigenic in
NOD/SCID mice than the ALDH() population. We have investigated the
expression of stem cell pathway genes in lung cancers of all histologic types
and in immortalized human bronchial and small airway epithelial cells
(HBECs, HSAECs) with and without defined oncogenic changes. We find
that HBECs and HSAECs are highly enriched with cells with stem like
properties, can differentiate, and with insertion of oncogenic changes can
give rise to cancers of several histologic types indicating they are a model
system for studying lung cancer stem cells. Like normal stem cells, CSCs
utilize developmental signaling pathways to undergo self-renewal. The Wnt,
SHH, Notch, hASH (ASCL1), TITF1, and SOX2 signaling and transcrip-
tional pathways have been implicated in normal stem cell development as
well as in CSCs from a variety of tumor types (9–10). In studies of a panel
of 50 stem cell signaling pathway genes we find large differences in
expression between the ALDH() and () lung cancer subpopulations. By
capitalizing on the differential expression of self-renewal signaling pathways
in lung CSCs, new therapies may be employed to selectively inhibit the
self-renewing cancer population.
Cancer stem cell-specific therapeutic approaches. (reviewed in detail in
[9]) Hedgehog (HH), Notch, and Wnt signaling are key stem cell self-
renewal pathways that are deregulated in lung cancer and thus represent
potential therapeutic targets. Agents inhibiting the hedgehog pathway in-
clude monoclonal antibodies against HH ligand and cyclopamine, which is a
small molecule inhibitor of smoothened (SMO). Monoclonal antibodies
against Wnt ligand and frizzled (FZD) receptor and inhibitors of protein
complexes mediating Wnt signaling, such as Wnt-FZD or ß-catenin–tran-
scription factor (ß-Cat-TCF), are examples of ways of targeting the Wnt
pathway. Strategies of blocking or silencing Notch signaling can be either
selective, such as the targeting of individual Notch receptors with antisense
or monoclonal antibodies, or nonselective, such as the use of soluble receptor
decoys that sequester Notch ligands or Y-secretase inhibitors. Our results
indicate Notch transcripts are elevated in highly tumorigenic ALDH() lung
cancer cells and that blockade of Notch with gamma-secretase inhibitors
reduces ALDH() cells. Other methods of targeting cancer stem cells
include immunotherapy-based approaches against antigens present on cancer
stem cells; targeting cancer stem cell mechanisms of resistance to cytotoxic
therapy by inhibiting DNA repair enzymes such as the checkpoint kinases
(Chk1, Chk2); targeting stem cell-specific survival mechanisms with telomerase
inhibitors (imetelstat); and inducing stem cell differentiation with soluble factors
such as bone morphogenetic proteins (BMPs). In conclusion, by identifying lung
CSCs and targeting the stem cell pathways in this subset of cells, new diagnostic,
prognostic, prevention and therapeutic approaches are possible.
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Plenary Session 4: Genome-wide Approaches
to Risk
Genome-wide approaches to risk: Lessons from breast and
prostate
Bruce A.J. Ponder, CRUK, Cambridge Research Institute, Cambridge,
United Kingdom
Each of the common cancers shows a tendency to cluster in families. Most
of this clustering has an inherited basis. In some cancers, such as breast
cancer, rare but strongly predisposing mutations in genes such as BRCA1
and BRCA2 account for a part of the total inherited effect; but for every
cancer at present the majority of the effect remains unexplained.
Almost certainly, the unexplained component of genetic predisposition is
accounted for by the combined effects of tens – or more likely hundreds – of
different variants, which may be common or rare but are individually small
in their contribution. This is the “polygenic model” of cancer susceptibility.
Common genetic variants of this sort can be searched for using genome-
wide association studies. Recent studies in breast and prostate cancer have
identified new gene variants which account for an additional roughly 6% and
18% respectively of the inherited genetic component of these cancers.
There are two broad questions to be addressed. (1) What types of genetic
variant account for the still unexplained 70% or so of genetic predisposition
to these cancers, and how should we best search for them? Here the current
money is on rare variants, that are not easily detected by association studies.
(2) Of what practical use are the common variants that have been identified?
Here the most secure answer is that new genes will provide new insights into
tumor biology and hence possibly new targets for intervention. The less
secure answer – but the one that has attracted most attention and controversy –
is that combinations of these variants will provide ‘risk profiles’ that will enable
the stratification of the population into different classes of risk, and that this will
be useful to individuals, to public health authorities who wish to target screening
programs to best effect, and to researchers assembling prospective cohorts for
intervention studies.
I will examine these issues in the light of experience from breast and
prostate cancer, and consider the lessons for lung cancer.
Convergence of genetic findings for nicotine dependence and
lung cancer
Laura J. Bierut and COGEND colleagues. Washington University School of
Medicine, St. Louis, MO
Despite reductions in smoking, over 400,000 people in the U.S. die each year
from tobacco-related illnesses. Lung cancer is the most striking disease
associated with smoking, and its prevalence over time directly mirrors
changes in smoking behavior. Recent genetic studies have identified genetic
factors that contribute to nicotine dependence and smoking quantity, and the
most compelling evidence of risk is on chromosome 15 in the region that
includes the 5-3-ß4 nicotinic receptor genes. Genetic association findings
for lung cancer converge with the findings for nicotine dependence, and the
same chromosomal 15 region is associated with lung cancer in several
independent lung cancer samples. Further dissection of this region demon-
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strates that there are at least two distinct genetic variants that are contributing
to the risk for both nicotine dependence and lung cancer.
Association testing represents an association with multiple correlated genetic
variants and the disease under study. The next step to understand the underlying
biology requires investigation of the genetic variants that potentially alter
biologic function to determine a mechanism of action. In this region of associ-
ation, a SNP (rs16969968) that causes an amino acid change in the 5 nicotinic
receptor is a compelling functional variant. This genetic variant results in a
change from aspartate to asparagine in the 5 protein subunit, and in 5
containing receptors, nicotinic agonist evoked responses show significant differ-
ences. Distinct from this amino acid change, non-coding genetic variants also
contribute to differences in 5 receptor subunit expression in the brain. These
two distinct biological mechanisms (amino acid change and expression level
differences) are associated with altered risk for both nicotine dependence and
lung cancer, and this work implicates the 5 receptor subunit as a major genetic
contributor to the development of both disorders.
Concurrent Session 4: Lung Cancer Profiling
with microRNAs
Application of miRNAs in the treatment of lung cancer
Glen J. Weiss. Translational Genomics Research Institute, Phoenix, AZ
Revealing a new level of gene regulation in the cell, microRNAs (miRNAs)
are making an impact in our understanding of cancer biology. By functioning
as tumor suppressors or oncogenes, miRNAs can play an important role in
carcinogenesis. Similar to work done with gene expression analysis, inves-
tigators are now applying miRNA expression profiling to samples with
various clinical contexts in the search for theranostic biomarkers. An update
on the current trends and reports in lung cancer miRNA profiling, including
emerging data on the association of miRNAs with metastasis, chemoresis-
tance, and early detection will be presented.
MicroRNA alterations in the pathogenesis of lung cancers
Takashi Takahashi. Division of Molecular Carcinogenesis, Center for Neu-
rological Diseases and Cancer, Nagoya University Graduate School of
Medicine, Chikusa-ku, Nagoya, Japan
Micro-RNAs (miRNAs) are small, endogenously expressed non-coding
RNAs sequentially processed by Drosha and Dicer from primary transcripts,
which regulate the expression of protein-coding genes through either trans-
lational repression or RNA degradation. Their expression patterns are de-
velopmentally regulated and/or tissue-specific, while recent studies have
clearly shown the presence of miRNA alterations in various human cancers.
We previously reported for the first time that members of the let-7 family
are frequently down-regulated in lung cancers in association with shortened
postoperative survival and that let-7 possesses a capability of inhibiting lung
cancer cell growth, suggesting an involvement in its development. This
notion was further substantiated by subsequent reports that identified the
RAS and HMGA2 oncogenes as targets of let-7. Interestingly, we recently
found that let-7 directly down-regulates Dicer, which in turn affects the
expressions of various mature miRNAs. Since let-7 itself is also processed by
Dicer, our findings suggested the existence of a novel negative feedback loop
comprised of let-7 and Dicer, and resultant fine-tuning of mature miRNA
expression profiles. It is also of note that recent reports indicate the existence of
additional complexity in regulation of miRNA biogenesis involving let-7, thus
forming negative feedback regulations together with LIN28/LIN28B, which
inhibit Drosha- and Dicer-mediated miRNA processing. Interestingly, we have
found that reduced Dicer expression is associated with poor prognosis of patients
with NSCLC, while Jacks and his colleagues demonstrated that conditional
deletion of Dicer1 enhances tumor development in a K-Ras-induced mouse
model of lung cancer. Given the complexity of the regulatory mechanisms,
equilibration of miRNA expression profiles may be set at the most favorable
state for cell growth in cancers harboring changes in the expression of the
regulators of miRNA processing as well as of let-7, a key regulatory miRNA.
In our search for miRNAs that are overexpressed in lung cancers in
contrast to let-7, we found that the miR-17–92 miRNA cluster is frequently
overexpressed preferentially in SCLC in association with occasional gene
amplification. Inhibition of miR-17–5p and miR-20a with antisense oligo-
nucleotides induced apoptosis selectively in lung cancer cells overexpressing
miR-17–92, suggesting the possible existence of an “OncomiR addiction,”
while others reported close relationships of miR-17–92 with normal lung
development and proliferation in gene-engineered mice. However, it remains
to be elucidated how overexpression of miR-17–92 contributes to lung
cancer development, especially in cases with an SCLC histology. In this
regard, we recently found that RB inactivation induces the formation of
Y-H2AX foci, reflecting the continuing presence of DNA damage, as well as
growth inhibition and reactive oxygen species generation, which were
canceled by overexpression of miR-17–92. These results indicate a counter-
balancing role for miR-17–92 overexpression in the pathogenesis of SCLC,
which invariably carries RB inactivation.
Taken together, these findings strongly suggest the involvement of alterations
of tumor suppressor-type and oncogene-type miRNAs in the molecular patho-
genesis of human lung cancers. Further studies are needed to better understand
their roles in carcinogenic processes, which may ultimately lead to clinical
applications.
MicroRNA binding site SNPs and lung cancer risk
Joanne B. Weidhaas, Yale University School of Medicine, New Haven, CT
Lung cancer is a major cause of cancer deaths in the U.S., and existing
therapies fail to treat this disease successfully in the overwhelming majority
of cases. The ability to identify individuals at greatest genetic risk for
developing lung cancer would allow early screening and intervention and
would thus significantly impact lung cancer morbidity and mortality. In
addition, identifying patients with altered responses to therapy would help in
tailoring personalized therapies.
Unfortunately, genetic markers of increased cancer predisposition and
response to therapy have been historically very difficult to identify. Recently,
a new class of global gene regulators called microRNAs (miRNAs) was
shown to be important in cancer. MiRNAs suppress translation of their target
messenger RNAs (mRNAs) through binding to complementary sites in the 3’
untranslated region (3’UTR), a region of DNA that is highly conserved, but
until recently has been largely ignored for cancer variation. One miRNA
family, the let-7 family, regulates critical oncogenes in cancer, such as KRAS,
and low levels of let-7 predict a poor outcome in cancer, likely due to its
control of cell differentiation.
We have identified an inherited germ-line single nucleotide polymorphism
(SNP) in a let-7 miRNA complementary site in the KRAS 3’UTR,
rs61764370, which predicts lung cancer risk (Chin et al, Cancer Research,
2008). While found in only 7% of the general population, this KRAS-variant
is found in approximately 20% of non-small cell lung cancer patients, and is
a biomarker of an increased risk for developing non-small cell lung cancer
(OR  2.3). The KRAS-variant appears associated with increased KRAS
expression and is associated with decreased let-7 levels in tumors in KRAS-
variant carriers.
We hypothesize that this biomarker will identify patients who may
someday respond to let-7 replacement therapy, and that this marker may
currently predict response to certain targeted agents. Background on this
finding and these future directions will be discussed.
Concurrent Session 5: Mouse Models of
Lung Cancer
The multiple roles of Kras in epithelial tumor development
Minh D. To. University of California San Francisco, San Francisco, CA
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Activating mutation in Kras occurs at high frequency in some of most
common human cancers, and is generally associated with a poor clinical
outcome. The Kras locus encodes two differentially spliced isoforms, 4A and
4B, which differ only at the carboxyl terminus. Importantly, Kras activating
mutations found in cancers jointly affect both 4A and 4B isoforms. Although
the minor 4A isoform is dispensable for mouse development and is expressed
at low levels in a tissue-restricted manner, it is in fact essential for the
development of lung and skin tumors in the mouse. Our data further show
that the 4A isoform is important for the previously described inhibitory effect
of wild-type Kras on the mutant allele. In normal lungs, Kras-4A expression
is detected in a subpopulation of Clara cells, including at the bronchio-
alveolar junctions, reported to contain putative stem cells involved in tumor
initiation and injury repair. However, the level of Kras-4A expression is
decreased in lung tumors, suggesting that the 4A isoform of Kras may be
required for tumor initiation but has a more limited role during tumor
progression. In summary, while Kras-4A has previously received little
attention, it may in fact be the more relevant isoform of Kras during
carcinogenesis. Since Kras-4A and Kras-4B undergo different post-transla-
tional modifications, these findings can have important implications for the
design of therapeutic strategies for inhibiting oncogenic Kras activity in
human cancers.
Concurrent Session 6: Other Biomarkers
Gene copy number for EGFR and IGF-1R: Clinical
implications
Fred. R. Hirsch, Murry W. Wynes, Rafal Dziadziuszko, Andrzej Badzio,
Shalini Singh, Wilbur A. Franklin, Marileila Varella-Garcia, Paul A. Bunn,
Jr. University of Colorado Cancer Center, Aurora, CO, Medical University
of Gdansk, Poland, Ventana Medical Systems Inc., Tucson, AZ
Epidermal growth factor receptor (EGFR) and insulin-like growth factor
receptor (IGFR) signaling pathways are both important in lung cancer. For
the treatment of non-small cell lung cancer (NSCLC), EGFR inhibitors are
most advanced in clinical development, but many IGFR inhibitors are in
phase I-III trials. Gene copy numbers of EGFR and IGF-1R have been
assessed—mostly with FISH—but also with other methods in order to study
the prognostic and predictive value of the assays.
EGFR gene copy number by FISH has been extensively studied. The
frequency of high copy number in NSCLC varies somewhat depending on
methodology, classification definition, histology, ethnicity and possibly stage
of disease. By using the Colorado scoring system (1) the frequency of EGFR
FISH positivity ranges from 30–50%. The prognostic role of increased
EGFR gene copy number has been studied in some series and tumors
harboring high EGFR gene copy number seem to have a more aggressive
behavior compared to tumors with low copy number (2,3,4). The predictive
association to outcome after chemotherapy alone is not quite clear. In our
experience we did not see any difference in outcome from chemotherapy
between patients with EGFR FISH and FISH- tumors (5). The predictive
value of increased EGFR gene copy number for EGFR inhibitors has been
studied in multiple clinical trials. In two large placebo-controlled studies for
second/third-line therapy with EGFR TKI therapy a clear survival advantage
with EGFR TKI was seen in both studies for patients who had EGFR FISH
positive tumors (3, 6). However, in another large chemotherapy controlled
study (INTEREST) no difference in outcome was seen between patients,
whose tumors were EGFR FISH positive or negative (7).
In first-line studies the definite predictive role of high EGFR gene copy
number is still not clear. In two studies performed in a western population:
the OSI-774 study, in which EGFR positive patients (IHC or FISH) were
randomized to erlotinib or chemotherapy plus erlotinib in first-line treatment
no association to outcome was seen related to high EGFR copy number (8)
and in the maintenance trial, SATURN, no association was seen as well (9).
In Asian populations, due to the high frequency of EGFR mutations, there is
a considerable (almost complete) overlap between tumors harboring EGFR
mutations and high EGFR copy number (10). However, the situation is
different in western population where EGFR mutations occur in about 10%.
While it seems clear today that EGFR TKI therapy alone as first-line
treatment is a good choice for patients with tumors harboring EGFR
mutations in patients with advanced NSCLC, there might be an independent
predictive role of EGFR FISH in “EGFR wild type” patients, which is
currently being explored.
Regarding therapy with the anti-EGFR monoclonal antibodies the ran-
domized phase SWOG 0342 phase II study demonstrated doubling of both
time-to-progression TTP and overall survival OS in the EGFR FISH positive
patients compared to the FISH negative patients (11). However, these
findings could not be seen in the two prospective studies phase III studies, the
FLEX and BMS 099 (12,13). Therefore, a prospective validation of the
predictive role of EGFR FISH for cetuximab therapy is currently studied in
the large phase III study SWOG0819.
IGF-1R inhibition as treatment of lung cancer is still mostly in early
clinical development, but some IGF-1R inhibitors are in phase III-studies and
very little information is acquired on predictive factors. We have studied
IGF-1R gene copy number in NSCLC by FISH and by silver in situ
hybridization (SISH, Ventana, AZ) with very similar conclusions; patients
with high IGF-1R copy number had a better overall survival (prognosis) in
patients who underwent pulmonary resections for NSCLC compared to patients
with low copy number (14,15). With SISH the median copy number was 2.5
(1.3–7.2) (cutoff for high versus low). Among patients with squamous cell
(SCC) histology 65% had high copy number versus 25% in adenocarcinomas
(16). The predictive value of IGFR-1 gene copy number for sensitivity to
IGF-1R inhibitors is currently being studied both in vitro and in vivo.
In small cell lung cancer (SCLC), we have studied IGF-1R gene copy
number by SISH in 81 evaluable patients and found median gene copies per
cell 2.36 and average gene copy number 2.99 (1.34–18.40). Amplification
(true clustering) was seen in five patients (6%). Fifteen patients (18.5%) had
4 or more copies per cell. However, no significant association to survival was
seen (unpublished data).
In conclusion, while EGFR gene copy number assessment has already has
demonstrated promise as predictive tool for EGFR inhibitors in NSCLC,
IGF-1R gene copy number assessment is a potential predictive assay for
IGF-1R inhibition, but needs more clinical validation. High IGF-1R gene
copy numbers seen in SCC and in SCLC should encourage further thera-
peutic approaches with IGF-1R inhibitors in those subtypes.
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Prognostic and predictive biomarkers for adjuvant
chemotherapy
Ming-Sound Tsao. Princess Margaret Hospital and University of Toronto,
Toronto, Ontario, Canada
Lung cancer is the most common cause of cancer death in North America and
worldwide, with an overall 5-year survival rate of 15% or less. Based on the
biology and therapeutic strategy, lung cancer may be broadly divided into
two types: small cell lung carcinoma and non-small cell lung carcinoma
(NSCLC). The latter constitutes80% of all lung cancers, but it is composed
of heterogeneous subtypes, the major ones being squamous cell carcinoma,
adenocarcinoma and large cell carcinoma. Overall, tumor stage is the main
determinant of prognosis for NSCLC. At present, 30–35% of newly diag-
nosed NSCLC are early stage (I–IIIA) and are potentially curable by
complete surgical resection. However, the 5-year survival rates of these early
stage patients remain relatively poor at 30–60%. Variation in survival
largely reflects heterogeneity in the tumor biology, with some tumors having
more aggressive growth and greater metastatic potential than others. Prog-
nostic markers that may identify patients who are at high risk of poor
outcome and yet could potentially benefit from adjuvant chemotherapy may
provide better criteria for selection of patients to receive adjuvant chemo-
therapy.
Prognostic markers are patient/tumor features that predict patient
outcome (usually survival), irrespective of treatment received. Predictive
markers are patient/tumor features that predict response (either tumor
shrinkage or survival) to specific treatments. Thus, prognostic markers
define the effect of tumor characteristics on the patient, while predictive
markers define of effect of treatment on the tumor. In general, prognostic
markers should be assessed on patients who are not receiving therapy
aside from surgical resection, while predictive markers should compare
the effect of markers in both the treated and untreated patients. Most
importantly, a prognostic marker is clinically useful only if it is also a
predictive marker for therapeutic benefit.
A large number of protein markers have been assessed by immunohisto-
chemistry (IHC) for their prognostic value in early stage NSCLC patients. To
date, none is sufficiently robust for adoption in patient care. With many
markers, published results have often been inconsistent and sometimes
contradictory. Some of the reasons include the lack of standards in the
reagents, technical and scoring methods used. Despite these challenges, more
recent studies conducted on tumor samples of patients involved in large
phase III randomized adjuvant chemotherapy trials have revealed potential
IHC markers that may be implemented clinically to select early stage
NSCLC patients for adjuvant chemotherapy. These include the excision
repair cross-complementing (ERCC) 1 protein, a rate limited nucleotide
excision DNA repair enzyme for cisplatin-induced DNA damages, and p53,
a multifunctional protein with important roles in cell cycle checkpoint
regulation and sensing DNA damage and cellular stress. However, the hazard
ratios for these markers remain modest at 1.6–1.9.
To expand the scope of investigation into potentially novel prognostic
genes in lung cancer, whole genome gene expression analyses by microarray
have been conducted. The results have confirmed that microarrays could
yield biologically relevant information to define tumor characteristics beyond
histology. While microarray derived prognostic signatures could be com-
posed of hundreds to thousands of genes, validation studies on these
signature genes by quantitative polymerase chain reaction (QPCR) have led
to the identification of smaller sets of prognostic gene classifiers. One of the
challenges in accepting the validity of gene expression signatures is the lack
of significant overlap between genes of signatures identified by different
studies. Despite this, recently reported classifiers have been validated in
independent and sometimes multiple patient cohorts. More recently, a large
scale permutation study has demonstrated that even with a limited enriched
set of individually prognostic genes, a large number of prognostic signatures
made up of non-overlapping gene sets may be identified. More importantly,
the strengths of multi-gene prognostic signatures have been consistently
greater than those of immunohistochemistry markers. In addition, gene
expression profiles that may characterize the activation of important
oncogenic pathways, as well as profiles that may predict response to
various chemotherapeutic agents, are also being actively pursued. The
rapid advances being made in the multiplex mRNA detection technolo-
gies will undoubtedly lead to the development of clinically applicable
robust gene expression-based prognostic tests. Small prognostic gene sets
may also allow the development of IHC-based multispectral tests. In
addition to mRNA and protein based signatures, ongoing studies will also
lead to the development of gene copy or microRNA based prognostic and
predictive signatures. These markers and tests will allow the tailoring of
individual patient therapy based on the molecular pathology of patient’s
tumor, leading to significant improvement in the overall effectiveness of
adjuvant chemotherapy.
Abstracts of Proffered Presentations
Plenary Session 1: Tyrosine Kinase Signaling
and Targeted Therapy
PR1
Activation of c-Met by EGFR modulates invasive phenotypes
in NSCLC
Austin M. Dulak and Jill M. Siegfried. University of Pittsburgh, Pittsburgh, PA
Lung cancer is currently the leading cause of cancer-related deaths in both
men and women in the United States. One signaling pathway currently being
explored for therapeutic intervention is the receptor tyrosine kinase c-Met
and its natural ligand hepatocyte growth factor (HGF). c-Met interacts with
HGF, also known as Scatter Factor, to promote the cancer phenotype of
invasive growth in many cancers including non-small cell lung cancer
(NSCLC). Recently, our studies demonstrate an HGF independent mecha-
nism of c-Met activation through the epidermal growth factor receptor
(EGFR) in NSCLC. Exogenous stimulation with 10 nM of EGFR ligands
EGF and TGF- induced a time-dependent accumulation of activated c-Met
in NSCLC cell lines up to 48 hours following serum deprivation. This
activation by EGF was accompanied by a 1.5 to 2-fold increase in c-Met
expression and downstream tyrosine phosphorylation of c-Met residues
Y1234, Y1235, Y1349, Y1365, and Y1003. The mechanism of trans-
phosphorylation was then explored further with pharmacological inhibitors.
Actinomycin D (0.01 g/mL), an inhibitor of transcription, ablated both
c-Met tyrosine phosphorylation as well as the accompanying increase in total
c-Met protein levels following EGF stimulation suggesting that a transcrip-
tional component is required for trans-phosphorylation. Moreover, induction
of c-Met phosphorylation as was blocked by pretreatment with both
PF2341066 (Pfizer) and SU11274 (1 M), two selective c-Met tyrosine
kinase inhibitors (TKI), or with gefitinib (100 nM), an EGFR TKI. This
demonstrates that kinase activity of both receptors is required. Moreover,
treatment with the pan-Src Family Kinase (SFK) inhibitors, PP2 (1 M) and
dasatinib (50 nM), prior to EGF addition abolished all c-Met phosphorylation
suggesting that the SFKs are critical intermediates in this signaling cascade.
Further, a Src dominant-negative construct reduced EGF-induced c-Met
phosphorylation 2-fold compared to the control. Autocrine production and
secretion of HGF was not involved in this trans-phosphorylation as shown by
HGF ELISA and quantitative PCR up to 72 hours after EGF treatment.
Inhibition and siRNA down-regulation of c-Met, decreased EGFR ligand-
induced phenotypes of invasion, motility, and cell proliferation, suggesting that
EGFR is not acting alone. EGFR action relies, in part, on activation of c-Met to
modulate downstream signaling cascades responsible for invasive growth in
NSCLC.
This talk was also presented as Poster A2.
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Plenary Session 2: Early Detection for
Premalignant Lesions and Field Cancerization
PR2
Sniffing NSCLC and SCLC using nanoparticle-based artificial
olfactory system NaNose®
Nir Peled1, Orna Barash2, Hossam Haick2, Paul R. Bunn, Jr.1, Fred R.
Hirsch1. 1University of Colorado Cancer Center, Aurora, CO, 2Russell
Berrie Nanotechnology Institute, Technion, Haifa, Israel
NSCLC differs from SCLC in its natural history, pathologic feature, treat-
ment algorithm and biology/molecular features. Thus, discrimination be-
tween the two states is crucial but still requires invasive procedure, which is
not always possible; e.g. due to small nodule size and difficult access. In this
study we have examined whether it possible to discriminate between NSCLC
and SCLC via unique pattern of volatile organic compounds (VOCs) detected in
the headspace of the cells’ environment. These examinations have been based on
our earlier findings that novel gold (Au) nanoparticles-based Artificial Olfactory
System[1], so-called NaNose, was able to distinguish between malignant and
non malignant cell lines via their “smell print” patterns (VOCs; 2).
Methods: Six adenocarcinoma (AC) cell lines, 2 large cell carcinoma cell
lines (all refer as NSCLC) and four SCLC cell lines were grown in duplicates
to 95% confluence using standard conditions (RPMI medium  10% serum;
5% CO2 environment). Medium without cells served as a control. The
headspace atmosphere of the cell lines was collected by SKCTM Ultra II
system and analyzed by: (i) gas-chromatography/mass-spectrometry (GC-
MS) combined with solid phase micro-extraction (SPME) for determining
the chemical nature of the cancerous VOCs; and by (ii) NaNose, which has
been developed in our (Technion) labs, for obtaining simple, real-time
discriminations between the samples. For the latter, the electrical properties
of the sensors were measured by a device analyzer using integration times
that spanned at least two power line cycles. In the second phase of the study
we were focusing on the unique VOCs per histology type and studying the
production vs. consumption VOCs profile between the two subtypes of lung
cancer subtracting the medium’s VOCs.
Results: GC-MS analysis identified 2000 different VOCs. Forward stepwise
discrimination analysis produced different VOCs profile for the two histologies
common to 80% of each. Unique VOCs to each of the histologies were found,
implying the differences in the consumption/production VOCs profiles. The
relative amount of VOCs that were consumed and produced was higher among
the SCLC than the NSCLC (in average by 50%), indicating higher rate of
metabolism. In addition, the principle component analysis of the nanoparticles
sensor array yielded a clear discrimination between the two subtypes of lung
cancer, which were both different significantly from the medium control. This
was achieved without a pre-concentration phase prior to the exposure. Two
VOCs (styrene and toulene) were produced by NSCLC but consumed by SCLC.
Conclusion: NSCLC and SCLC have different VOCs profiles that are driven
from differences in their consumption/production profile representing differ-
ences in the cell metabolism. The NaNose allows discrimination between
NSCLC and SCLC based on differences in their VOCs profiles. Translation
to human breath is needed for applying this data into the clinic.
REFERENCES
1. Peng G, Tisch U, Adams O, Hakim M, Shehada N, Broza YY, Billan S,
Abdah-Bortnyak R, Kuten A, Haick H. Diagnosing lung cancer in exhaled
breath using gold nanoparticles. Nature Nanotech. 2009;4:669–73.
2. Barash O, Peled N, Hirsch FR, Haick H. Sniffing the unique “odor print”
of non-small-cell lung cancer with gold nanoparticles. Small. 2009.
PR3
Blood-based biomarker profiles for detecting lung cancer
Gina Lee1, Jay M. Lee1, Brian K. Gardner1, Tonya C. Walser1, Kostyantyn
Krysan1, P.S. Pak1, Jenny Mao2, Saswati Hazra1, Steven M. Dubinett1.
1David Geffen School of Medicine, University of California Los Angeles,
Los Angeles, CA, 2New Mexico Veterans Affairs Health Care System,
Albuquerque, NM
Introduction: Approximately 1 in 500 chest x-rays demonstrates a lung
nodule of indeterminate significance, totaling more than 150,000 abnormal
cases annually in the U.S. Nearly 25% of patients who undergo surgical
evaluation for suspicious lung nodules will be diagnosed with benign lung
pathologies. This underscores the need for diagnostic strategies to improve
early lung cancer detection and survival and to reduce invasive surgical
procedures.
Our preliminary data show a select panel of proteins was differentially
expressed in patients with any stage lung cancer compared to non-cancer
high risk control subjects. We hypothesize that biomarkers produced by the
early, developing tumor and the local tumor microenvironment will be
present in the peripheral blood of subjects with preclinical lung cancer. These
biomarkers could be utilized in a prediction model to develop a diagnostic
test for early cancer detection and/ or assist in the diagnosis of the indeter-
minate nodule. We anticipate that the plasma protein biomarkers identified in
this investigation will add important information and, in combination with
additional clinical parameters, aid in the diagnosis of lung cancer.
Methods: We assembled a 40- marker panel of potential biomarkers based
on our own investigations in the pathogenesis of lung cancer and the
published results of others. These potential biomarkers are comprised of
proteins hypothesized to contribute to lung cancer progression or whose
levels may be altered as a result of tumorigenesis. To determine the
concentration of these potential biomarkers we utilized a bead-based multi-
plexed immunoassay to determine the concentration levels from patient
plasma specimens. The bead-based immunoassay system requires only a
limited amount of sample (100 l) for up to 100 analytes. We accessed
plasma from 90 lung cancer subjects and 56 high-risk control subjects
comprised of former smokers at risk for lung cancer (30 pack years,
age 45, smoking cessation of at least 1 year). These specimens are
complemented with collection of general health and medical information,
including clinical and pathologic stages, medication history and comorbidi-
ties. All lung cancer and control samples were collected and processed
utilizing a standardized collection and storage protocol that was based on the
blood sample collection protocol utilized by the NIH/NHLBI sponsored
Lung Health Study trial (LHS).
Results: 33 out of the 40 biomarkers were significantly different (p0.05)
between all stages of NSCLC and control samples (CXCL1/GRO, CXCL5/
ENA-78, CCL1/I309, CXCL9/MIG, CXC11/ITAC, CXCL12/SDF, CCL3/
MIP1a, CCL4/MIP1b, CCL5/RANTES, CCL11/eotaxin, CCL15/MIP1d,
CCL19/MIP3b, CCL22/MDC, IL-2, IL-3, IL-4, IL-6, IL-7, IL-10, IL-12 p40,
IL-12 p70, IL-13, IL-15, IL-17, bFGF, GCSF, GMCSF, IFNg, IL-1a, IL-1b,
IL-1Ra, TNFb, and VEGF. Based on a stepwise, logistic regression model
we identified a 4-biomarker panel that provided 88% sensitivity and 79%
specificity in predicting lung cancer versus high-risk controls. In order to
determine if the biomarkers in our panel could be used to identify early stage
lung cancer, we compared the plasma from 31 stage I NSCLC subjects in our
sample set to the controls. We found that there were 21 markers that were
significantly different between stage I NSCLC and control (p  0.05)
suggesting that this method is adequately sensitive to detect early stage
tumors. These preliminary findings serve as the justification for further
investigation with this platform in larger cohorts.
Conclusions: A common clinical problem is a current or former smoker who
presents with an abnormal radiological image such as a chest-computed
tomography (CT) scan suspicious for lung cancer but will often require
invasive, costly diagnostic procedures. We hypothesized that biochemical
changes associated with tumor initiation and progression could provide an
opportunity for the development of a blood test that could be utilized in
conjunction with other clinical parameters as part of a multimodal lung
cancer risk model for improved sensitivity and specificity in the diagnosis of
lung cancer. We found that tumor-associated biomarkers can be detected in
the systemic circulation of lung cancer patients at differentially expressed
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levels compared to high risk control subjects. These biomarkers may provide
additional information to aid in discriminating malignant from non-malig-
nant pulmonary nodules.
This talk was also presented as Poster A13.
Concurrent Session 2: Other Thoracic Cancers
(Mesothelioma, Thymic, Neuroendocrine)
PR4
Mouse models to study roles of tumor suppressor and
signaling pathway in SCLC development
Kwon-Sik Park, Bethany Schaffer, Julien Sage. Stanford University, Stan-
ford, CA
Small cell lung carcinoma (SCLC) is a neuroendocrine subtype of lung
cancer and remains the deadliest with a 5-year survival rate of less than 10%.
A mouse model for human SCLC has been developed based on the fact that
the RB and p53 tumor suppressor genes are mutated in more than 90% of
human SCLC tumors. Rb/p53 mutant lung tumor resembles human SCLC in
many aspects, including histopathology and genetic aberrations, and has
allowed us to study the mechanisms underlying the development and the
maintenance of SCLC in vivo.
First, to determine the molecular aberrations contributing to the initiation
of SCLC, we have taken a mouse genetics approach. Emerging evidence in
patients and mouse models suggest that p130, a gene related to RB, may act
as a tumor suppressor in SCLC cells. To test this idea, we used conditional
mutant mice to delete p130 in combination with loss of Rb and p53 in adult
lung epithelial cells. We found that loss of p130 resulted in increased
proliferation and significant acceleration of SCLC development in this mouse
model, compared to the Rb/p53 mutant model. The histopathological features
of the triple mutant mouse tumors closely resembled those of human SCLC.
Genome-wide expression profiling further showed that Rb/p53/p130 mutant
mouse tumors were similar to human SCLC. These findings indicate that
p130 plays a key tumor suppressor role in SCLC. In addition, Rb/p53/p130
mutant mice provide a novel pre-clinical model for human SCLC to identify
and test novel therapeutic targets against this deadly cancer.
Second, we have sought to determine the signaling mechanisms underly-
ing the homeostasis of SCLC. Based on preliminary evidence in a small
number of human samples, we hypothesized that SCLC tumor cells may
re-activate the Hedgehog (Hh) signaling pathway. Hh signaling plays a key
role during normal lung development and response to injury but normally has
low activity in the lung epithelium. Indeed, when we studied Rb/p53 mutant
mice crossed with a reporter mouse line of the Hh pathway (Ptch1lacZ/
mice), we found that Hh signaling was active in all the lung tumors that
develop in this mouse model of SCLC. Experiments with cell lines derived
from tumors also indicated that the activation of Hh signaling in these cells
was cell-autonomous. Inhibition of the Hh pathway with small molecules
such as cyclopamine reduced the survival of mouse SCLC cells, while early
activation of Hh pathway enhanced the tumorigenesis of SCLC in vivo.
These findings indicate that the Hh pathway is active in SCLC and plays a
role in the initiation and the maintenance of SCLC. These observations
indicate that activation of Hh signaling is critical for the homeostasis of
SCLC and suggest that inhibition of this signaling pathway may provide a
novel means to treat SCLC patients.
PR5
Matching phenotype-genotype interactions identifies mTOR as
a druggable molecule in malignant pleural mesothelioma
targeted therapeutic approach
Simona Inghilleri1, Ymera Pignochino2, Michele Zorzetto1, Patrizia Mor-
bini1, Ernesto Pozzi1, Giulia M. Stella1. 1University of Pavia and Fondazione
IRCCS Policlinico San Matteo, Pavia, Italy, 2IRCC-Institute for Cancer
Research and Treatment, Candiolo, Italy
Purpose: Malignant pleural mesothelioma (MPM) is an aggressive tumor,
with an extremely poor prognosis and an increasing incidence as a result of
widespread exposure to asbestos. Representing a still unsolved clinical
problem, it lacks of effective therapeutical regimens. A better understanding
of molecular mechanisms involved in mesothelial carcinogenesis is a clear
priority to both assess targeted agents and to select patients that are likely to
achieve a clinical benefit. On the other hand individual variability plays a key
role in modulating drug response. In respect to alchylant agents, the Nucle-
otide Excision Repair (NER) system is involved in response to platinum
compounds. ERCC1 is the most important molecule in NER pathway:
ERCC1 defective cells show a severe deficit in DNA damage repair (plati-
num sensitivity); as apposite, the highest is the expression, the worst is the
efficacy (platinum resistance).
This work aims matching MPM onco-markers and host genetic determi-
nants of drug response in order to dissect the pharmacogenomic profile of
such a complex disease. To this goal we used different approaches: i)
identification of MPM activated oncogenic pathways and we specifically
focused on the PI3K-mTOR-AKT signaling ii) evaluation of ERCC1 expres-
sion in order to validate in MPM its role as stratification biomarker iii) in
vitro studies with molecular targeted drugs already commercially available
such as the multikinase inhibitor sorafenib and the mTOR specific inhibitor,
everolimus.
Experimental Procedures: We select 10 patients who underwent thoraco-
scopic diagnosis of MPM-unresectable disease, IMIG stage III- and were
treated with platinum-based chemotherapy, as first line approach. They all
referred previous work-related exposure to asbestos. Eight cases were his-
tologically classified as epithelial types whereas 2 displayed a biphasic
pattern. Objective response to therapy was evaluated according to RECIST
criteria. Corresponding formalin-fixed paraffin-embedded sections were ob-
tained. ERCC1 and mTOR expression was checked by immunohistochem-
istry (IHC). Tumor genomic DNA was then extracted and the mutational
status of PIK3CA signaling molecules was assessed by direct sequencing.
For in vitro assays human MPM cell lines were established from the pleural
effusion of 3 patients with histologically confirmed MPM. Mesothelial
origin was confirmed by IHC. 3000cell/well were treated for 72 hours
with escalating doses of sorafenib and everolimus alone or in combina-
tion and cell viability was evaluated with cell TiterGlo (Promega)
following manufacturer’s instructions. The IC50 values (concentration of
drug inhibiting 50% of cell line proliferation) were calculated with
Calcusyn software (Biosoft).
New Data: The mTOR kinase was overexpressed in all tumor samples
and in the adjacent hyperplastic mesothelium but not in normal mesothe-
lium. No mutations were found in “hot spot” coding regions of EGFR
(exons 18–21), KRAS (exon 2), BRAF (exon 15) PIK3CA (exons 9–20)
genes. In vitro assays demonstrated that sorafenib and everolimus have
synergistic effect in the inhibition of MPM cell line proliferation after 72
hours of treatment. In the analyzed cohort the median survival was of 26
months; 8 patients partially responded to platinum whereas 2 were
classified as not responders. High ERCC1 IHC positivity was stained in
9 samples; the patient lacking ERCC1 did not respond to platinum.
Moreover, no correlation was found between ERCC1 expression level
and overall survival.
Conclusions: Our results suggest that the mTOR kinase is active in MPM
onset; its overexpression is not sustained by activating mutations affect-
ing the PIK3CA signaling. The mTOR inhibitor everolimus represents a
promising MPM therapeutic molecule, mainly when used in combinato-
rial schedules.
Unexpectedly the identification of ERCC1 expression alone is unlikely to be
valuable in selecting MPM patients eligible for platinum-based chemotherapy.
This talk was also presented as Poster B44.
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Plenary Session 3: Cancer Stem Cells
PR6
Lung cancer cells asymmetrically divide their template DNA
strands during cell division
Brid M. Ryan, Sharon R. Pine, Ana I. Robles, Lyuba Varticovski, Curtis C.
Harris. Laboratory of Human Carcinogenesis, National Cancer Institute,
Bethesda, MD
The cancer stem cell hypothesis purports a hierarchical model of carcino-
genesis whereby tumors are initiated and maintained by a small population
of stem-like cells. Indeed, recent data has demonstrated the existence of
cancer stem-like cells in solid tumors that share the properties of normal stem
cells and give rise to phenotypically heterogeneous tumors. However, the
mechanism by which this occurs is unknown. Normal stem cells have the
unique ability to generate daughter cells with differing self-renewal and
differentiation potentials via asymmetric cell division. The “Immortal Strand
Hypothesis” was proposed to explain how adult stem cells might avoid
replication errors by asymmetrically dividing the “immortal” template DNA
strand to the daughter stem cell while segregating the newly synthesized
DNA to the differentiating cell. Though it has been demonstrated in several
types of mammalian tissue, direct evidence for asymmetric division of
template DNA during cell division has never been demonstrated in cancer.
By performing pulse-chase experiments with halogenated thymidine ana-
logs, we observed that a small fraction of cells within human lung cancer cell
lines and short-term cultures from primary tumor samples asymmetrically
divide their template DNA strands. Specifically, the frequency of asymmetric
division of template DNA ranged between 0.7 and 5.6% in several NSCLC
cell lines and between 15 and 25% in primary cultures. In addition, 4% of
immortalized human bronchial epithelial cells demonstrated co-segregation
of template DNA. These data were further confirmed in A549s by real-time
imaging. As in normal stem cells, our data show that the frequency of
asymmetric division in cancer cells is altered in response to changes within
the microenvironment, including cell density, serum deprivation and hyp-
oxia. We also show the first evidence that that direct cell-cell contact is
necessary for asymmetric division to occur, thus providing intriguing in-
sights into the mechanism of this novel aspect of cancer biology.
Asymmetric cell division involves the differential segregation of cell fate
determinants in other model systems. Therefore, we sought to link template
DNA co-segregation with expression of cell differentiation markers. Indeed,
using both cell lines and primary cultures as a model system, we found that
in lung cancer cells which asymmetrically divide both DNA and proteins,
differentiation markers are segregated to the daughter cell destined to
differentiate, while the lung cancer stem cell marker, CD133, is segregated
with the template DNA.
Thus, we have convincingly shown that lung cancer cells can asymmetri-
cally divide their DNA, that this phenomenon is modulated by factors within
the microenvironment and that it is linked to cell fate. Our work suggests that
a hierarchical cellular pattern within lung tumors may be regulated, at least in
part, by an orchestrated mechanism of self-renewal and differentiation, involving
segregation of template and newly synthesized DNA.
PR7
Targeting Rac1 GTPase benefits both human lung
adenocarcinoma stem cell and non-stem cell therapies
Shailaja Akunuru, James Johnson, Yi Zheng. Children’s Hospital Research
Foundation, University of Cincinnati, Cincinnati, OH
The cancer stem cell theory predicts that a small population of cancer cells
possesses unique self-renewal activity and is the source of cells with varying
expansion and differentiation capabilities in tumor propagation. While this
theory remains controversial particularly in solid tumor studies, the drug-
resistant side population (SP) cells, along with cells expressing a number of
cell surface markers including CD133, have been recently characterized in
lung, brain, blood, colon, or breast cancers to represent an enriched cancer
stem cell population. Given the implicated role of Rac1 GTPase in cancer
cell proliferation, migration, invasion and metastasis, we have investigated
the hypothesis that Rac1 is a critical mediator of tumor initiating activity and
metastasis of human non-small cell lung adenocarcinoma and constitutes a
target in cancer stem cell therapy. Using the human lung cancer cell lines
A549 and H441 and cell marker-based mouse xenograft models, we have
found that (1) Rac1 knock down by shRNA suppresses the adhesion,
migration, invasion, and lung colonization of the bulk population of the lung
cancer cells; (2) SP cells isolated from the lung cancer cells shown previ-
ously to be enriched for tumor initiating potential in s.q. xenografted mice
have increased lung colonizing activities in tail vein injected mice over the
non-SP or bulk population of the cells; (3) SP cells contain elevated
Rac1-GTP activity, display unique morphology, actin cytoskeleton pattern,
migration, and invasion in vitro; (4) pharmacological or shRNA targeting of
Rac1 inhibits the migration and invasion activities in vitro, and lung colo-
nization activities in vivo, of both SP and non-SP cells; and (5) the SP cells
represent a distinct population from the CD133 cells, with both displaying
an enrichment of tumor-initiating activity. Whether these results apply to
tumor initiating and metastasis potentials of primary human lung adenocar-
cinoma is currently under investigation. Our studies raise interesting possi-
bilities that multiple cell populations displaying cancer stem cell properties
may exist in human lung cancer, and Rac1 represents a useful target in both
the cancer stem cell and non-cancer stem cell populations.
This talk was also presented as Poster A8.
Concurrent Session 4: Lung Cancer Profiling
with microRNAs
PR8
The role of microRNA 125a-3P in the pathogenesis of lung cancer
Saswati Hazra1, Brian K. Gardner1, Kostyantyn Krysan1, Tonya C. Walser1,
John Brothers II2, Jill E. Larsen3, Alexander Pertsemlidis3, Jerry W. Shay3,
John D. Minna3, Avrum Spira2, Steven M. Dubinett1. 1Geffen School of
Medicine, University of California Los Angeles, Los Angeles, CA, 2Boston
University School of Medicine, Boston, MA, 3UT Southwestern Medical
Center, Dallas, TX
Tobacco exposure results in specific oncogene and tumor suppressor gene
alterations in lung epithelial cells that often lead to lung cancer development.
Activating point mutation of the K-ras proto-oncogene is one of the most
frequently occurring genetic changes found in lung cancer both in active and
former smokers. Understanding how K-ras mutations mediate the malignant
phenotype may yield more effective prevention and diagnosis strategies to be
applied to individuals at elevated risk for lung cancer. MicroRNAs (miR-
NAs) are a class of short (19–24 nucleotides) noncoding RNAs that play a
critical role in post-transcriptional gene regulation. A rapidly developing
literature supports an important role for miRNAs in the regulation of lung
carcinogenesis and tumor progression. In order to better understand the role
of miRNAs in the K-ras-mutated bronchial epithelium, we utilized hTERT
and Cdk4-immortalized human bronchial epithelial cells (HBECs) express-
ing oncogenic Kras.V12 We next generated the miRNA profile (TaqMan
miRNA array v.2, Applied Biosystems, Foster City, CA), gene expression
profile (Affymetrix U133 plus 2 array), and protein expression profile
(50-plex inflammatory marker panel) of the K-ras mutated and vector control
HBECs. We found that miRNA miR-125a-3p was significantly suppressed in
K-ras-mutated HBECs compared to the vector control cells. We then eval-
uated basal expression of miR-125a-3p in both HBEC and NSCLC cell lines
containing mutated K-ras by real time RT-PCR. Both K-ras-mutated HBEC
and NSCLC cell lines expressed low levels of miR-125a-3P. In order to
further evaluate the role of miR-125a-3p, we expressed this miRNA in
K-ras-mutated HBECs. The expression of miR-125a-3p downregulated sev-
eral factors that could be tumor-promoting, including Gro-, HGF, VEGF,
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GM-CSF, and G-CSF. Further studies revealed that suppression of Gro-
and HGF, but not VEGF, is regulated at the level of mRNA expression.
Overexpression of miR-125a-3p downregulated Gro- and suppressed pro-
liferation of the K-ras-mutated HBECs but did not alter the proliferation of
the vector control HBECs. Recently, an association has been found between
the use of rosiglitazone and reduced risk of lung cancer. Rosiglitazone, a
thiazolidinedione PPARY agonist, has been shown to prevent progression of
pre-invasive lung cancer in murine models and to suppress human lung
carcinoma cell growth. We found that rosiglitazone upregulated miR-
125a-3P 8.3-fold more in K-ras-mutated HBECs compared to vector control
HBECs. Current studies are evaluating the specific role of miR-125a-3P in
the rosiglitazone-mediated suppression of tumor progression.
PR9
MicroRNA affinity assay
Miao Shi, Weiguo Han, Simon Spivack. Albert Einstein College of Medi-
cine, Bronx, NY
Introduction: MicroRNAs (miRNAs) are small noncoding RNAs function-
ing in gene regulation. In animal cells, miRNAs bind to target sites in the 3’
UTR of mRNAs, causing posttranscriptional repression or degradation of
mRNAs. The identification of specific miRNAs to target a 3’UTR of a given
gene is essential for studies in gene regulation. However, the sequence
software programs conventionally used to predict binding of individual
microRNAs to a given mRNA transcript are notoriously unreliable, and
specific microRNA-mRNA binding is very difficult to directly affirm using
currently available techniques. We have developed a microRNA affinity
assay that addresses this need.
Methods: We chose a candidate gene that had been extensively studied
experimentally for microRNA regulation; it is known that miR-200c and
miR-200b can bind to 3’UTR RNA of TCF8 [Hurteau 2007]. Here, a 500bp
fragment of the 3’UTR RNA of TCF8 was generated by IVT, and used as a
bait sequence to identify miRNAs that bind a mixture of known miRNA
composition, and alternately a naturally produced cellular miRNA pool.
After separation, miRNA qPCR was used to check recovery rate of miRNA,
and cloning and sequencing was used to identify miRNAs.
Results: Specific miRNAs from a synthetic mixture miRNAs, miRNA qPCR
results displayed excellent recovery rates (151.57% with pipetting error, for
miR-200c), 88.88% for the closely related miR-200b, 0.31% for the sequence-
unrelated miR-9, 0.67% (miR-10a), 0.1% (miR-20a), 8.78% (miR-34a with
some 3’UTR homology), 0.11% (miR-100), 0.16% (miR-140–5p), 0.98% (miR-
144), 0.33% (miR-802) and 1.58% (miR-1234). After cloning the captured
miRNAs, there were 10 sequences frommiR-200c, 7 sequences frommiR-200b,
and one other sequence in 18 sequenced clones. When separating specific
miRNAs from naturally produced NHBE cell miRNA pool, miRNA qPCR
results show that their recovery rates are 88.88% (miR-200c), 80% (miR-200b),
0.07% (miR-20a), less than 0.006% (miR-34a) and 0.01% (miR-100).
Conclusions: For both simple known and complex unknown microRNA pools,
this pull-down strategy is effective in determining microRNA-mRNA binding.
In future work, we will use other 3’UTR RNA sequences of candidate genes as
bait sequence, for microRNA-related discovery and confirmation.
Concurrent Sessions 5: Mouse Models of Lung
Cancer
PR10
BRAF deletion and pharmacologic inhibition enhance
KRAS driven tumorigenesis
Christopher L. Murriel, Honglin Chen, Denise Kenski, Hani Bou-Reslan, Wen-
lin Yuan, Yuxin Liang, Richard Carano, Suzana Cuoto, Somasekar Seshagiri,
David P. Davis, Leisa Johnson. Genentech, Inc., South San Francisco, CA
The Ras GTPase family controls numerous downstream signaling cascades
in response to signals that regulate cellular processes including proliferation
and survival. While Ras is one of the most prevalent targets for gain-of-
function mutations in human tumors, questions remain regarding how the
Ras effector pathway functions in mutant KRAS-driven tumorigenesis. Since
an important function of K-ras involves B-Raf activation within the canon-
ical MAPK signaling pathway, we initiated a study to determine B-raf’s role
in the context of mutant K-ras tumor promotion and maintenance.
We began by delivering adenovirus expressing the Cre recombinase to the
lungs of genetically engineered mice possessing a conditional K-rasG12D
allele (K-rasLSL-G12D) and either 0, 1 or both copies of the BRAF gene flanked
by LoxP sites (B-rafCKO). This procedure results in expression of mutant
K-rasG12D in the presence or absence of one or both BRAF alleles deleted
within the mouse lung. Surprisingly, we observe that B-raf deletion signif-
icantly enhances lung tumor number and burden and decreases overall
survival. When we used a highly specific small-molecule inhibitor that
targets B-raf in a murine non-small cell lung carcinoma line harboring the
K-rasG12D mutation, we observed an increase in cell proliferation and soft
agar colony formation. Further investigation revealed that treating K-rasG12D
expressing cells with the B-raf inhibitor enhanced MEK and Erk phosphoryla-
tion. Therefore, our data suggests that while B-raf deletion does not inhibit
K-ras-driven tumor initiation and disease progression, its presence may play a
pivotal role in establishing negative feedback regulation of constitutive mutant
K-ras activity.
PR11
Novel lung cancer model mediated by lentiviral gene delivery
Yifeng Xia, Narayana Yeddula, Mathias Leblanc, Reuben Shaw, Inder
Verma. Salk Institute for Biological Studies, La Jolla, CA
Lung cancer, the leading cause of cancer deaths, is responsible for 1.3
million lives lost worldwide every year. Based on the difference of responses
to treatment, lung cancer is divided into two major classes: small cell lung
cancer (SCLC) and non-small cell lung cancer (NSCLC), among which the
lung adenocarcinoma is one of the dominant forms. The recent analysis of
somatic mutations in lung cancers has shed light on the molecular and
pathological studies in lung adenocarcinoma. According to the direct se-
quencing data in 623 target genes from 188 adenocarcinoma patients, at least
26 genes are mutated at significant high frequency. These genes function
mainly in MAPK pathway, PI3K/Akt, cell cycle/apoptosis, and mTOR
pathway. About 30% of all lung adenocarcinomas have mutations in Kras,
and the KrasG12D mouse model from T. Jacks lab is one the most widely
used models to study lung adenocarcinoma. However, to study the cross-talk
among oncogenes and tumor suppressors, researchers have to breed
KrasG12D mice with mice carrying other conditional alleles, which appears
to be the biggest hurdle to study the complexity of tumorigenesis.
Here we describe a novel lung cancer model mediated by intratracheal
infection of lentiviral vector expressing tissue-specific Cre to activate
KrasG12D and siRNAs against certain tumor suppressors sufficient to
initiate rapid tumor development. The first vector we tested was CA2Cre-
sip53, which has carbonic anhydrase 2 driven Cre and siRNA against mouse
p53. In this vector induced tumor model, we observed a median survival time
of 100 days and the advanced tumor showed typical grade 5 adenocarcinoma
lesions with all the characteristics described by Jackson et al. These results
faithfully recapitulated the data from KrasG12D-p53F/F mice. Taking ad-
vantage of our single vector model, we were able to carry out the study of
cross-talk among different tumor suppressor genes. For example, CA2Cre-
sip53-sip16 mice showed similar tumor initiation and progression as
CA2Cre-sip16 mice, indicating the overlap of the p53 and p16 tumor
suppressor pathways; CA2Cre-sip53-siLKB1 mice showed significant longer
latency, indicating the antagonistic action of these two pathways; while
CA2Cre-sip53-sipTEN mice showed shorter latency with massive inflam-
matory response. Detailed molecular mechanisms are under investigation.
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Inflammation and cancer development have attracted researchers’ atten-
tion for more than decades. With our CA2Cre-sip53 vector, we studied the
tumorigenesis in KrasG12D mice and KrasG12D-IKK2F/F mice, in the latter
NF-kappaB pathway was ablated only in tumor cells. As expected,
KrasG12D-IKK2F/F mice showed much longer median survival time (150
days vs. 100 days) with slower tumor development. The results were further
confirmed in KrasG12D mice with CA2Cre-sip53-siIKK2 vector. Interest-
ingly, we found sustained KrasG12D activation in the cells induced DNA
damage response, which activated NF-kappaB signal pathway. High NF-
kappaB activity significantly enhanced the cytokines/chemokines secretion
by the KrasG12D cells, favoring cell proliferation, inflammatory cells infil-
tration and tumor progression. Our KrasG12D-IKK2F/F mice data supports
the important role of IKK2/NF-kappaB in KrasG12D induced tumorigenesis,
which suggests a possible therapeutical application of NF-kappaB inhibitors
in treating lung cancer.
In addition to Kras mutation induced lung adenocarcinoma, we are now
applying this unique lentiviral tool in the study of SCLC with appropriate
promoter driven oncogenes and siRNA combinations. We hope that our
unique mouse model will definitely simplify and accelerate the study to
understand the big signal pathway complex leading to tumorigenesis in the
lung.
Concurrent Session 6: Other Biomarkers
PR12
High-throughput protein biomarker discovery and translation
into clinical diagnostics for oncology using the SomaLogic
SOMAmer-based assay
Rachel Ostroff, Jennifer Bertino, Chris Bock, Edward Brody, Tracy Keeney,
Stephan Kramer, Bridget Lollo, Alex Stewart, Jeff Walker, Stephen Wil-
liams, Dom Zichi. SomaLogic, Inc., Boulder, CO
Secreted proteins and those released during apoptosis from tumor cells and
surrounding tissues undoubtedly contain important biologic information that
would theoretically enable early diagnosis and prognostic and therapeutic
decisions in oncology. However, there is great difficulty in finding and
quantifying such signals for large numbers of low abundance proteins.
ELISA assays are sensitive but antibodies are not available for most proteins
of interest and assays are difficult to multiplex at the level (many 100s to
1000s of analytes) required to discover novel biology. Mass spectrometry
measures many proteins, but throughput is low and the technology cannot
easily quantify low abundance proteins.
SomaLogic therefore created a highly multiplexed proteomic assay which
is continuously expanding in breadth. It currently measures 825 proteins
simultaneously from15uL blood, with a throughput equivalent to 1 million
ELISA assays per week. The average dynamic range of each protein in the
assay is3 logs – with nearly seven logs of dynamic range achieved through
multiple dilutions – and the median lower limit of quantification is below 1
pM, with many low-abundance proteins being measurable at 100 fM. The
median coefficient of variation for each protein is 5% between runs. The
outstanding assay performance arises from the selection of extremely high
affinity aptamers that bind selectively to their target proteins with very slow
off-rates. This is achieved, among other means, through incorporating
non-naturally-occurring nucleotides into the aptamers.
The platform is currently being used broadly in collaboration with phar-
maceutical and university investigators to discover serum biomarker signa-
tures for disease and therapeutic response in oncology which can be seam-
lessly translated into diagnostic products for clinical application. Preliminary
results in several cancers are promising; in lung cancer detection a signature
of 12 proteins has an area under the ROC curve of 90% for both diagnosis
of patients with suspicious pulmonary nodules and long term smokers.
Unexpected but biologically revealing proteomic responses to antiangiogenic
therapy have also been detected. Biomarker discovery opportunities leading
to diagnostics for early detection are being pursued in a variety of tumor
types, including lung, ovarian, breast, colon, pancreas, carcinoid, and mela-
noma as well as therapeutic selection and monitoring. Our experience to date
points strongly to the conclusion that the SOMAmer platform is enabling and
relevant to many important problems in biomarker discovery.
This talk was also presented as Poster B33.
PR13
Gene expression changes in the bronchial airway epithelium
of smokers with lung cancer may reflect common pathways of
tobacco-related carcinogenesis
Adam C. Gower1, Avrum Spira2, Marc E. Lenburg2. 1Boston University,
Boston, MA, 2Boston University School of Medicine, Boston, MA
Smoking causes point mutations, changes in methylation, and loss of het-
erozygosity throughout the airway, which results in altered patterns of gene
expression and can lead to the development of lung cancer. However,
although smoking accounts for 90% of lung cancer, only 15% of lifetime
smokers will develop this malignancy. One hypothesis that might explain
this is that the cellular response to tobacco smoke is qualitatively different
between smokers who do or do not develop lung cancer. Previous work has
demonstrated that numerous changes in gene expression in the cytologically
normal airway epithelium of smokers are associated with lung cancer and can
be used to build sensitive and specific biomarkers. However, the mechanisms
responsible for these changes are not well understood.
It would be useful to know if the changes in gene expression that occur in
the airway of smokers with lung cancer are reflected in other disease
processes. Recent advances in microarray technology have made it feasible
to profile genome-wide gene expression in many disease states and experi-
mental perturbations and have spurred the creation of public repositories to
store and retrieve these profiles. Several computational methods have been
introduced to query these compendia for specific patterns of differential gene
expression, but these have been limited to specific comparisons between
predefined groups. To overcome this limitation, we have developed a new
method (openSESAME; open-ended Search for Expression Signatures
Across Many Experiments) to find sets of microarrays in which a signature
of up- and down-regulated genes is coordinately differentially expressed.
This pattern-based search method does not require any prior knowledge of
sample annotation or experimental design.
As proof of principle, two previously reported signatures were used to
query 45,000 human Affymetrix microarrays from the NCBI Gene Expres-
sion Omnibus (GEO) microarray data repository. The first, a signature of
estradiol treatment in the breast cancer cell line MCF7, identified other
experiments in which MCF7 cells were treated with estrogens and anties-
trogens. The second, a signature of silencing p63 (a key regulator of
squamous epithelial differentiation), separated squamous epithelium from
lymphatic tissue and discriminated between primary and metastatic mela-
noma.
We then used openSESAME to query GEO with a 100-gene profile
created by comparing the cytologically normal airway of smokers with and
without lung cancer. This profile identified data sets comparing normal and
tumor tissue in bladder and head and neck cancers, in which tumor tissue
displayed a pattern of gene expression similar to that of the airway of
smokers with lung cancer. This is an intriguing finding, as the incidence of
bladder and head and neck cancers are both strongly associated with tobacco
use, and suggests that common tobacco-sensitive pathways may contribute to
carcinogenesis in these organs.
We conclude that openSESAME is a useful method for discovering
relevant similarities between gene expression data sets from different bio-
logical states without prior knowledge of experimental design. Furthermore,
we have found that common patterns of gene expression are present in the
airway of smokers with lung cancer and in bladder and head and neck cancer,
suggesting that common biological pathways are involved in these disease
processes.
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Plenary Session 5: Angiogenesis and the
Tumor Microenvironment
PR14
Phase II studies of ASA404 (vadimezan, DMXAA) plus
carboplatin and paclitaxel in advanced squamous and
nonsquamous non-small cell lung cancer: Blood and lymphatic
adverse events
M.J. McKeage1, M.B. Jameson2. 1The University of Auckland, Auckland,
New Zealand, 2Waikato Hospital, Hamilton, New Zealand
Background: Treatment options for patients with advanced stage non-small
cell lung cancer (NSCLC) are limited, particularly for those with squamous
histology where some agents exhibit limited efficacy or serious toxicity
concerns. Blood and lymphatic adverse events (AEs) were the most common
AEs in phase II studies of chemotherapy with ASA404 (vadimezan, 5,6-
dimethylxanthenone-4-acetic acid, DMXAA), a tumor-vascular disrupting
agent (tumor-VDA) that disrupts the existing tumor vasculature, selectively
inhibiting tumor blood flow and causing extensive necrosis of the tumor core.
Methods: Previously untreated patients with stage IIIb/IV NSCLC enrolled
in the phase II multicenter, open-label study were randomized to receive up
to six cycles of paclitaxel (P; 175 mg/m2) and carboplatin (C; AUC 6
mg/ml●min) alone or with ASA404 (1200 mg/m2). Patients enrolled in the
extension study received P/C and ASA404 (1800 mg/m2). Differences
between subgroups were calculated using Fisher’s exact test.
Results: Of 108 enrolled patients, safety data from the 104 patients included
in the safety population were pooled to compare results between histology
subgroups (squamous vs non-squamous) and treatment (P/C alone vs P/C 
ASA404). Addition of ASA404 to the standard chemotherapy regimen did
not appear to substantially increase toxicity, and there were no serious AEs
associated with bleeding, pulmonary hemorrhage or hemoptysis. The most
commonly reported grade 3/4 AEs were blood and lymphatic disorders
(n19; 18.3%). In patients receiving P/C  ASA404, rates of grade 3/4
anemia (13.6% and 4.3%, p0.32) and thrombocytopenia (13.6% and 2.2%,
p0.10) were not statistically different between squamous and nonsquamous
histologies, respectively, and the rate of neutropenia (13.6% and 13.0%,
p1.00) was similar for the two histologies. In patients with squamous
histology receiving P/C alone, there were no reports of grade 3/4 anemia,
neutropenia or thrombocytopenia, whereas these AEs occurred in 1 (4.0%),
2 (8.0%), and 1 (4.0%) patients, respectively, with nonsquamous histology
(p1.00 for each comparison). Comparison by treatment (all histologies)
showed rates of grade 3/4 blood and lymphatic AEs of 13.9% and 20.6%
(p0.59) for P/C alone and P/C  ASA404, respectively. Similarly, rates of
the individual AEs were not statistically different when ASA404 was added:
grade 3/4 anemia (2.8% and 7.4%, p0.66), neutropenia (5.6% and 13.2%,
p0.32), and thrombocytopenia (2.8% and 5.9%, p0.66) for P/C alone and
P/C  ASA404, respectively. In patients with squamous histology, P/C 
ASA404 resulted in three reports (13.6%) each of grade 3/4 anemia, neutropenia
and thrombocytopenia, which was not statistically different from the 0% rate
observed in this patient subgroup treated with P/C alone (p0.53). The non-
squamous subgroup also exhibited similar rates of grade 3/4 anemia (4.0% and
4.3%, p1.0) neutropenia (8.0% and 13.0%, p0.70) and thrombocytopenia
(4.0% and 2.2%, p1.00) for P/C alone and P/C  ASA404, respectively.
Conclusions: Addition of ASA404 to P/C was generally well tolerated in
patients with squamous or nonsquamous histology. Rates of grade 3/4 blood
and lymphatic AEs were not significantly different between the two histo-
logic subgroups of patients receiving P/C  ASA404. Similarly, the grade 3/4
AE rates in P/C-treated patients were not significantly different from those
treated with P/C  ASA404. This safety assessment should be considered
hypothesis-generating due to the retrospective nature of the analysis and small
sample size. However, combined with promising overall survival data in patients
with squamous (P/C: 5.5 months; P/C  ASA404: 10.2 months) or nonsqua-
mous histology (P/C: 11.0 months; P/C ASA404: 14.9 months), these results
support the ongoing phase III trials in first-line (ATTRACT-1) and second-line
(ATTRACT-2) NSCLC, with no restriction on histology.
This talk was also presented as Poster A22.
PR15
Identification of tumor cell-derived factors associated with
resistance to anti-VEGF therapy in non-small cell lung cancer
Laura A. Sullivan, Juliet G. Carbon, Jason E. Toombs, Rolf A. Brekken. UT
Southwestern Medical Center, Dallas, TX
Strategies that target angiogenesis are now an established anticancer para-
digm. Bevacizumab is a monoclonal antibody (mAb) that binds vascular
endothelial growth factor-A (VEGF) and prevents VEGF-induced activation
of VEGF receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2). The FDA
has approved bevacizumab for the treatment of several tumor types, includ-
ing nonsquamous non-small cell lung cancer (NSCLC). Although promising
in pre-clinical studies, bevacizumab and other antiangiogenic therapies have
only added modest gains in survival of NSCLC patients. The variation of
NSCLC response to anti-VEGF therapy suggests a complex mechanism of
drug action within different tumors, and data now indicate that some tumors
may be intrinsically resistant to bevacizumab. Therefore, the success of
anti-VEGF therapy may rely on a better understanding of genes associated
with responsiveness or resistance. We have developed a fully human mAb (r84)
that recognizes mouse and human VEGF and specifically blocks VEGF binding
to and activation of VEGFR2. Use of r84 allows the evaluation the function of
stromal-derived VEGF and VEGFR1 signaling in tumor progression and pro-
vides a useful comparison to bevacizumab treatment of NSCLC xenografts in
mice. Using xenograft models, we evaluated the efficacy of bevacizumab and
r84 to control the growth of NSCLC in vivo, and identified NSCLC cell lines
that are sensitive, display intrinsic resistance, or are moderately sensitive to
bevacizumab therapy. Tumors that were sensitive to therapy had reduced tumor
growth and final tumor weight (as compared to treatment with a non-specific
control IgG), and relevant vascular changes including decreased tumor mi-
crovessel density, lymphatic vessel density, and VEGFR2 expression. Microar-
ray analysis of sensitive and resistant cell lines have been used to generate a
preliminary gene signature that may mark relevant tumor cell derived genes
associated with response to anti-VEGF treatment. A better understanding of the
mechanisms of response to anti-VEGF therapy may lead to the development of
more effective therapies and could ultimately assist in the identification of
patients that would benefit the most from anti-VEGF strategies.
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A1
Fibroblast growth factor-9 in non-small cell lung carcinomas
Pinpin Lin1, Han Chang2, Chien-Kai Wang1. 1National Health Research
Institutes, Zhunan, Miaoli County, Taiwan, 2Chung Shan Medical Univer-
sity, Taichung, Taiwan
Fibroblast growth factor-9 (FGF-9) is a critical regulator of proliferation of
airway epithelium and mesenchymal growth during lung embryogenesis. Re-
cently we reported that FGF-9 expression was more common in adenocarcino-
mas than in squamous cell carcinomas. Our results also suggested that FGF-9
expression positively correlated with expression of aryl hydrocarbon receptor in
lung adenocarcinomas, which might promote tumor growth by modulating
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communication between tumor cells and fibroblasts. We further analyzed the
relationship between FGF-9 expression and prognosis in non small cell lung
carcinomas (NSCLC). A total of 146 patients with lung adenocarcinoma or
squamous cell carcinoma were included in the study. FGF-9 expression was
determined with immunohistostaining method. We found that FGF-9 expression
was positively associated with distant metastasis. FGF-9 expression was more
common in the late stage (IV) than in early stages (I and II). However, FGF-9
expression was not associated with 5 year-survival of these patients.
A2
Activation of c-Met by EGFR modulates invasive phenotypes
in NSCLC
Austin M. Dulak and Jill M. Siegfried. University of Pittsburgh, Pittsburgh,
PA
This abstract was presented as a short talk in Plenary Session 1. A full
abstract is printed in the Proffered Presentations section (PR1).
A3
IL-1 dependent epithelial mesenchymal transition in non-
small cell lung cancer
Eileen L. Heinrich, Miriam Dohadwala, Tonya Walser, Steven Dubinett.
University of California, Los Angeles, Los Angeles, CA
Pulmonary diseases associated with a heightened risk of lung cancer, such as
emphysema and pulmonary fibrosis, show both increased and deregulated
inflammation. Tobacco smoke exposure is associated with chronic airway
inflammation and is a strong risk factor for the development of lung cancer.
Inflammatory mediators and inflammatory cells are overexpressed in the
pulmonary microenvironment of both smokers and patients with non-small
cell lung cancer (NSCLC). Expression of interleukin 1 (IL-1) is increased
in a number of cancers, including lung cancer and is associated with tumor
aggressiveness and poor patient outcomes. A chronic increase in inflamma-
tory mediators in the lung tumor microenvironment can lead to increased
tumor promotion, invasion, angiogenesis and metastasis; however the mech-
anism by which this occurs has yet to be elucidated.
We have found that IL-1 exposure induces epithelial-mesenchymal
transition (EMT) in a subset of NSCLC cell lines. EMT is a process where
epithelial cells lose cell-cell junctions, undergo cytoskeletal reorganization
and basement membrane degradation and switch from cadherin to integrin
mediated adhesion. This transformation results in cells with a mesenchymal
phenotype. An important feature of mesenchymal cells is their ability to
migrate independently and invade locally - which are considered prerequi-
sites for metastasis. Following IL-1 exposure we see changes in cellular
morphology, disruption of the cells’ ability to form spheroids in 3-D culture
and increased motility. This is accompanied by loss of E-cadherin and an
upregulation of mesenchymal markers, particularly N-cadherin, vimentin and
Slug (SNAI2) - a transcriptional repressor of E-cadherin. Slug expression is
increased at both the mRNA and protein levels and is found via chromatin
immunoprecipitation to be bound to the E-cadherin promoter following
IL-1 exposure. Further, in NSCLC cell lines which no longer express
E-cadherin, Slug expression is elevated. Blocking Slug expression using
siRNA inhibits IL-1 mediated downregulation of E-cadherin.
IL-1 has many well-characterized effects on signaling pathways and
protein expression, including the upregulation of COX-2 which has been
shown previously to decrease E-cadherin expression. However, the IL-1
mediated downregulation of E-cadherin presented here is COX-2 indepen-
dent. Blocking COX-2 activity with celecoxib does not abrogate the IL-1
dependent E-cadherin downregulation. Additionally, others have found that the
loss of E-cadherin is associated with resistance to epidermal growth factor
receptor tyrosine kinase inhibitors which are currently in use as treatment and
have been suggested as prevention agents for NSCLC. In light of the effect
IL-1 has on E-cadherin expression, its presence in the pulmonary microenvi-
ronment may play a specific role in setting the stage for metastasis and
promoting resistance to targeted prevention and therapy.
[These studies were supported by: UCLA SPORE in Lung Cancer NCI
P50CA90388 and Tobacco-Related Disease Research Program 18DT-0005.]
A4
Hepatocyte growth factor alters the expression of the Sim1
transcription factor in non-small cell lung cancer (NSCLC)
Nicole Lee Rodriguez1, Kostyantyn Krysan1, Jerry W. Shay2, John D.
Minna2, Steven M. Dubinett1. 1University of California, Los Angeles, Los
Angeles, CA, 2UT Southwestern Medical Center, Dallas, TX
The c-Met RTK is expressed in normal lung tissue and is often overexpressed
or constitutively activated in lung cancer. Constitutive activation can be
achieved via mutations within the activation domain as well as by constant
ligand stimulation. The only known ligand for the c-Met receptor, hepatocyte
growth factor (HGF), is also found to be elevated in NSCLCs and in the
tumor microenvironment at all stages of tumor progression. HGF found in
the tumor can be attributed to tumor cells that aberrantly express HGF,
creating an autocrine signaling loop, as well as by tumor infiltrating neutro-
phils or by surrounding lung fibroblasts. The presence of c-Met overexpres-
sion or elevated HGF levels in NSCLC patients is associated with poor
prognosis, decreased overall survival, as well as increased incidence of
recurrence and metastasis regardless of tumor stage. Aberrant HGF/c-Met
signaling contributes to a number of cancer associated phenotypes: increased
cell proliferation, motility, invasion, survival, angiogenesis, and epithelial to
mesenchymal transition (EMT). These pro-cancer phenotypes are controlled
by downstream signaling pathways, which include, but are not limited to
PI3K, Rac/Rho, and MEK/Erk. NSCLC cell lines as well as non-malignant
human bronchial epithelial cell (HBEC) lines demonstrated a morphologic
change in response to HGF treatment in vitro. Gene expression array analysis
was performed on several of these HGF responsive NSCLC and HBEC lines.
Among the genes that were differentially expressed in response to HGF
exposure was the basic helix-loop- helix (bHLH) transcription factor, Sim1.
Preliminary data suggests that HGF regulation of Sim1 expression is asso-
ciated with the KRAS mutational status of the NSCLC and HBEC lines.
Sim1, HIF1, Aryl Hydrocarbon Receptor (AhR), and the Aryl Hydrocarbon
Receptor Nuclear Translocator (Arnt) are all members of the bHLH tran-
scription factor family. Sim1, HIF1, and AhR all compete for heterodimer-
ization with Arnt in order to activate or repress gene expression, often
regulating one another’s activity. The hypoxic response element (HRE) is
often activated by HIF1 during hypoxia. Promoters containing the HRE are
known to control genes that are involved in angiogenesis, proliferation, cell
adhesion, and survival. Sim1 has been shown to preferentially bind with Arnt
rather than HIF1 during normoxic conditions as well as activate gene expres-
sion in promoters containing the HRE. AhR is a ligand dependent transcription
factor that is activated by chemical ligands in the cytosol and then enters the
nucleus in order to regulate downstream gene targets. Benzoapyrene (BaP) is
a known ligand of AhR, and once bound to AhR, induces its own metabolism
into a toxic carcinogen. Sim1 can mediate repression of AhR genes by compet-
ing for Arnt binding. Alterations in Sim1 expression may allow for increased
expression of HRE under normoxic conditions, in contrast, Sim1 downregula-
tion may allow for chemicals, such as BaP to become metabolized, and
therefore become carcinogenic. Studies are now in progress to determine the
importance of HGF-dependent regulation of Sim1 in tumorigenesis.
A5
A putative tumor-initiating progenitor cell population predicts
poor prognosis in smokers with non-small cell lung cancer
Aik T. Ooi1, Vei Mah1, Derek W. Nickerson1, Jennifer L. Gilbert1, Vi Luan
Ha1, Ahmed E. Hegab1, Steve Horvath1, Mohammad Alavi1, Erin Maresh1,
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David Chia1, Adam C. Gower2, Marc E. Lenburg2, Avrum Spira2, Tonya C.
Walser1, William D. Wallace1, Steven M. Dubinett1, Brigitte N. Gomperts1.
1University of California, Los Angeles, Los Angeles, CA, 2Boston University,
Boston, MA
Background: Smoking is the most important known risk factor for the
development of lung cancer. Tobacco exposure results in chronic inflamma-
tion, tissue injury, and repair. A recent hypothesis argues for a stem/
progenitor cell involved in airway epithelial repair that may be a tumor-
initiating cell in lung cancer, and which may be associated with recurrence
and metastasis. In the airway epithelium, cells that express keratin 5 (K5) and
its intermediate filament binding partner keratin 14 (K14) are considered to
be progenitor cells in the adult large airways at steady state and during
airway epithelial repair.
Methods:We used immunostaining on mouse and human lung tissues, along
with a human lung cancer tissue microarray (399 patients) to identify
subpopulations of airway epithelial stem/progenitor cells under steady state
conditions, normal repair, aberrant repair with premalignant lesions and lung
cancer, and their correlation with injury and prognosis. Quantitative real-time
PCR, Western blots, and analyses of publicly available lung cancer microar-
ray expression data sets were used to validate the observed expression
patterns of K5 and K14. A heterotopic, syngeneic murine tracheal transplant
model was used to examine the repairing processes of the airway epithelia.
Results: We found K5 and K14 expression in the steady state submucosal
glands and gland ducts. In the basal layer of normal airway pseudostratified
columnar epithelium, however, K14 expression was absent while K5 expres-
sion was prominent. In a mouse model of repairing airway epithelium, we
identified a population of progenitor epithelial cells expressing K14 that was
temporally involved in normal repair after injury. Dysregulated repair re-
sulted in persistence of K14 cells in the airway epithelium of premalignant
lesions. The presence of K14 cells in non-small cell lung cancer (NSCLC)
samples predicted poorer outcomes (P  0.004). This was especially true in
patients who are smokers (P  0.001), with predictive value more pro-
nounced in current smokers (P  0.01) compared to former smokers (P 
0.04). In never smokers, the presence of K14 cells had no predictive value
for outcome. We found that the presence of K14 cells in the primary
tumors of current smokers was associated with metastatic disease (P 0.02).
We further found that nonadenocarcinoma NSCLCs from current smokers
with metastases had a higher percentage of K14 cells in the primary tumor
sites. (P  0.004). Examination of K14 expression in distant metastatic sites
revealed a significant increase in the number of K14-expressing cells in
metastases compared to the primary sites in squamous lung cancer, but not
in other histologic subtypes.
Conclusions: Our data suggest that dysregulated repair after injury leads to
a self-renewing K14 progenitor cell population in premalignant lesions.
The presence of K14 progenitor airway epithelial cells in NSCLC pre-
dicted a poor prognosis and the strongest predictive value was in smokers,
where it correlated with metastasis. This suggests that reparative K14
progenitor cells are the putative tumor-initiating cells in this subgroup of
smokers with NSCLC. Furthermore, identifying the genetic and epigenetic
changes that occur in the K14 cell population that lead to dysregulated
repair may result in the discovery of novel biomarkers and therapeutic targets
for chemoprevention in smokers.
A6
Functional erythropoietin receptor is undetectable in solid
tumor cell lines including non-small cell and small cell lung
carcinoma cell lines
Angus M. Sinclair, Susan Swift, Aaron Ellison, Paul Kassner, Ian McCaf-
fery, John Rossi, C. Glenn Begley, Steve Elliott. Amgen, Inc., Thousand
Oaks, CA
Several recent clinical studies using erythropoiesis stimulating agents (ESAs)
to prevent or treat anemia in cancer patients have reported worse outcomes
compared with the placebo arm. One hypothesis proposed to explain the
adverse outcomes observed is that ESAs directly stimulate erythropoietin
receptors (EpoR) expressed on tumor cells to enhance tumor growth and/or
survival. However, preclinical data in support of this hypothesis are conflict-
ing and confounded by multiple methodological issues including the use of
nonspecific anti-EpoR antibodies that provide false positive results. To
further investigate the potential for EpoR expression on the tumor cell
surface we have performed studies to examine EpoR expression and function
in NSCLC and SCLC cell lines as well as other tumor cell types.
An analysis of EpoR mRNA levels in 209 human cell lines representing 16
tumor types (including 31 NSCLC and 12 SCLC cell lines) was initially
performed. Though EpoR mRNA was detected in the majority of cell lines,
levels were generally very low with only 5 solid tumor cell lines having a
maximum of approximately 5–10% that of a rHuEpo responsive hematopoi-
etic positive control cell line UT-7/Epo. EpoR protein production was
subsequently evaluated in a subset of 61 solid tumor cell lines, including 11
NSCLC and 9 SCLC cell lines, using a novel anti-EpoR antibody A82 that
is specific and sensitive for the immunoblot detection of EpoR. Using a
semi-quantitative analysis, EpoR positive hematopoietic control cells lines
had an estimated 10,000–100,000 EpoR homodimers/cell when whole cells
lysates were examined. In contrast, 56 of 61 lines had EpoR protein levels
below 400 homodimers/cell. Solid tumor cell lines with the highest levels of
EpoR protein were SCLC cell lines NCI-H510A and DMS-79 (1,600–3,200
homodimers/cell), NSCLC cell lines NCI-H1299 and NCI-H661 (1,600–
3,200 homodimers/cell) and ovarian carcinoma line A2780 (400–1,600
homodimers/cell).
To further investigate the potential for EpoR expression on the cell surface
125I-rHuEpo binding studies and signaling studies were performed. Surface
EpoR as determined by specific binding of 125I-rHuEpo was only detected in
one NSCLC carcinoma cell line (NCI-H661) at levels 6% that of positive
control UT-7/Epo cells. However, though cell lines signaled in response to
positive control growth factors (rHuHGF, rHuEGF and rHuIGF), rHuEpo
was unable to induce phosphorylation of downstream molecules (STAT5,
AKT, ERK1/2 and S6RP) even when suprapharmacologic doses of 300 U/ml
rHuEpo were used in NCI-H661 and other tumor lines. In addition, EpoR
knockdown analyses using siRNAs did not affect viability in three solid
tumor cell lines examined including a NSCLC cell line (NCI-H1299) and
two ovarian cell lines previously reported to express functional EpoR
(A2780, SK-OV-3). Taken together, these results do not support the hypoth-
esis that EpoR is functionally expressed in lung carcinomas as well as other
solid tumors.
A7
Aldehyde dehydrogenase selects for Notch-signaling-dependent
lung cancer stem cells
James P. Sullivan1, Monica Spinola1, Michael Dodge1, Maria G. Raso2,
Boning Gao1, Chunxian Huang1, Katja Schuster1, Pier P. Scaglioni1, Ignacio
I. Wistuba2, John D. Minna1. 1UT Southwestern Medical Center, Dallas, TX,
2UT M. D. Anderson, Houston, TX
Cancer stem cells (CSCs) are hypothesized to be rare, drug resistant,
stem-like tumor cells that drive tumor progression and metastasis through
aberrant self-renewal and differentiation. Although CSCs have been de-
scribed in leukemia, breast, brain and colon cancers, little is currently known
about the biology of human lung CSCs. This is due in large part to the lack
of validated lung CSCs markers. Previous studies in breast, brain and colon
cancers have demonstrated that rare tumor cells with elevated aldehyde
dehydrogenase activity (ALDH), as well as elevated expression of
ALDH1A1, are enriched in CSCs. Therefore we set out to investigate the
expression and activity of aldehyde dehydrogenase as a selectable marker for
lung CSCs. Here we report that non-small cell lung cancer (NSCLC) cells
with increased ALDH have stem/progenitor properties. Using a flow cyto-
metric based assay, an ALDH subpopulation was detected in 5/5 resected
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NSCLC tumors and 24/27 NSCLC cell lines. Initial experiments assaying the
expression of ALDH1A1, the protein that drives ALDH in lung cancer, in
282 clinically annotated NSCLC samples revealed a significant correlation
between ALDH1A1 expression and reduced overall survival time, suggest-
ing a link between ALDH cells and prognosis. The aggressive phenotype of
the ALDH cell subpopulation was confirmed when ALDH lung cancer
cells isolated by FACS, were observed to generate larger tumors more
frequently in immunodeficient mice compared to the majority of ALDH-
lung tumor cells. Furthermore, ALDH lung cancer cells possessed an
enhanced clonogenic capacity in vitro. In addition, only the ALDH lung
fraction was observed to possess the stem cell attribute of self-renewal,
generating both ALDH and ALDH- cell in culture whereas this ability was
restricted in the majority of ALDH- lung cancer cells. Finally, the analysis of
stem cell self-renewal genes by qPCR revealed elevated levels of Notch
pathway transcripts in ALDH lung cancer cells compared to the bulk
ALDH- lung cancer cell population, suggesting increased pathway activity in
the ALDH fraction. Suppression of the Notch pathway by treatment with
either a gamma-secretase inhibitor or stable expression of shRNA against
Notch3 transcripts resulted in a significant decrease in ALDH cells,
suggesting Notch signaling may play a role in ALDH lung cancer cell
maintenance. Taken together these findings suggest that ALDH NSCLC
cells represent a population of aggressive lung CSCs and highlight the
therapeutic potential for targeting Notch signaling in controlling lung CSC
populations.
A8
Targeting Rac1 GTPase benefits both human lung adenocarcinoma
stem cell and non-stem cell therapies
Shailaja Akunuru, James Johnson, Yi Zheng. Children’s Hospital Research
Foundation, University of Cincinnati, Cincinnati, OH
This abstract was presented as a short talk in Plenary Session 3. A full
abstract is printed in the Proffered Presentations section (PR7).
A9
GEP100 binding to HER2 receptor promotes lung cancer
invasion and metastasis
Toshi Menju1, Shigeru Hashimoto2, Ari Hashimoto2, Tsuyoshi Takahashi1,
Ei Nakayama1, Ryutaro Kikuchi1, Masashi Ishikawa1, Masashi Kobayashi1,
Jiro Kitamura1, Makoto Sonobe1, Ryo Miyahara1, Kenichi Ookubo1, Hiroshi
Date1, Hisataka Sabe2. 1Kyoto University, Sakyo-Ku Kyoto, Kyoto, Japan,
2Hokkaido University, Sapporo, Hokkaido, Japan
Introduction: HER2 receptors are well known to be a poor prognostic factor
in some of epithelial tumors, including breast cancer and lung cancer. We
have shown that epidermal growth factor receptor signaling leads to breast
cancer invasion via EGFR-GEP100-Arf6 pathway in previous reports. Here
we have examined whether HER2 receptor interacts GEP100 and its signal-
ing leads to lung cancer invasion and / or metastasis through Arf6.
Methods: In vitro co-immunoprecipitation (IP) of HER2-EGFP with GST-
fused pleckstrin homology (PH) domains of GEP100 and ARNO, both of
which are known to be a guanine exchanging factor for Arf6, were analysed
by glutathione-beads pulldown and anti-GFP immunoblots. HER2-EGFP
and haemagglutinin (HA)-tagged GEP100 were reconstitutively co-ex-
pressed, and the cell lysate with anti HA antibody was co-immunoprecipi-
tated by pulldown assay. Co-IP with the anti-GEP100 antibody of the lysate
of H522 lung adenocarcinoma cells, which endogenously overexpressed
HER2 receptor, was performed in the same way. To confirm the importance
of this binding in invasive mechanisms in lung cancer, in vitro Matrigel
invasion assays were performed in H522 cells according to three conditions
as follows: the addition of 10nM of Tyrphostin AG825 for 72 hours which
was a selective HER2 inhibitor, the silencing of GEP100 by siRNA method,
and the blockage of HER2-GEP100 binding by exogenous expression of the
PH domain of GEP100, truncated form. To obtain evidence supporting the
involvement of GEP100 in the invasive or metastatic activities of human
lung adenocarcinoma, immunohistochemical analyses of GEP100 and HER2
expression for 112 cases of resected clinical specimens of primary lung
adenocarcinoma were performed by using the standard avidin-biotin-perox-
idase complex method. All samples were reviewed independently by two
investigators and scored with the maximum intensity of tumor lesion:
GEP100; 02, HER2; 03. It was also judged that GEP100 expression was
negative (0, 1) and positive (2), and HER2 expression was negative (0, 1) and
positive (2, 3). Clinical data together with these scores were statistically
analysed with ANOVA, or chi-square test. Results of these analyses were
judged as significant when P-value was less than 0.05.
Results: The reconstitution system showed that GEP100, not ARNO, bound
HER2 receptor through its PH domain and that the starvation for 24 hours
weakened its binding. Co-IP and immunoblots showed that GEP100 endo-
genously binds HER2, but neither EGFR nor HER3, in this cell line. It
suggested that the signal transduction through GEP100 was mainly origi-
nated from HER2 signaling in this cell line, neither from EGFR nor HER3.
The deprivation of HER2 signaling, expression of GEP100 or the binding
between them all decreased in vitro invasive activities in H522 cells by about
4060%. These results showed that a part of lung adenocarcinoma cells
utilized HER2-GEP100 signal transduction in invasive mechanisms. Immu-
nohistochemical analyses showed that the positivity of GEP100 and HER2
was 49.1% (55 / 112: 0; 28, 1; 29, 2; 55) and 40.7% (46 / 112: 0; 28, 1;
38, 2; 27, 3; 19), respectively. The distribution of pathological T factor
and N factor with 112 cases was as follows: T1/ T2/ T3/ T4; 72/ 27/ 6/ 7, N0/
N1/ N2; 84/ 10/ 18. The immunohistochemical scores of GEP100 and HER2
protein were both statistically higher in pN2 cases compared with pN1 cases.
Furthermore, in cases of very strong HER2 expression (3), positive
expression of GEP100 tended to be correlated with the high frequency of
lymphatic metastasis (100% vs 61.5%, p0.08).
Conclusion: GEP100 binding to HER2 receptor promotes lung cancer
invasion and metastasis. Taking account of the mediation of GEP100 in
invasive mechanisms related with both EGFR and HER2 signaling, this
GEP100 molecule appears to be a quite promising target to prevent cancer
invasion and metastasis.
Early Detection, Chemoprevention, Functional
and Molecular Imaging
A10
Protein biomarker panel distinguishes malignant lung cancer
lesions from benign pulmonary nodules
Charles E. Birse1, William M. FitzHugh1, Jenny Heidbrink1, Gulshan Dhari-
wal1, Thomas Pollard2, Luke Doiron3, Marshall Schreeder3, Steve M.
Ruben1. 1Celera, Alameda, CA, 2East Tennessee Cardiovascular Surgery
Group, Knoxville, TN, 3Conversant Healthcare Systems, Huntsville, AL
Introduction: A considerable percentage of smokers considered at high risk
for developing lung cancer demonstrate solitary pulmonary nodules upon
radiologic imaging. Biomarkers may have considerable value at various
stages in detection/diagnosis of lung cancer: in screening high risk individ-
uals for subsequent imaging analysis, in combination with imaging technol-
ogies to improve resolution of malignant nodules and in a post-imaging
setting as a means of assisting physicians in management of pulmonary
nodules. We have employed a novel mass spectrometry (MS)-based ap-
proach to identify a collection of biomarkers which we have subsequently
shown to be differentially expressed in the circulation of patients with
non-small cell lung cancer (NSCLC) relative to appropriate controls. Here
we demonstrate that a panel of these biomarkers can accurately distinguish
serum specimens from patients with malignant pulmonary lesions from those
with benign nodules.
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Methodology: Discovery of candidate biomarkers was achieved through
liquid chromatography/ mass spectrometry (LC/MS). Candidate biomarkers
identified by MS were screened using ELISA analysis in a pilot set of plasma
samples derived from 15 individuals with NSCLC and 15 healthy controls.
Subsequent validation was performed on sera collected from subjects with
benign solitary pulmonary nodules and subjects with lung cancer. Malignant
samples represented all stages of disease (I-IV) and major histological cell
types. Benign and malignant nodules ranged in size from 0.4 cm-3.8 cm and
0.5–9.1 cm respectively.
Results : From 500 cell surface/secreted proteins expressed at elevated
levels in lung carcinoma, cell lines and conditioned media by MS analysis,
a panel of 9 biomarkers was assembled that detected lung cancer with high
performance. These 9 markers were then tested on sera collected from
patients with pulmonary nodules (malignant or benign). In a preliminary
analysis, the 9 marker panel accurately distinguished benign lesions (93%
sensitivity) from malignant cases (92% sensitivity). Collection and analysis
of additional samples is underway as part of an ongoing prospective study.
Conclusion: A panel of biomarkers derived from proteomic analyses of lung
tumors and cell lines was shown to be expressed at elevated levels in sera
from lung cancer patients, but not in the sera of healthy controls or
individuals with benign pulmonary nodules. The ability of this biomarker
panel to differentiate benign from malignant solitary pulmonary nodules
opens up opportunities for development of tests suitable for a variety of
diagnostic applications in lung cancer.
A11
Different gene expression profiles between current and former
smokers in lung squamous carcinogenesis
Celine Mascaux1, Christopher Coldren1, Benjamin Haibe-Kains2, Ge´raldine
Anthoine2, Annick Haller2, Vincent Ninane3, Arsene Burny4, Jean-Paul
Sculier2, Fred R. Hirsch1. 1University of Colorado Denver, Denver, CO,
2Institut Jules Bordet, Brussels, Belgium, 3CHU Saint Pierre, Brussels,
Belgium, 4Faculty of Agronomic Sciences, Gemboux, Belgium
Introduction: The study of the molecular biology of the lung carcinogenesis
would help finding candidate targets for early diagnosis and chemopreven-
tion study. Recently, a chemoprevention study showed differences in re-
sponses to Iloprost between current and former smokers (R. Keith, 13th
WLCL, abstract M30.1). The purpose of the current study is to characterize
genomic profiles discriminating current and formers smokers in the lung
squamous carcinogenesis based on previous studies on the evolution of gene
expression profiles during the successive steps of lung squamous carcino-
genesis (C. Mascaux, 13th WLCL, abstract PRS.2).
Material and Methods: A total of 122 human bronchial biopsies at all
successive stages of lung squamous carcinogenesis obtained by fluorescence
bronchoscopy among 74 high risk individuals were analyzed by gene
expression microarrays. The 40/34 current/former smokers were distributed
in histological groups as following: 8/6 in normal normofluorescent, 8/6 in
normal hypofluorescent, 7/8 in hyperplasia, 5/10 in metaplasia, 8/5 in mild
dyslasia, 7/8 in moderate dysplasia, 1/10 in severe dysplasia, 5/8 in carci-
noma in situ and 5/9 invasive squamous cell carcinoma.
Results: In total, 740 genes were found significantly differentially expressed
between current and former smokers (minimal fold change 1.5, FDR of 0.05,
ANOVA 1-way Welch’s t test). The most significantly related canonical
pathways (ingenuity pathways analyses) to these 740 genes was the pathways
related to the metabolism of xenobiotic by cytochrome CP450 eg CYP1A1,
CYP2A6, ALDH1L1. Genes modified in current smokers were also related
to cancer genes like metallopeptidases, IGF binding proteins and to cell
growth and proliferation genes, eg EGF or apoptosis, eg survivin. We
compared genes which differed between current and former smokers in our
data set of pre-invasive lesions (performed on Agilent platform, two colors
based arrays, RNA extracted from the whole biopsy, samples from lower
airways, different morphological steps of preneoplasia) with data previously
published on normal bronchial epithelium (performed on Affymetrix plat-
form, one color based arrays, RNA extracted from cells obtained by brush-
ing, samples from upper airways, normal tissue) (Spira, PNAS 2004). The
transcripts up-regulated in current smokers as compared with former smokers
are consistant with Spira’s data (normalized enrichment score (NSE) 1.43,
FDR 19%). The transcripts downregulated trend in the same direction that
Spira’s data (NSE 0.84) but do not reach significance. Genes involved in
transition between different morphological steps of lung squamous carcino-
genesis were also significantly correlated to those induced by smoking and
particularly when bronchial mucosa is transformed in metaplasia.
Conclusions: Genes differentially expressed between current and former
smokers during lung carcinogenesis, includes genes involved in metabolism
of xenobiotic by cytochrome CP450 and genes related to cancer and cell
proliferation. The effects of cigarette smoke exposure in the upper and lower
airway, as well as its effects on normal epithelial cells and on preneoplasia
are related. Genes differentiating current and former smokers are also
correlated to transition between steps of squamous carcinogenesis.
Celine Mascaux is a postdoctoral researcher of the F.R.S-FNRS (National
Fund of Scientific Research) in Belgium and a research fellow of the IASLC
(International Association for the study of Lung Cancer).
A12
A potential panel of markers for differentiating high- from
low-grade lung neuroendocrine tumors
Nava K. Nawaz1, Azadeh Stark1, Nikita Patel1, Fan Lin2, Conrad Schuerch2.
1Center for Health Research, Geisinger Medical Center, Danville, PA,
2Geisinger Medical Center, Danville, PA
Background: Distinction of low-/intermediate-grade neuroendocrine tumors
(carcinoid and atypical carcinoid) from a high-grade neuroendocrine carci-
noma (small-cell carcinoma and large-cell neuroendocrine carcinoma, “LC-
NEA” of the lung can be challenging, especially in small biopsy specimens.
The accurate diagnosis has critical clinical implications since patients diag-
nosed with a low or intermediate grade tumor would be surgical candidates
and patients diagnosed with a high grade carcinoma (small cell carcinoma
and LCNEA) would be more likely to be treated with chemotherapy.
Expression of biomarkers potentially can provide diagnostic values. CD117
(KIT-C-KIT), a cytokine receptor and KOC (K hemology domain), a
member of the insulin-like growth factor-II protein, have been reported to be
overexpressed in high grade neuroendocrine tumors of the lung. Ki-67, a
proliferation index that is expressed in rapidly dividing cells has been
reported as a valid biomarker for tumor of malignant phenotype. The VHL
gene product (pVHL) is a tumor suppresser gene and a part of an E3
ubiquitin ligase complex that targets the alpha subunits of the heterodimeric
transcription factor HIF (hypoxia-inducible factor) for degradation in the
presence of oxygen. The p16 (INK4A/MTS-1/CDKN2A), is a tumor sup-
presser and a major target in carcinogenesis. It functions by binding to and
thereby inactivating the cyclin D-cyclin-dependent kinase 4/6 complex. It
blocks the transcription of several cell-cycle regulatory proteins that results
in cell cycle arrest. Given the need for a more accurate diagnostic assessment
than histologic evaluation of specimens per se, we evaluated expression of
these biomarkers as a panel.
Method: We studied 42 consecutive cases of neuroendocrine tumors of the
lung (20 small cell carcinomas, 7 large cell neuroendocrine carcinomas, 12
carcinoids and 3 atypical carcinoids) with the primary objective of compar-
ing the expression of the panel of biomarkers (CD117, KOC, Ki-67, pVHL
and p16) between the low and high grade neuroendocrine tumors of the lung.
Tissue micro arrays were constructed and expression of each biomarker was
evaluated using immunohistochemistry. Staining was standardized and
scored as “0/Nenegative”, “1/Focal”, “2/ 30% or  cells staining and
“3/ 50% 100% cells staining”. For the purpose of the present study,
expression of each biomarker was dichotomized as either positive or nega-
tive. A specimen was scored as “0” or “1” was classified as negative, while
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a specimen with scores of “2” or “3” as positive. In estimating the
likelihood of expression of the panel of biomarkers by histopathologic
diagnosis, specimens were categorized into low grade (atypical carcinoid and
carcinoid) and high grade (LCNEA and small cell carcinoma). Two-sided
non-parametric statistical analyses were performed using the SAS v. 9.3
(SAS Institute, Cary, NC).
Results: The overall distribution of cases demonstrating overexpression of
KOC, p16 and Ki67 was significantly different among the four histologic
categories of neuroendocrine cases. No significant difference was observed
for the CD117. The probability for overexpression of Ki-67 (OR13.85,
95% CI 3.34–57.47, p0.0003), p16 (OR3.52, 95% 1.75–7.11, p0.0004)
and KOC (OR4.24, 95% CI 1.88–9.56, p0.0005) while, the pVHL
overexpression in high grade relative to low grade neuroendocrine cases was
significantly lower (OR0.31 95% CI 0.12–0.84, p.022). We detected
statistical significance for the probability of joint overexpression of three of
the biomarkers [p16 and KOC and Ki 67] in small cell carcinoma relative
to atypical carcinoids (OR2.53. 95% CI 1.24–5.17, p.011).
Conclusion: Findings from this pilot project suggest that Ki-67, KOC and
p16 are an effective antibody panel in differentiating low/intermediate grade
neuroendocrine tumors from a high grade neuroendocrine carcinoma.
A13
Blood-based biomarker profiles for detecting lung cancer
Gina Lee1, Jay M. Lee1, Brian K. Gardner1, Tonya C. Walser1, Kostyantyn
Krysan1, P.S. Pak1, Jenny Mao2, Saswati Hazra1, Steven M. Dubinett1.
1David Geffen School of Medicine at UCLA, Los Angeles, CA, 2New Mexico
Veterans Affairs Health Care System, Albuquerque, NM
This abstract was presented as a short talk in Plenary Session 2. A full
abstract is printed in the Proffered Presentations section (PR3).
A14
Low-dose CT irradiation increases lung tumorigenesis in a
Ki-ras driven mouse model: Results from a pilot study
Mark S. Miller, Joseph E. Moore, John Olson, Nancy D. Kock, J. Gregory
Zora, Kenneth Wheeler, Michael T. Munley. Wake Forest University School
of Medicine, Winston-Salem, NC
Annual low-dose CT has been studied to determine its value for screening
asymptomatic individuals that are at high risk for lung cancer (i.e., significant
smoking history). However, there are unknown risks associated with CT
screening for lung tumors, particularly in individuals with a significant
smoking history, because the low energy ionizing radiation employed has the
potential to initiate, promote, and/or accelerate the growth of lung tumors.
We determined the effect of clinically relevant CT screening procedures on
the potential to cause radiation-induced carcinogenesis in a transgenic mouse
model. In this model, treatment with 500 ug/ml of doxycycline (DOX) results
in inducible, lung specific expression of the human Ki-rasG12C allele and the
development of benign focal hyperplasias and adenomas following 9–12
months of treatment. This model thus represents the earliest stages of lung
tumorigenesis, where the asymptomatic smoker or ex-smoker contains
smoke-induced genetic damage in the lung parenchyma but have small,
undetectable lesions. Starting one week after initiation of DOX treatment,
mice received weekly doses of 0, 5, 15, or 25 mGy of CT radiation once per
week for four weeks in a clinical GE LightSpeed multi-detector row (8-slice)
CT scanner. Follow-up imaging to monitor tumor growth was performed by
CT or with a 7T magnetic resonance imaging (MRI) device 3, 6, and 9
months after the last fraction of irradiation. The mice received doses of
radiation ranging from 20 to 100 mGy from the 4 fractionated doses, and a
total of 80 to 160 mGy when the radiation exposures from the later screening
doses are included. At 9 months post-irradiation mice were euthanized by
CO2 asphyxiation/exsanguination, and the number and size of lesions from
imaging data and histological examination were determined. We successfully
visualized and measured lung tumors  0.3 mm using the 7T MRI, although
tumors near the heart were difficult to distinguish. Mice developed both
individual tumors and a small percentage of coalesced tumors (rasG12C
transgene. Our preliminary data on a small sample size suggested that in
mice expressing the mutant Ki-ras transgene, exposure to low doses of CT
irradiation results in a significant increase in both tumor multiplicity and
tumor size, with no apparent dose response relationship. Tumor multiplicity
increased 57% (p0.01) from 16.1 	 4.7 (expressed as mean 	 S.E.) in
unirradiated mice to 25.2 	 11.6 in irradiated mouse; tumor size increased
10% (p0.012) from 0.7	 0.02 mm in unirradiated mice to 0.77	 0.02 mm
in irradiated mice. There was no statistically significant difference in the
number of coalesced tumors across the experimental groups. Our preliminary
results from this pilot study suggest the possibility that screening of smokers
and ex-smokers with low dose CT might result in an increased lung tumor
incidence as a result of the interaction of radiation with the already damaged
lung epithelial cells. Currently, additional mice are being accrued into the
study; histopathology analyses and analyses for oxidative stress and DNA
damage are also ongoing in our laboratory. Studies are continuing in our
laboratory with additional mouse models to provide more definitive data in
this area. (Supported by NIH grant CA136910 and CCCWFU/Radiation
Oncology Pilot Grant).
A15
High-throughout library screening identifies phytochemical
inducers of phase II metabolism enzymes GSTP1 and NQO1
in human lung cells
Xiang-lin Tan, Miao Shi, Aldo Massimi, Weiguo Han, Simon Spivack.
Albert Einstein College of Medicine, Bronx, NY
Many phytochemicals possess antioxidant and cancer-preventive properties,
some putatively through phase II metabolism-mediated mutagen/oxidant
quenching. However, in studies to date, most candidate agents are not active
in human lung cells. In vitro and in vivo screening studies for discovery are
clearly needed for new, more potent chemopreventive agents for lung cancer.
Here we applied an mRNA-specific gene expression-based high-throughout
screening approach to identify phytochemical inducers of phase II metabo-
lism enzymes GSTP1 and NQO1 in primary normal human bronchial
epithelial (NHBE) cells and immortalized human bronchial epithelial cells
(HBEC). We have screened 800 compounds in the MicroSource Natural
Products Library for inducers of GSTP1 and NQO1 expression, and identi-
fied 2, 3-dihydroxy-4-methoxy-4’-ethoxybenzophenone, triacetylresveratrol,
ivermectin, sanguinarine sulfate, and daunorubicin as new inducers for
GSTP1 and NQO1 mRNA expression. Consistent with this effect, the
induction of NQO1 protein expression by immunoblot was found for all
these agents in both HBEC and NHBE cells at the same concentration that
induced NQO1 mRNA expression. However, GSTP1 protein expression did
not significantly change with any selected agents. Proliferation/viability
assays showed that HBEC and NHBE were significantly inhibited by
ivermectin, sanguinarine sulfate, and daunorubicin. These data demonstrate
the feasibility of high-throughput screening for inducers of NQO1 Moreover,
the data identify 2, 3-dihydroxy-4-methoxy-4’-ethoxybenzophenone and
triacetylresveratrol as the most potent and low toxicity inducers [3–6-fold,
at the protein level], implying they are potential new agents for further in
vitro and preclinical in vivo testing for prevention of oxidant-related disease.
Model Systems: In vivo and in vitro
A16
A novel loss-of-function screen identifies Wt1 as a key regulator of
lung cancer driven by oncogenic K-ras
Silvestre Vicent1, Ron Chen1, Leanne C. Sayles1, Chenwei Lin1, Randal G.
Walker1, Anna K. Gillespie1, David E. Root2, Aravind Subramanian2, Greg
Abstracts Journal of Thoracic Oncology • Volume 5, Number 6, Supplement 3, June 2010
Copyright © 2010 by the International Association for the Study of Lung CancerS230
Hinkle2, Xiaoping Yang2, Vicki Huff3, William C. Hahn2, E. Alejandro
Sweet-Cordero1. 1Stanford University, Stanford, CA, 2Broad Institute of
Harvard and MIT, Cambridge, MA, 3UT M. D. Anderson, Houston, TX
K-ras is the most frequently mutated human oncogene in lung cancer, with
approximately 20% of patients presenting mutations in this gene. Previous
work had identified a K-ras specific signature, representative of K-ras driven
lung cancer tumors, that was common to mouse and human. In the present
study, we tested the relevance of this signature and its upstream transcrip-
tional regulators using a novel loss-of-function screen with the goal to
identify genes that may be potential therapeutic targets in lung cancers in
which K-ras is mutated. Using this approach, we identified Wt1 as a critical
gene that determines the outcome of oncogenic K-ras expression. In brief,
loss of Wt1 had little effect on cell proliferation of wild-type K-ras cells but
significantly impaired growth of both epithelial and mesenchymal mutant
K-ras cells. In addition, Wt1 knock-down in K-ras-driven mouse lung cancer
cells by two independent shRNAs impaired cell viability, induced number of
Annexin-V positive cells and increased the number of cells in S-phase with
regard to control cells. Moreover, these cells formed significantly smaller
tumors than control cells when subcutaneously injected in immunodeficient
mice. The relevance of these findings to K-ras driven oncogenesis in vivo
was tested using a conditional mouse model of lung cancer where K-ras is
activated and Wt1 is deleted upon intranasal infection with Adenoviral Cre
recombinase. Using this model, we demonstrated that Wt1 loss leads to
decreased tumor burden in K-ras driven lung adenocarcinoma. To extend
these observations to human lung cancer, we showed that shRNAs against
Wt1 significantly impaired cell viability of human NSCLC cell lines depen-
dent on oncogenic K-ras. Lastly, Wt1 inactivation in primary cells with
defined K-ras mutations uncovered a gene expression signature which was
prognostic of survival only in K-ras-dependent lung cancer patients. These
observations reveal a novel role for Wt1 as a key regulator of the genetic
network downstream of oncogenic K-ras in lung cancer, and suggest that
specific pathways downstream of Wt1 could be exploited to target cells
expressing oncogenic K-ras.
A17
Transforming growth factor-beta type II receptor deficiency
promotes invasion and metastasis of lung adenocarcinoma
tumors in the oncogenic Kras model
Steven Albelda1, Alain Borczuk2, Rebecca L. Toonkel2, Charles A. Powell2.
1University of Pennsylvania School of Medicine, Philadelphia, PA, 2Colum-
bia University School of Medicine, New York, NY
Introduction: The role of transforming growth factor-beta signaling in
promoting or suppressing carcinoma progression and metastasis is context
dependent. In well differentiated human lung adenocarcioma tissues and in
animal models of breast cancer, loss of expression of the TGF-beta type II
receptor (TBRII) is associated with tumor invasion and progression. We
hypothesized that loss of TBRII in lung adenocarcinoma cells in a controlled
animal model would directly increase invasion and metastasis in vivo.
Experimental Procedures: We crossed LSL-KrasG12D/ mice with mice
conditionally inactive for Tgfbr2 (TBRII flox/flox) to generate LSL-
KrasG12D/ TBRII flox/flox animals in C57/BL6 background. Animals
were then treated with intranasal adenovirus expressing Cre and tumor
progression assessed. Results. Morphology. In LSL-KrasG12D mice that
were heterozygous for the TBRII flox allele, we saw no effect on histology
or mortality compared to TBRII wildtype (Kras/TBRIIwt) animals. In
LSL-KrasG12D mice that were homozygous for the TBRII flox allele
(Kras/TBRII-/-), we noted marked differences in mortality and in tumor
histology. Survival was shortened in Kras/TBRII-/- animals (mean 32 days)
vs. Kras/TBRIIwt (mean 78 days), p  0.0001. We examined tumor
morphology with a panel of immunostains. TTF-1, CK18, and TBRII
staining confirmed that tumors were comprised of lung epithelial cells that
were deficient of TBRII expression in Kras/TBRII-/- mice. Elastin and
trichrome staining showed extensive tumor cell invasion into basement
membranes and vessels, as well as marked deposition of desmoplastic stroma
with SMA myofibroblasts and CD31 microvessel formation in Kras/
TBRII-/- animals. Lymph node metastases were detected in the mediastinum
of 60% of the Kras/TBRII-/- mice and in none of the Kras/TBRIIwt animals.
Molecular Mechanisms: To identify the TGF-beta signaling pathway me-
diators important for lung adenocarcinoma invasion and metastasis in the
Kras/TBRII-/- model, we performed gene expression profiling of laser
capture microdissected tumor cells. Unsupervised hierarchical clustering
showed clear discrimination of Kras/TBRII-/- tumors vs. Kras/TBRIIwt
tumors. We performed LS/KS permutation test and Efron-Tibshirani’s GSA
maxmean test to identify differentially expressed molecular function gene
ontology classes. We found an overrepresentation of biological process
classes: Immune response (regulation of leukocyte activation, regulation of
lymphocyte proliferation); cell-matrix adhesion; and epithelial development.
To examine the immune response profiles, we performed qRT-PCR in tumor
homogenates and immunostains in tumor frozen sections. qRT-PCR results
suggested that Kras/TBRII-/- tumors have an immunosupressive M2 pheno-
type with upregulation of Arginase and downregulation of Interferon gamma
and STAT-1. Immunostaining suggested an increase of CD11b cells in the
tumor microenvironment of Kras/TBRII-/- mice with no obvious differences
in CD4, CD8, or B cells.
Conclusion: Our animal model of transforming growth factor-beta type II
receptor deficiency in oncogenic K-Ras mice shows that loss of TBRII in
vivo promotes tumor progression, invasion, and metastasis. The tumor
microenvironment of invasive tumors had extensive matrix deposition and
showed an M2 immunosuppressive phenotype with increased infiltration of
CD11b staining cells. Further study of this novel model are ongoing to
evaluate the mechanisms by which alterations of the TGF-beta signaling
pathway on tumor cells alters immune response and progression, in vivo.
These animals represent a new lung cancer model that recapitulates the
morphology, matrix environment, and progression of human lung adenocar-
cinoma tumors and should be useful for a wide range of studies.
A18
Mouse models and small molecule inhibitors to explore the
MAP kinase signaling cascade in non-small cell lung
adenocarcinoma
Christy Trejo1, Anthony Karnezis1, David Dankort2, Martin McMahon1.
1University of California San Francisco, Helen Diller Family Comprehen-
sive Cancer Center, San Francisco, CA, 2McGill University, Montreal, QC,
Canada
Lung cancer causes 165,000 deaths a year in the United States. Adeno-
carcinoma, the most prevalent subtype, is particularly difficult to treat. The
MAP kinase signaling pathway plays a major role in the development of lung
adenocarcinoma. Two signaling molecules in this pathway, KRas and BRaf,
are mutated in 20–30% and 4% of cases, respectively. Conditional mouse
models for both of these oncogenes have been developed. Upon intranasal
infection with Adeno Cre, the KRasLSL mouse model develops lung adeno-
mas and at later time points, malignant adenocarcinoma. Likewise, the
BRafCA mouse model permits the inducible expression of the BRafV600E
oncogene in response to Cre recombinase. BRafV600E efficiently induces
the development of benign lung adenomas. Overt adenocarcinoma is very
rarely seen in these mice unless key tumor supressors such as Trp53 or
Ink4A/Arf are lost. We used this model of BRafV600E- induced pre-
malignant lung tumors to test the effectiveness of targeted kinase inhibitors
in the chemoprevention and elimination of lung cancer initiating cells. The
specific MEK1/2 inhibitor PD0325901 induces complete regression of pre-
existing adenomas; however upon cessation of treatment, tumors rapidly
reappear. This can be monitored in vivo by use of a Luciferase reporter
mouse. Ongoing studies indicate that PD0325901 may also have an effect in
the prevention and treatment of KRasG12D driven lung tumors in the
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conditional KRasLSL mouse model. In vivo imaging is ongoing to demon-
strate tumor regression in vivo in this model as well. Furthermore, a head to
head comparison of KRas and BRaf driven lung tumors has been conducted
to explore the activation of other signaling pathways in these two mouse
models.
A19
Primary non-small cell lung cancer xenografts: Association
between engraftment, mutation profile, and clinical outcome
Nhu-An Pham, Thomas John, Naoki Yanagawa, Derek Kohler, Ming Li,
Devang Panchal, Fannong Meng, Melania Pintilie, Frances A. Shepherd,
Ming S. Tsao. University Health Network, Ontario Cancer Institute/Prin-
cess Margaret Hospital, Toronto, ON, Canada
Introduction: Patient-derived primary non-small cell lung cancer (NSCLC)
xenografts potentially are more clinically relevant models to evaluate mo-
lecular targets and pathways and to test novel therapeutics. Mutations in
oncogenes, growth factor receptors, signal trans-duction and tumor suppres-
sor genes may impact on prognosis and response to therapy. We sought to
characterize primary tumors that formed xenografts with those that did not in
order to correlate mutational profiles with clinical outcome.
Method: Fresh primary tumor fragments from NSCLC patients who under-
went curative resection were implanted into the subcutaneous tissue of
non-obese diabetic severe combined immunodeficient (NOD-scid) mice
within 24 hours of harvest. The ability to engraft was correlated with
clinicopathological features and disease free survival (DFS). Patient tumor
DNA was analyzed using the OncoCarta™ Panel v1.0 (Sequenom, San
Diego, CA), which has the potential to identify 238 mutations across 19
oncogenes. These mutations have been reported to occur in multiple cancer
types including NSCLC.
Results: From 2005 to 2008, 54 xenografts were established from 133
implantations (overall engraftment rate 41%). These included 27/42 (64%)
for squamous cell carcinoma (SCC), 23/83 (28%) for adenocarcinoma (AC)
and 4/8 (50%) for other types. Tumor xenograft histology was similar to the
initial primary tumors. Engraftment was significantly higher in SCC than in
AC, (p0.001), despite AC demonstrating a higher frequency of mutations.
Mutations were found in the KRAS, EGFR, PI3K3CA, MET and BRAF
genes. Among the AC, EGFR mutant tumors demonstrated lower engraft-
ment rate. Successful engraftment was not significantly associated with
tumor grade or stage. Patients whose tumors formed xenografts had signif-
icantly shorter DFS than those whose tumors failed to form xenografts (HR
5.99, 95%CI 2.5–14.33, p0.0001). Tumors that engrafted and harbored a
KRAS mutation had the highest rates of relapse.
Conclusions: Clinically more aggressive NSCLC demonstrated a greater
capacity to establish primary xenografts and may reflect genetic alterations
that modulate clinical outcome.
A20
Synthesizing new proteins from 3-dimensional spheroids
compared to 2-dimensional cell line culture
Ki-Up Kim, Kim Yang Ki, Lee Young Mok, Uh Soo-taek. Soonchunhyang
University, School of Medicine, Seoul, Republic of Korea
Introduction: Researches are basically in vitro. However, their results apply
to in vivo were disappointed. That may be caused by 3-dimensional structure,
not pure cell components, and cell to cell/matrix interactions. If artificial
organisms, multicellular tumor spheroids (MCTS), have similar cell compo-
nents, it may be closer to tumor and more advanced model. The represented
protein from 2- and 3-dimension. We tried a multicellular tumor spheroids
(MCTS) from cancer cell line, fibroblasts from human, and PBMC by
combination or singly as a model to cancer research. And we tested the
differences from represented proteins at 2- and 3-dimensional condition from
A549 cancer cell line. al culture may be different because their milieu is
changed.
Methods: Cell from 3 conditions were cultured to agarose coated plate
singly or combined at DME media. Their formation of spheroids were
observed daily by inverted microscope and got samples serially for 4 weeks.
Cell components from combined spheroids were stained immunohistochemi-
cally by their specific antibody. Proteins, which were cultured from 2-di-
mension and 3-dimension at 3 day from A549 cancer cell line, were loaded
by 2-dimensional gel electrophoresis and were analyzed by MALDI-TOF.
Results: Cells were conglomated and made clusters except PBMC within a
few days and formed spheroids between 4 to 7 days. The mixed cluster with
A549, fibroblast and PBMC were formed round shape. Cell components
from spheroids had been confirmed by immunohistochemical stain. Compare
to 2-dimensional culture, 23 proteins by 2-dimensional gel electrophoresis
were newly detected from spheroids. The most prominent protein was heat
shock protein 90.
Conclusions: MCTS is a new model for tumor research, and heat shock
protein 90 is an important role for 3-dimensional structure.
Molecular Epidemiology, Nicotine, and
Behavioral Research
A21
Smoking, green tea consumption, genetic polymorphisms in
the insulin-like growth factors and lung cancer risk
I-Hsin Lin1, Ya-Ru Deng1, Hsuan-Yu Chen2, Yu Hui Lien1, Chi-Wen Hsu1,
Yu-Hao He1, Chia-Chen Huang1, Yin-Hung Chu1, Shiau-yun Lin1, Lee
Chiung-Ju1, Chang Fang-Yu1, Ming-Lin Ho3, Ruey-Hong Wong1. 1Chung
Shan Medical University, Taichung, Taiwan, 2Institute of Statistical Science,
Academia Sinica, Taipei, Taiwan, 3Changhua Christian Hospital, Chang-
hua, Taiwan
Insulin-like growth factors (IGFs) are major mediators of the effects of the
growth hormones; they thus have a strong influence on cell proliferation and
differentiation. The high expression level of insulin-like growth factor-
binding protein (IGFBP)-3, suppresses the mitogenic action of insulin-like
growth factors, is inversely associated with the cancer risks. However,
limited information is available on the molecular role of IGF1, IGF2 and
IGFBP3 in human lung cancer. Experimental studies have shown that tea
polyphenols are strong antioxidants and may inhibit the induction of a variety
of cancers including lung cancer. However, epidemiological studies on tea
consumption and cancer are limited and the results are inconclusive. Exper-
imental studies have also observed that green tea polyphenols have a
substantial reduction in the levels of IGF1 and significantly increase in the
levels of IGFBP3. Furthermore, smokers with susceptible IGF1, IGF2 and
IGFBP3 genotypes might have an elevated lung cancer risk. In addition, the
role of IGF1, IGF2, and IGFBP3 genotypes on lung cancer survival is still
unknown. Therefore, we designed a hospital-based case-control study to
evaluate the effects of smoking, green tea consumption, and IGF1 (CA)n
repeat, IGF2 820 and IGFBP3202 polymorphisms on lung cancer risk. We
also investigated the associations of IGF1, IGF2 and IGFBP3 polymor-
phisms with lung cancer survival among our patients. In total, 170 primary
lung cancer cases and 340 healthy controls were recruited in this study.
Questionnaires were administered to obtain demographic characteristic,
cigarette smoking habits, green tea consumption, dietary intake of fruits and
vegetables, cooking practices, and family history of lung cancer. The overall
survival was calculated from 136 lung cancer patients. The genotypes for
IGF1 (CA)n repeat, IGF2 820 and IGFBP3 202 were identified by
polymerase chain reaction. In our multiple conditional logistic model, smok-
ing, green tea consumption less than one cup per day, and exposure to the
fume of cooking more than 3 hours per week were associated with elevated
lung cancer risks. After adjusting the effects of exposure to the fume of
cooking, a significantly higher risk was observed in smokers who never
drank green tea, as compared to nonsmokers who drank green tea more than
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one cup per day (odds ratio [OR]  12.71; 95% confidence interval [CI] 
2.96–54.52). The significant interaction between smoking status and green
tea consumption on lung cancer risk was also observed. After adjusting the
effects of green tea consumption and exposure to the fume of cooking, we
also observed the obvious interactions of cumulative smoking dose with
IGF1, IGF2 and IGFBP3 genotypes on lung cancer. Among green tea
drinkers, those who carrying IGF1 (CA)19/(CA)19 and (CA)19/X genotypes
had a significantly reduced the risk of lung cancer (OR  0.34; 95% CI 
0.17–0.69) compared with those who carrying the IGF1 X/X genotype.
Similar result is found in the lung cancer risk and genotype of IGF2.
However, no apparent association was observed between the IGF1 (CA)n
repeat, IGF2 820 and IGFBP3 202 genotypes in overall survival of lung
cancer. In conclusion, our study may represent a clue that in the case of lung
cancer, smoking-induced carcinogenesis could be modulated by green tea
consumption and their growth factor environment.
Novel and Targeted Therapy, Drug Design
A22
Phase II studies of ASA404 (vadimezan, DMXAA) plus
carboplatin and paclitaxel in advanced squamous and
nonsquamous non-small cell lung cancer: Blood and lymphatic
adverse events
M.J. McKeage1, M.B. Jameson2. 1The University of Auckland, Auckland,
New Zealand, 2Waikato Hospital, Hamilton, New Zealand
This abstract was presented as a short talk in Plenary Session 5. A full
abstract is printed in the Proffered Presentations section (PR14).
A24
Addressing right drug/right target/right patient in phase I
studies to accelerate bench to clinical benefit time: ALK gene
rearrangements and the development of PF-02341066 in
NSCLC
D. Ross Camidge1, James Christensen2, Yung Jue Bang3, Alice T. Shaw4,
Daniel B. Costa5, Ravi Salgia6, Bruce J. Dezube5, Geoffrey I. Shapiro7, Pasi
A. Janne7, Robert G. Maki8, Benjamin Solomon9, Eunice L. Kwak4, Weiwei
Tan2, S. Martin Shreeve2, Keith Wilner2, Jeffrey W. Clark4, A. John Iafrate4.
1University of Colorado, Denver, CO, 2Pfizer Pharmaceuticals, La Jolla,
CA, 3Seoul National University, Seoul, Republic of Korea, 4Massachusetts
General Hospital, Boston, MA, 5Beth Israel Deaconess, Boston, MA, 6Uni-
versity of Chicago, Chicago, IL, 7Dana-Farber Cancer Institute, Boston,
MA, 8Memorial Sloan-Kettering Cancer Center, New York, NY, 9Peter
MacCallum Cancer Centre, Melbourne, Australia
Oncogenic rearrangements of anaplastic lymphoma kinase (ALK) within the
short arm of chromosome 2 were first described in anaplastic large-cell
lymphomas over a decade ago. Subsequently they have also been found in
diffuse large B-cell lymphomas, malignant histiocytosis and in several solid
tumors including inflammatory myofibroblastic tumors, squamous cell car-
cinomas of the esophagus, neuroblastoma and, in 2007, they were reported in
non-small cell lung cancers (NSCLC). Gene rearrangements result in fusion
proteins with constitutive activation of the ALK kinase domain. In NSCLC,
the most commonly identified fusion partner for ALK in these rearrange-
ments is the 5’ end of the echinoderm microtubule-associated protein-like 4
gene (EML4). In an unselected NSCLC population, ALK gene rearrange-
ments occur with a frequency of 3–5%. Adenocarcinomas arising in light
ex-smokers or never smokers appear to have significantly higher frequencies
of ALK gene rearrangements.
PF-02341066 is a small molecule synthesized in 2005 as both a potent oral
ATP competitive inhibitor of ALK and MET. PF-02341066 blocked the
proliferation of NPM-ALK-positive ALCL (Karpas-299 and SU-DHL-1)
cells and in a mouse model with Karpas-299 xenografts, induced a complete
tumor regression after 13 days of dosing. In cells expressing the EML4-ALK
fusion, PF-02341066 inhibited cell growth and induced apoptosis with mean
cellular IC50 value of 24 nM. Additional efficacy was demonstrated in
NSCLC, glioma, prostate, RCC, and gastric xenograft models.
Given the favorable preclinical cell line and xenograft data, a phase I trial
was initiated in 2006. This trial included a dose escalation phase conducted
in all-comers followed by a planned expanded cohort of molecularly defined
patients to be treated at the predicted recommended phase II dose. Originally,
this expanded cohort was focused largely on tumors with markers of cMET
activation, however with the report of ALK gene rearrangements occurring
in NSCLC during the dose escalation phase, lung cancer patients with proven
ALK gene rearranged tumors were also recruited. The trial continues to
enroll ALK positive patients in the expanded cohort. To date, thirty-one
evaluable heavily pre-treated (65%  2 prior regimens) NSCLC patients
with proven FISH-positive ALK gene rearrangements achieved an overall
response rate of 65% (19 PR and 1 CR). Patients remain on therapy with a
median duration of treatment exceeding 24 weeks. Progression-free survival
has not yet been reached. Adverse events associated with PF-02341066 at the
250mg BID doses used in the expanded cohort have usually been mild and
include gastrointestinal and dark-light vision disturbances.
The impressive efficacy of PF-02341066 validates oncogenic ALK rear-
rangements as a therapeutic target in this molecularly defined subset of
NSCLC patients and justifies evaluating PF-02341066 in a randomized phase
III setting without the need for a separate phase II study. In 2009, a phase III
randomized study of PF-02341066 vs. standard second-line chemotherapy in
NSCLC patients with known ALK rearrangements events was initiated.
Within 3 years of the discovery of the EML4-ALK fusion protein in
NSCLC and the entry of PF-02341066 into the clinic, a phase III study has
been initiated. Because of the strength of clinical signals when the right
targeted drug is appropriately matched with the right target in the right
patient, molecular efficacy hypotheses can now be tested effectively within
first-in-human phase I studies. The development of PF-02341066 highlights
the importance and feasibility of incorporating prospective molecular pro-
filing within early-phase clinical trials of novel targeted therapies.
A25
Delivery of short interfering RNA to alveolar epithelium-
derived cells using adeno-associated virus type 2/5
Hidenori Kage, Mitsuhiro Sunohara, Masanori Kawakami, Kentaro Kitano,
Noriko Emoto, Kousuke Watanabe, Naomi Aki, Masashi Kusakabe, Emi
Hamano, Takahide Nagase, Nobuya Ohishi, Daiya Takai. University of
Tokyo, Tokyo, Japan
Although RNA interference has been a powerful tool to analyze gene
function and shows promise as gene therapy, delivery of short interfering
RNA (siRNA) to target cells and organs has been difficult. Knockdown of
gene expression in the lung alveolar epithelium has been achieved mostly by
using naked siRNA, and the length of gene inhibition is known to be short.
Adeno-associated virus (AAV) vectors are known to have the lowest toxicity
among the viral vectors, and the capsid protein derived from AAV serotype
5 is known to transduce airway and lung alveolar epithelial cells with high
efficiency. Therefore, we generated an AAV type 2/5 vector carrying short
hairpin RNA against mouse Tgf1 and transduced this vector to mouse lung
alveolar epithelium-derived LA-4 cells and fibroblast 3T12–3 cells. We first
designed ten different siRNAs and found that only one siRNA suppressed
Tgf1 protein expression. After production and transduction of this vector to
LA-4 and 3T12–3, we detected -galactosidase activity in more than 90% of
the cells with minimum toxicity in both cell types; however, 50 times higher
titers of AAV was necessary in 3T12–3 cells than in LA-4 cells. Again using
50 times lower titers of AAV in LA-4 cells, we suppressed Tgf1 protein
expression in both cells by approximately 50%. Tgf1 mRNA knockdown
was only seen in LA-4 cells, suggesting that using the same vector and the
same siRNA sequence can result in mRNA degradation in one cell type and
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translational inhibition in another cell type. Delivery of this vector to these
cells resulted in accelerated cell growth in LA-4 cells and growth inhibition
in 3T12–3 cells. Finally, we sought to determine the ability of this vector to
transduce human lung cancer cell lines, and found that transduction efficien-
cies were variable. This variability was not related to platelet-derived growth
factor receptor expression, which has been reported as a receptor for AAV
type 5. In conclusion, we suppressed Tgf1 protein expression by using
AAV type 2/5 vector carrying short hairpin RNA.
A26
Synergy between the novel Hsp90 inhibitor STA-9090 and
taxanes in preclinical models of NSCLC
Kevin P. Foley1, David Proia1, Takeshi Shimamura2, Christa L. Borgman2,
Takayo Inoue1, Tim Korbut1, Danan Li2, Samanthi A. Perera2, Jim Sang1,
Luisa Shin Ogawa1, Don Smith1, Noriaki Tatsuta1, Weiwen Ying1, Chaohua
Zhang1, Haili Zhang1, Geoffrey I. Shapiro2, Kwok-Kin Wong2, Ronald K.
Blackman1. 1Synta Pharmaceuticals Corp., Lexington, MA, 2Dana-Farber
Cancer Institute, Boston, MA
The molecular chaperone heat shock protein 90 (Hsp90) plays a key role in
regulating the correct folding, stability and activity of many important signal
transduction molecules that have been implicated in the pathophysiology of
non-small cell lung cancer (NSCLC), including: BRAF, EGFR, HER2, MET
and VEGFR. STA-9090 is a novel small molecule Hsp90 inhibitor that is
structurally unrelated to the first-generation anasamycin Hsp90 inhibitors
17-AAG and IPI-504. STA-9090 competes with ATP for binding to the
N-terminal domain of Hsp90, thereby inducing proteasome-mediated degra-
dation of Hsp90 client proteins preferentially in cancer versus normal cells.
STA-9090 is currently being evaluated in multiple Phase 1/2 clinical trials in
solid tumor and hematological malignancies, as well as in an open-label,
multi-center Phase 2 clinical trial in patients with advanced NSCLC that
harbor wild type or activated forms of EGFR and KRAS. We have investi-
gated the activity of STA-9090 alone and in combination with taxanes in
preclinical NSCLC models.
In vitro, STA-9090 potently inhibited cell proliferation in 24/24 human
NSCLC cell lines (median IC50  6.5 nM; range 1–26 nM), irrespective of
EGFR, HER2 or KRAS mutational status. In vivo, intravenous treatment
with STA-9090 at its highest non-severely toxic dose induced stable disease
in both the HCC827 (erlotinib-sensitive EGFRdel746–750) and NCI-H1975
(erlotinib-resistant EGFRL858R/T790M) xenograft models in mice. In the
HCC827 model, tumor progression could be prevented for at least 7 weeks
using a one time per week dosing schedule. Further, in an inducible
bitransgenic mouse model in which expression of mutant HER2YVMA re-
sulted in the development of adenosquamous lung tumors, 3/4 animals
treated with STA-9090 displayed partial responses as measured by MRI.
This result correlated with decreased HER2 expression in tumors.
The taxanes paclitaxel and docetaxel are widely used in the treatment of
advanced-stage NSCLC. To examine the combination of STA-9090 plus
taxanes, in vitro studies were conducted with HCC827 and NCI-H1975 cells.
Using the median-effect method of Chau and Talalay, STA-9090 in combi-
nation with either paclitaxel or docetaxel displayed combination index values
within the synergistic range (0.3–0.7 CI). In vivo in the NCI-H1975 xeno-
graft model, the combination of STA-9090 and paclitaxel displayed greater
efficacy than either single agent alone (%T/C values of 8, 42 and 44, for the
combination, STA-9090 and paclitaxel, respectively). Synergy between STA-
9090 and paclitaxel was not due to alterations in the pharmacokinetics of either
agent, and the combination treatment did not result in additional toxicity.
Our results demonstrate that STA-9090 is a highly potent Hsp90 inhibitor
that displays broad in vitro and in vivo anti-cancer activity in preclinical
models of NSCLC. STA-9090 also synergizes with paclitaxel and docetaxel.
Taken together, these results suggest that further exploration of STA-9090 as
both a single agent and in combination with taxanes in NSCLC patients is
warranted.
A27
Regression of murine lung tumors by the let-7 microRNA
Phong Trang1, Pedro P. Medina1, Jason F. Wiggins2, Lynnsie Ruffino2,
Kevin Kelnar2, Michael Omotola2, Robert Homer1, David Brown2, Andreas
G. Bader2, Joanne B. Weidhaas1, Frank J. Slack1. 1Yale University, New
Haven, CT, 2Mirna Therapeutics, Inc., Austin, TX
MicroRNAs (miRNAs) have recently emerged as an important new class of
cellular regulators that control various cellular processes such as cell death,
differentiation, and development and are implicated in human diseases,
including cancer. Aberrant expression of specific miRNAs is associated with
tumorigenesis and miRNA coding genes are often found in fragile genomic
regions gained and lost in cancers. Many members of one miRNA family in
particular, let-7, map to chromosomal regions frequently deleted in lung
cancer, and reduced let-7 expression in non-small cell lung cancer (NSCLC)
patients is correlated with poor prognosis. Moreover, let-7 miRNAs are
thought to function as tumor suppressors through their negative regulation of
multiple oncogenes, such as RAS, MYC, HMGA2, and promoters of cell
cycle progression, such as CDC25A, CDK6, and Cyclin D2. Administration
of let-7 blocks the growth of cultured lung cancer cells and also prevents the
onset of tumor formation in a mouse model of NSCLC. Here we now show
that loss of let-7 function enhances lung tumor formation in vivo, strongly
supporting the hypothesis that let-7 is a tumor suppressor. Moreover, we
report that exogenous delivery of let-7 to established tumors in mouse
models of NSCLC significantly reduces tumor burden. These results dem-
onstrate the therapeutic potential of let-7 in NSC lung cancer and point to
miRNA replacement therapy as a promising approach in cancer treatment.
A28
Targeting ER-Golgi homeostasis is an advantageous
therapeutic strategy in lung cancer
Victoria Zismanov, Liat Drucker, Maya Gottfried. Meir Medical Center,
Kfar Saba, Israel
Introduction: Protein levels are regulated by the protein homeostasis net-
work that generates and protects the protein fold (endoplasmic reticulum
[ER] and Golgi included). A growing number of reports recognize novel
therapeutic targets in control of ER and Golgi homeostasis, some of which
can be specifically targeted by drugs.
The heat shock protein 90 (Hsp90) is an essential molecular chaperon
involved in the posttranslational folding and stability of proteins. It is
required for conformational maturation of multiple oncogenic kinases that
drive signal transduction and proliferation of cancer cells. However, in the
case of unfolded protein accumulation that leads to ER stress, several
pathways, e.g. proteasome and histone deacetylases (HDACs) functions are
activated. The ubiquitin proteasome system orchestrates the turnover of
innumerable cellular proteins. The HDACs play an important role in the
management of the ER stress response by recruiting aggregates of misfolded
proteins that cannot be degraded efficiently by the proteasome, into dedicated
organelles.
Hsp90 inhibition leads to accumulation of unfolded proteins and ER stress.
The therapeutic efficacy of such inhibition may be augmented by co-
administering it with other drugs that disrupt ER-Golgi homeostasis. Thus,
we aimed to examine the effect of combined treatment of Hsp90 antagonist
with proteasome or HDAC inhibitors on human lung cancer cell lines.
Methods: Non small cell lung cancer (NSCLC) cell lines A549 and H1299
and small cell lung cancer (SCLC) cell line H460 were treated by Hsp90
inhibitor 17-Dimethylamino-ethylamino-17-demethoxygeldanamycin (17-
DMAG) with/without HDAC inhibitor PTACH or proteasome inhibitor
Velcade (Bortezomib) for 24 hours and tested for: viability (WST1), prolif-
eration and ER stress (immunoblotting), cell death (Annexin/Propidium
Iodide), cell cycle (flow cytometry).
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Results: Co-administration of 17-DMAG and PTACH or Velcade yielded a
synergistic increased apoptotic cell death in both SCLC and NSCLC cell
lines. Elucidation of underlying mechanism is underway.
Reduced viability was demonstrated in all cell lines with all drug combi-
nations with the exception of 17-DMAG and PTACH co-administration to
H1299 cells. Indeed, 17-DMAG and PTACH resulted in elevated viability in
addition to the increased H1299 cell death. We hypothesized that this
phenomenon maybe a result of H1299 cell proliferation and in fact deter-
mined significant higher levels of Proliferating Cell Nuclear Antigen
(PCNA) in 17-DMAGPTACH treated cells.
Currently, we are analyzing ER stress markers (BiP, GADD153/CHOP,
and pJNK) in the treated cancer cells.
Conclusion: Our findings provide proof of concept that targeting ER-Golgi
homeostasis is therapeutically beneficial in SCLC and NSCLC cell lines.
Specifically, combined treatment with Hsp90 inhibitor and HDAC or pro-
teasome inhibitors yield synergistic anti lung cancer impaired effect.
A29
Mer and Axl receptor tyrosine kinases are novel therapeutic
targets in NSCLC
Rachel M.A. Linger, Deryck H.G. Middleton, Justine Migdall, Rebecca A.
Cohen, Atul Mehta, Grace K. Kim, Wilbur A. Franklin, Daniel T. Merrick,
Xiayuan Liang, Paul Jedlicka, Lynn E. Heasley, Douglas K. Graham.
University of Colorado Denver School of Medicine, Aurora, CO
Lung cancer is the primary cause of cancer mortality worldwide. Less than
25% of patients treated on current chemotherapy protocols survive 2 years,
and new treatment strategies are needed to obtain improved patient out-
comes. The identification of new targeted biologic therapies which syner-
gistically interact with standard chemotherapy is one approach to enhance
patient survival. Axl and Mer are two related receptor tyrosine kinases and
are novel candidates for targeted inhibition since they are abnormally
expressed and activated in many human cancers including lung cancer.
Studies from other laboratories have demonstrated that expression of Axl
correlates with invasive ability of human non-small cell lung cancer
(NSCLC) cell lines. Furthermore, in patient samples of NSCLC, Axl over-
expression has been statistically associated with metastatic disease. In this
study, we used immunohistochemical staining to demonstrate that both Axl
and Mer are expressed in the majority of NSCLC patient samples. In human
NSCLC cell lines, qRT-PCR and immunoblotting indicate that Axl and Mer,
as well as the Gas6 and Protein S ligands which activate them, are co-
expressed suggesting that this family of RTKs may constitute an autocrine
loop resulting in constitutive activity of these kinases. Knockdown of Axl or
Mer expression in the human NSCLC cell lines A549 and H2009 was
accomplished via constitutive and inducible lentiviral short hairpin RNA
(shRNA) contructs. In vitro assays of cell proliferation and survival indicated
that constitutive knockdown of Axl or Mer did not have a significant impact
on short-term (48h) growth of NSCLC cells. However, when NSCLC cells
were cultured for 8 days to evaluate long-term growth, both Mer and Axl
knockdown cells exhibited reduced growth rates relative to control cells. To
evaluate the role of Axl and Mer in apoptosis, we performed flow cytometric
analysis of cells stained with YO-PRO-1 and propidium iodide. These
experiments revealed that constitutive inhibition of Mer, but not Axl, results
in increased induction of cell death suggesting that Axl and Mer may be
contributing to NSCLC proliferation and survival via distinct mechanisms.
Additional in vitro assays demonstrated that inhibition of Mer or Axl
significantly increased the sensitivity of NSCLC cells to numerous chemo-
therapeutic agents. For example, when wild type or non-silencing shRNA
control (shControl) cells were treated with carboplatin, an IC50 could not be
determined because the cells were robustly resistant to killing with this agent.
However, the Axl and Mer knockdown lines demonstrated remarkable
sensitivity (IC50 values 9 M and 90 M, respectively) to carboplatin
(P  0.05). In other cases, the wild type/shControl lines were sensitive to
treatment with chemotherapeutic agents but an increase in sensitivity was
observed with Axl or Mer inhibition. Taken together, these results suggest
that inhibition of Axl and/or Mer may increase the efficacy of standard
chemotherapy and thereby improve patient outcome. While previous studies
have suggested a role for Axl in the progression of NSCLC, these studies are
the first to describe a role for the related receptor tyrosine kinase Mer in
NSCLC or to define a potential synergistic role of Axl or Mer inhibition with
commonly used chemotherapy agents. Our findings demonstrate that Mer
and Axl are novel biological targets for treatment of NSCLC and possibly a
spectrum of other cancers known to aberrantly express Mer and/or Axl.
A30
Prime time for prospective randomized trials of targeted
therapies with validated targets in lung cancer: FDA
perspective
Shakun Malik, Robert Justice, Rajeshwari Sridhara, Ian Waxman, Richard
Pazdur. CDER/FDA, Silver Spring, MD
Gefitinib (Iressa; ZD1839) was the first tyrosine kinase inhibitor (TKI) to
receive accelerated approval from the United States Food and Drug Admin-
istration (FDA) for the treatment of advanced lung cancer. On May 2003,
gefitinib was approved as monotherapy for the treatment of locally advanced
or metastatic non-small cell lung cancer (NSCLC) after failure of treatment
with both platinum-doublet and docetaxel chemotherapy. This approval was
based on the surrogate endpoint of response rate (RR) in two Phase II
randomized, double-blind, parallel group, multicenter studies, Iressa Dose
Evaluation in Advanced Lung Cancer (IDEAL) 1 and 2 (Fukuoka, JCO 2003
and Kris, JAMA 2003) studies. Under accelerated approval, the sponsor was
required to conduct additional studies to verify that gefinitib therapy dem-
onstrated a clinical benefit. Failure of the Iressa Survival Evaluation in Lung
Cancer (ISEL) study (Thatcher, Lancet 2005) to demonstrate a survival
benefit with gefitinib compared to placebo led to labeling revisions by FDA
in March 2005 restricting gefitinib use to patients already receiving and
benefiting from the drug. On November 18, 2004, FDA approved another
TKI, erlotinib, as monotherapy in the 2nd or 3rd line setting for NSCLC.
This approval was based on a statistically significant improvement in overall
survival (OS) compared to BSC (Shepherd, NEJM 2005). Gefitinib is
approved for metastatic NSCLC in 36 countries and has recently been
approved by EMEA (European Medicines Agency) for NSCLC patients with
EGFR mutations.
Even with improved methods for identifying molecular alterations, there is
still debate regarding the best method for predicting benefit of gefitinib in
patients with tumors exhibiting high EGFR protein expression determined by
immunohistochemistry (IHC), EGFR gene copy number determined by
fluorescent in situ hybridization (FISH), and EGFR mutation status deter-
mined by gene sequencing. Data from the Iressa NSCLC Trial Evaluating
Response and Survival vs. Taxotere (INTEREST) study did not show
superiority of gefitinib in patients with high EGFR-gene-copy number
(median OS of 8.4 vs 7.5 months, respectively) (Kim, Lancet 2008).The
Iressa Pan-Asia Study (IPASS) (Mok, NEJM 2009) was a phase 3, multi-
center, randomized, open-label, parallel-group study comparing gefitinib
with carboplatin plus paclitaxel as first-line treatment in East Asian patients
with advanced NSCLC. According to the reported results, the study met its
primary objective of improved progression-free survival (PFS) in the ge-
fitinib treatment arm compared with the carboplatinpaclitaxel arm
(P0.001). In a subgroup analysis, a significant correlation between muta-
tion status and outcome between treatment arms was also reported. However,
whether gefitinib in EGFR mutated NSCLC patients will improve overall
survival compared to standard chemotherapy is unknown.
Studies report that patients with wild-type EGFR could also derive
survival benefit from treatment with TKIs, though this benefit may be less
than in patients with mutations (Shepherd, NEJM 2005). When evaluating
the risk-benefit ratio of a drug, the magnitude of benefit is of critical
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importance. Retrospective collection of biomarkers in small numbers of
patients in most of the randomized trials has made this interpretation of
results almost impossible.
FDA believes that these issues emphasize the need for integration of the
investigation of biomarkers into clinical trial design, including prospective
collection of samples in all patients enrolled in a randomized controlled study
for evaluation of biomarkers as prognostic or predictive markers, and
validation of the tests used to detect such biomarkers.
Prognostic and Predictive Factors, Molecular
Profiling, Proteomics
A31
Use of Scorpion-amplified refractory mutation system is more
sensitive to detect EGFR mutant and responders in patients
with advanced/metastatic NSCKL before starting firstline
erlotinib therapy
Dae Ho Lee. Asan Medical Center, Seoul, Republic of Korea
Background: Somatic mutations of epidermal growth factor receptor
(EGFR) are associated with an objective response to EGFR tyrosine kinase
inhibitors (TKIs). However, it is difficult to obtain sufficient tumor samples
to detect EGFR mutation from patients with non-small cell lung cancer
(NSCLC), so a more sensitive method is needed to identify these mutations.
The aim of this study was to compare detection rates of EGFR mutations
between direct sequencing and a highly sensitive assay (Scorpion Amplified
Refractory Mutation System; DxS; Manchester, UK) [ARMS], and to pro-
spectively compare these results with response rates to EGFR TKI therapy.
Methods: We prospectively enrolled 21 patients whose EGFR mutational
status was known to be either wild type or mutant before starting first-line
erlotinib therapy; median age was 63 (42–79); 20 had adenocarcinoma; 8
were male; and 13 were never-smokers. We extracted DNA from the tumor
samples, and EGFR mutations were analyzed using both direct sequencing
(exons 18, 19 and 21) and the Scorpions ARMS method (E746 A750del and
L858R).
Results: ARMS method detected a mutation in 12 patients while direct
sequencing methods detected a mutation in 8 patients (57.1% vs. 38.1%). Out
of 21 patients, there were 11 PRs but 10 PDs. Out of 12 patients whose
mutation was identified by ARMS method, there were 10 PRs and 2 PDs,
while out of the other 9 patients whose mutation was absent, there was 1 PR;
the sensitivity, specificity and positive predictability of ARMS method was
90.9%, 80.0%, and 83.3% respectively. On the other hand, when using direct
sequencing, out of 8 patients who had a mutation, there were 6 PRs and 2
PDs while out of 13 patients who might not have a mutation, there were 5
PRs, the sensitivity, specificity, and positive predictability of direct sequenc-
ing method was 54.5%, 80% and 75%, respectively.
Conclusions: Scorpions ARMS method is more sensitive than direct se-
quencing and has a higher predictive value to predict a response. Considering
that a recent study showed that first-line EGFR TKI is more beneficial to
those having an EGFR mutation while this is harmful to those having not,
more sensitive method should be used to select a patient who might benefit
from EGFR TKI therapy.
A32
Oncogenes and uniparental disomy: Changing the landscape
of the lung cancer genome
Adi F. Gazdar1, Raj Chari2, Will Lockwood2, Bradley Coe2, Junichi Soh1,
Calum MacCaulay2, John Minna1, Stephen Lam2, Wan Lam2. 1UT South-
western Medical Center, Dallas, TX, 2British Columbia Cancer Agency,
Vancouver, BC, Canada
Purpose: To investigate the relationship between activating mutations, copy
number and uniparental disomy in lung adenocarcinomas.
Background and Methods: We recently found that in lung cancer cells the
mutant allele of oncogenes was frequently imbalanced either by increased
copy number or by uniparental disomy (UPD, with both alleles derived from
the same parent)(Soh et al., PLoS One, 2009). Mutant allele specific
imbalance (MASI) resulted in greatly enhanced oncogene activity and a poor
survival. We used SNP technology for analysis of 45 microdissected paired
lung adenocarcinomas/adjacent lung tissues to map the regions of gain, loss
and UPD in the lung cancer genome.
Results: We found that there were extensive regions of non-random UPD
(12% of the cancer genome), along with regions of gain or loss (together
accounting for about 50% of the cancer genome). These three extensive
regions of genetic alterations (UPD, gains, losses) were present in over 40%
of the tumor samples, and they showed minimal areas of overlap with each
other. Previous data has indicated that UPD may be a mechanism for the
“second hit” for tumor suppressor genes, and BRCA2, RB1, WT1, MAP2K4
and others mapped to regions of non random UPD. UPD has been described
in solid tumors previously, but, except for hematopoietic malignancies, has
not been associated with oncogenes. Mapping of activating oncogenes genes
involved in lung cancer pathogenesis indicated that many mapped to regions
of gain (including AKT1, EGFR and MYC) or UPD (including (KRAS,
PIK3CA, FLT3 and CD44). Our findings suggest that, contrary to common
scientific belief, oncogenes often are activated by two hits – mutation plus
gains or UPD. Genes mapping to regions of UPD may need to be evaluated
for their role in lung cancer pathogenesis.
Concluding Remarks: Our findings add an intriguing and unexpected
complexity to the cancer genome landscape that may result in a re-evaluation
of how oncogenes are activated, and may also have implications for opti-
mizing targeted therapy.
A33
Two-gene prognostic model with ERCC1 and BRCA1 in non-
small cell lung cancer patients treated with platinum doublets
Jeong Seon Ryu1, Eun Soon Shin2, Hae Seong Nam1, Jae Hwa Cho1, Seung
Min Kwak1, Hyun Jung Kim1, Jong Eun Lee2. 1Inha University Hospital,
Inchoen, Republic of Korea, 2DNA Link, Seoul, Republic of Korea
The median age was 63 years (range, 28 to 89 years). Histologically, 139
(46.3%) of the patients had squamous cell carcinomas and 137 (45.7%) had
adenocarcinomas. Median survival time of Pts. was 13.0 months. We
observed no significant association between ten SNPs (Q504K, IVS5–
425C/T, IVS533C/A, IVS486A/G, N118N, and 284G/T for ERCC1;
S1613G, IVS13–1893A/C, IVS12–1207 C/T, and IVS12112C/A for
BRCA1) and overall survival. In gene-gene interaction analyses between
ERCC1 and BRCA1, Pts. with variant (homo or hetero) genotype of ERCC1
N118N and wild-type genotypes of four tagging SNPs of BRCA1 showed
statistically significant shorter survival in both analyses of Kaplan Meier and
Cox’s proportional hazard model (adjusted HR, 95% CI: 1.984, 1.103 to
3.569 for N118N1613S/S; 1.889, 1.089 to 3.277 for N118NIVS13–
1893A/A; 2.205, 1.077 to 4.517) for N118NIVS12–1207C/C; 2.248, 1.095
to 4.615 for N118N IVS12112C/C). In haplotype to haplotype analyses,
Pts. with variant type haplotype (ATG) of ERCC1 and wild-type haplotype
(AACC) of BRCA1 showed statistically significant shorter survival (adjusted
HR, 95% CI: 2.643, 1.416 to 4.932).
A34
A five-gene signature predictive of survival in early-stage lung
adenocarcinoma but not in squamous cell carcinoma
Humam Kadara1, Carmen Behrens1, Luisa Solis1, John D. Minna2, Waun-Ki
Hong1, Ignacio I. Wistuba1, Reuben Lotan1. 1UT M. D. Anderson Cancer
Center, Houston, TX, 2UT Southwestern Medical Center, Harold C. Simmons
Comprehensive Cancer Center, Dallas, TX
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Lung cancer still remains the leading cause of cancer-related deaths in the
United States and worldwide. Identification of novel molecular markers for
lung carcinogenesis, outcome and response to therapies would favorably
impact the clinical management of lung cancer such as non-small cell lung
cancer (NSCLC). We have previously derived gene expression signatures
indicative of differential gene expression among cells constituting an in vitro
model of human lung carcinogenesis, including six genes that were capable
of separating lung adenocarcinoma patients from several datasets into two
clusters with significant differences in expression of the genes. In this study,
we investigated the prognostic efficacy of our previously described six genes
by using multiple algorithms of prediction and a leave-one-out-cross-vali-
dation (LOOCV) strategy. The NCI Director’s Challenge datasets were used
as a training set (n443) and gene expression data of adenocarcinomas from
the Duke and Harvard cohorts (n183) were pooled as a validation set (DH
cohort). Five out of the six genes demonstrated a significant differential
expression between two groups of lung adenocarcinoma patients in the
training set categorized based on clustering patterns by the six genes and a
p-value-5 of the t-test. The performance of this five-gene classifier was
superior as the lowest specificity or sensitivity of the six prediction algo-
rithms was 0.943. Importantly, all six prediction algorithms showed that the
overall survival of human lung adenocarcinoma patients in the DH validation
cohort that expressed the five-gene signature was significantly poorer than
that of patients predicted to lack the signature (all p0.001). Moreover, the
five-gene signature also robustly predicted poor survival when stage-I lung
adenocarcinoma patients were analyzed alone using all prediction models (all
p0.001). We then sought to test the predictive capacity of this five-gene in
vitro lung carcinogenesis model signature (FILM) in squamous cell carci-
nomas (SCCs) of the lung using independent published datasets comprised of
130 and 58 patient samples pooled as a lung SCC validation test. There were
no differences in overall survival between lung SCCs predicted to express or
lack FILM demonstrating the prognostic specificity of this classifier for lung
adenocarcinomas. We then developed a risk score-prediction model for lung
adenocarcinoma based on the Cox regression coefficients of FILM’s genes
and their normalized expression data in the training cohort (n443). Lung
adenocarcinoma patients identified to be at high risk based on the FILM risk
model exhibited significantly worse survival (p5.4 
 10-7, 100 months
follow-up) than patients at low risk. For validation of the FILM risk model,
Cox regression coefficients and the dichotomization cut-off threshold gen-
erated from the training cohort were directly applied to the DH validation
cohort (n183). All stages or stage-I only lung adenocarcinoma patients in
the validation cohort and predicted to be at high risk displayed significantly
worse survival than patients predicted to be at low risk by the FILM risk
model (p0.0006 and p0.0005 of the log-rank test, respectively). Further-
more, multivariate Cox proportional hazard regression analyses, using all
datasets, revealed that FILM was an independent predictor of poor survival.
Our findings highlight a novel five-gene signature which, although derived
originally from an experimental laboratory model, is highly effective in
predicting survival of lung adenocarcinoma patients. Studies to validate the
effectiveness of FILM in predicting, in particular, the response of lung
adenocarcinoma patients to various therapies are highly warranted. Grant
support: Supported in part by Department of Defense (VITAL) grant
W81XWH-04-1-0142.
A35
Characterization of targeted-therapy-related molecular
biomarkers from NSCLC ever-smokers versus never-smokers
by a novel qRT-PCR for microdissected tissues methodology
Wusheng Yan1, Joanna H. Shih1, Gabriela Raso2, Jaime Rodriguez-Canales1,
Carmen Behrens2, Vali A. Papadimitrakopoulou2, Roy S. Herbst2, Michael
R. Emmert-Buck1, Ignacio I. Wistuba2, Heidi S. Erickson2. 1National
Cancer Institute, Gaithersburg, MD, 2UT M. D. Anderson Cancer Center,
Houston, TX
Several studies have focused on the identification of biologic markers that
predict early recurrence and death in patients with NSCLC; however, few
studies have focused on indicators of outcome in ever-smoker and never-
smoker lung cancer patients. We hypothesize that NSCLC primary tumors
from ever-smokers and never-smokers differ significantly in the expression
of molecular abnormalities and their corresponding biomarkers. In addition,
we believe that the different pattern of molecular pathway abnormalities in
NSCLCs based on smoking status may explain different response to targeted
therapy in both patients’ populations.
To test our hypotheses, and better understand the results of biomarker
analysis in molecularly targeted clinical trials, we have developed a novel
qRT-PCR preamplification methodology for gene expression analysis of
microdissected tissues to determine and compare the gene expression pat-
terns of targeted therapy related molecular biomarkers and pathways from
surgically resected tissue specimens obtained from NSCLC patients. Previ-
ously only 9 genes of interest could be analyzed from a typical microdis-
sected sample (Erickson et al. 2009 Nature Protocols). Our new methodology
allows for the use of 8 ng of total RNA for the analysis of up to 24 genes of
interest or 24 ng of total RNA for the analysis of up to 72 genes of interest.
Comparative analysis of qRT-PR with and without cDNA pre-amplification
demonstrated no addition of bias by preamplification.
We then applied this methodology to 40 microdissected OCT frozen
adenocarcinoma NSCLC tissues specimens, including 20 ever-smokers and
20 never-smokers, for EGFR, KRAS, HER2N, BRAF, PIK-3, IGFR-1,
LKB-1, mTOR, and AKT qRT-PCR analysis. Tumor samples were obtained
from stage I/II NSCLC adenocarcinomas. Normal tissue samples were
obtained from matched normal bronchial epithelium from the same patient.
From each tissue sample an average of 77.3 ng of total RNA (average RIN
5.0) was recovered from 5000 microdissected epithelial cells (1500 laser
shots). Gene expression was Ct method. Our results show thatanalyzed by
relative quantitation using the 2- the analysis of the expression of multiple
genes using a preamplification step is a feasible approach for small tissue
specimen specimens obtained from clinical trials with advanced lung cancer
patients. Preliminary analysis has revealed distinct gene expression patterns
in ever-smokers compared to never-smokers tumors compared to their
corresponding adjacent normal bronchial epithelium. Our future plans in-
clude correlating gene expression with gene mutation, copy number varia-
tion, and immunohistochemistry analysis of these tissue specimens.
This novel qRT-PCR methodology for gene expression analysis of micro-
dissected tissues will be used to analyze fine needle aspiration (FNA) and
core needle biopsy (CNB) tissue specimens from biomarker-driven clinical
trial patients (e.g. BATTLE) for validation of profiles and analysis of
multiple molecular pathway targets that can predict response to chemother-
apy and targeted therapy.
A36
Rho GDP dissociation inhibitor 2 (RhoGDI2) is a functionally
important molecule in EGFR signaling pathway in pulmonary
adenocarcinoma
Jin-Hyoung Kang1, Jung-Young Shin2, XiangHua Zhang2, Seong-Ae Yoon2.
1Seoul St. Mary’s Hospital, the Catholic University of Korea, Seoul, Repub-
lic of Korea, 2The Catholic University of Korea, Seoul, Republic of Korea
It has been known that Rho GDP dissociation inhibitor 2 (RhoGDI2) is a
regulator of Rho family GTPase. We identified a RhoGDI2 protein through
the protein expression profile and investigated functional roles of RhoGDI2
expression on EGFR downstream signaling molecules in adenocarcinoma
cell lines of NSCLC (non-small cell lung cancer).
Three adenocarcinoma cell lines were selected according to the EGFR and
K-RAS mutation status; PC9 (E476-A750 del in exon 19, wild type K-RAS),
H1975 (T790M in exon 20 and L858R in exon 21, wild type K-RAS), A549
(wild type EGFR, K-RAS mutation in codon 12). Using proteome analysis,
among 342 protein spots detected on the 2D gel, 134 spots were initially
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selected as differentially expressed proteins in these adenocarcinoma cell
lines. It was noteworthy that the ubiquitination-related proteins were highly
expressed in EGFR TKIs-sensitive PC9 cells. On the other hand, the EGFR
TKIs-resistant H1975 cells containing both T790M and L858R mutations
expressed the signal transduction-related proteins such as Zinc finger protein,
G protein-coupled receptor and Ras oncogene family protein. It was found
that p-EGFR (Y1047), p-AKT, and p-ERK were highly activated in PC9
cells in contrast to no or weak activation of these signaling proteins in A549
and H1975 cells.
We observed that the expression of RhoGDI2 was significantly reduced
after gefitinib treatment in PC9 cells; however it was enhanced by gefitinib
in H1975 cells. Accordingly, RhoGDI2 of the final six protein spots was
selected for further study.
Western blot analysis was used to detect RhoGDI2 and EGFR expression
in six NSCLC cell lines. The highest level of RhoGDI2 expression was
observed in PC9 cells. When RhoGDI2 siRNA was transfected in PC9 cells,
it was found that RhoGDI2 protein expression was markedly reduced.
Additionally, in this transfected PC9 cells, no changes in the expression of
p-EGFR and active caspase-3 were detected, but p-AKT expression was
modestly increased. When gefitinib was added in the PC9 cells transfected
with RhoGDI siRNA, the expression level of p-EGFR was less decreased
compared to that of PC9 cells transfected with GAPDH (positive control).
The RhoGDI2 siRNA transfected PC9 cells treated with gefitinib showed
more increased expression level of actin compared to that of positive control.
We observed that the metastatic potential of the RhoGDI2 siRNA transfected
PC9 cells with lack of its expression was significantly increased in transwell
migration assay.
Taken together, it was suggested that RhoGDI2 protein is an important
down-stream molecule of EGFR signaling pathway, and playing a functional
role in cell migration and metastasis.
A37
Latent class is associated with patient survival in squamous
cell carcinoma of the lung: Results from Illumina GoldenGate
methylation profiling
Heather H. Nelson1, Brock C. Christensen2, E.A. Houseman2, Carmen J.
Marsit2, Joseph Wiemels3, Margaret R. Karagas4, Margaret R. Wrensch3,
Shichun Zheng3, John K. Wiencke3, Karl T. Kelsey2. 1University of Min-
nesota, Minneapolis, MN, 2Brown University, Providence, RI, 3University of
California, San Francisco, San Francisco, CA, 4Dartmouth University,
Hanover, NH
Dense methylation array genotyping, such as the Illumina goldengate array,
holds promise as a tool for identifying epigenetic change associated with
cancer development and outcome. Here, we have applied this technology
(n1413 CpGs in 800 affiliated genes), to identify patterns of change
associated with clinical outcome in non-small cell lung cancer. 99 lung
cancer tumors were screened: 42 squamous cell carcinomas and 57 adeno-
carcinomas. Methylation profiles were generated using recursively parti-
tioned mixed models (RPMM). Considering all tumors, RPMM class was
significantly associated with tumor histology (p0.02). In addition, for
squamous cell carcinoma, RPMM class was associated with poor patient
survival (p0.03). Specifically, methylation class 1 was associated with
reduced survival, after adjustment for age and stage (HR 7.1, CI 2.2 – 22.3).
Area under the curve analysis, locus-by-locus association testing, and ran-
dom forest analysis identified a candidate list of genes contributing to this
methylation profile. Four of these genes were bisulfite pyrosequenced in both
the test set of squamous cell carcinomas and a replication set of tumors from
the same case series (n60). Pyrosequencing data were well correlated with
data from the goldengate array within the test set (r2 values all 0.87).
Individually, none of the loci were significantly associated with survival in
the replication set. However, there was significant gene-gene interaction
(p0.02). These results suggest that promoter methylation profiling is
strongly associated with survival in squamous cell carcinoma of the lung.
However, this association is not attributable to any single gene, but rather a
combination of epigenetic effects.
A38
MUC1-associated proliferation signature predicts outcomes in
lung adenocarcinoma patients
Dhara M. MacDermed1, Nikolai N. Khodarev2, Sean P. Pitroda2, Darrin C.
Edwards2, Charles A. Pelizzari2, Lei Huang3, Donald W. Kufe3, Ralph R.
Weichselbaum2. 1The Scripps Research Institute, La Jolla, CA, 2The Uni-
versity of Chicago, Chicago, IL, 3Dana-Farber Cancer Institute, Boston, MA
Background: MUC1 protein is highly expressed in lung cancer. The cyto-
plasmic domain of MUC1 (MUC1-CD) induces tumorigenesis and resistance
to DNA-damaging agents. We used a DNA array approach to characterize
MUC1-dependent transcriptional programs and examined their significance
in lung cancer patients treated with adjuvant radiation or chemoradiation.
Results: We identified 254 genes that were differentially expressed in cell
lines transformed by MUC1-CD compared to control cell lines. We then
employed statistical analysis to select a MUC1-Associated Proliferation
Signature (MAPS) that was highly prognostic in 441 lung adenocarcinomas
from a publicly available database. The MAPS was further validated for
prognostic significance in 84 lung adenocarcinoma patients from an inde-
pendent database. MAPS genes were found to be associated with prolifera-
tion and cell cycle regulation and included CCNB1, CDC2, CDC20,
CDKN3, MAD2L1, PRC1 and RRM2. MAPS expressors (MAPS) had
inferior survival compared to non-expressors (MAPS-). In the initial data set,
5-year survival was 65% (MAPS-) vs. 45% (MAPS, p  0.0001). In the
validation data set, 5-year survival was 57% (MAPS-) vs. 28% (MAPS,
p 0.005). MAPS was also used to predict outcomes in patients treated with
adjuvant radiation or chemoradiation (5-year survival 44% in MAPS- and
28% in MAPS, p  0.04) and adds to the prognostic ability of lymph node
status.
Conclusions: The MAPS signature, comprised of MUC1-dependent genes
involved in the control of cell cycle and proliferation, is associated with poor
outcomes in patients with adenocarcinoma of the lung. In patients treated
with adjuvant radiation or chemoradiation, this signature has prognostic/
predictive value and identifies potential targets of radiosensitization of lung
adenocarcinomas.
A39
ERCC1 protein expression is not associated with survival
after platinum-based chemotherapy in patients with metastatic
non-small cell lung cancer (NSCLC)
Nathan A. Pennell1, Lucian R. Chirieac2, Fadi El Karak3, Thomas J. Lynch4,
Rebecca S. Heist3, David C. Christiani3. 1Cleveland Clinic Taussig Cancer
Institute, Cleveland, OH, 2Brigham and Women’s Hospital, Boston, MA,
3Massachusetts General Hospital, Boston, MA, 4Yale Cancer Center, New
Haven, CT
Purpose: Low levels of excision repair cross complementation group 1
(ERCC1) protein expression have been associated with prolonged survival in
early stage NSCLC patients after adjuvant treatment with platinum-based
chemotherapy. The association of ERCC1 expression and survival after
platinum chemotherapy in metastatic NSCLC is less well defined and the
results to date have been conflicting. The purpose of this study was to
examine the association between ERCC1 expression and survival in meta-
static NSCLC patients treated with platinum-based chemotherapy at a single
institution.
Patients and Methods: In this retrospective cohort study, tumor tissue from
59 patients enrolled on clinical trials at the Massachusetts General Hospital
(MGH) between 2002–07 utilizing first-line platinum-based chemotherapy
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was evaluated for ERCC1 protein expression by immunohistochemistry
(IHC). All patients had histologically or cytologically proven metastatic
NSCLC and paraffin-embedded tissue available for analysis. ERCC1 expres-
sion was assessed using a semi-quantitative histology score (H-score) based
on both the percentage of positive tumor nuclei and staining intensity, and
the median H-score was chosen as the cut-off point for ERCC1 positive and
negative tumors. Using a log rank test, the overall survival (OS) of patients
with ERCC1 positive and ERCC1 negative tumors was compared as the
primary outcome of interest. Exploratory endpoints included the association
of ERCC1 expression with time to progression (TTP) and with tumor
shrinkage on radiologist reading (original images not available for tumor
response assessment by RECIST).
Results: The patient characteristics were as follows: the median age was 60
(range 31–81); 51% were male; the PS was 0 in 50% of patients, 1 in 47%,
and 2 in 3%; the histology was 83% adenocarcinoma, 10% squamous, and
7% other; and the median number of subsequent therapies was 2 (range 1–8).
12% of patients were treated with cisplatin and 88% with carboplatin. The
median OS for the entire cohort was 15.3 months. 51% of tumors were
ERCC1 negative by IHC. Median OS was 14.6 months in the ERCC1
negative patients versus 12.9 months in ERCC1 positive patients (p0.62 by
log rank). Median TTP was 5.2 months for ERCC1 negative versus 6.2
months for ERCC1 positive (p0.55). There was also no association be-
tween ERCC1 expression and tumor shrinkage (p0.8).
Conclusions: In this cohort of patients with advanced NSCLC treated with
platinum-based chemotherapy as part of clinical trials at MGH, there was no
association between ERCC1 protein expression and OS, TTP, or tumor
shrinkage. There are a number of possibilities for the discrepancy between
this study and the positive association seen in early stage patients treated with
adjuvant chemotherapy. Expression of ERCC1 in the primary tumor may be
relatively concordant with expression in micrometastatic disease, thus pro-
viding a better assay for platinum sensitivity compared to the more hetero-
geneous ERCC1 expression seen in established metastatic foci. Other pos-
sible factors include our small sample size and heterogeneity across multiple
treatment regimens in the cohort.
Supported by the following grants: RO1CA092824, RO2CA074386,
P42CA090578 (D.C.C.), K12 CA087723.
A40
ODC mRNA expression in curatively resected non-small cell
lung cancer (NSCLC)
Peter P. Grimminger1, Peter V. Danenberg1, Vallbo¨hmer Daniel2, Paul M.
Schneider3, Arnulf H. Ho¨lscher2, Jan Brabender2. 1University of Southern
California, Los Angeles, CA, 2University of Cologne, Cologne, Germany,
3University Clinic Zu¨rich, Zu¨rich, Switzerland
Introduction: The effect of the ornithine decarboxylase (ODC) in the
pathogenesis in NSCLC remains poorly investigated. Hence the aim of this
study was to explore the potential role of ODC mRNA expression as a
prognostic biomarker in patients with curatively resected NSCLC.
Methods: 91 tumor and matching non-tumorous lung tissue samples from
patients with NSCLC were analyzed using a quantitative real-time RT-PCR
method. The relative ODC mRNA expression was measured in tumorous and
non-tumorous lung tissue using -actin as a reference gene. Squamous cell
carcinoma was found in 43 patients (47%), adenocarcinoma in 33 (36%) and
in large cell carcinoma in 15 (17%) of the patients. All patients were R0
resected.
Results: ODC was detected in all 91 tumor and non-tumorous lung tissue
samples. The median tumorous expression of 9.11 (0.92–155.35) signifi-
cantly elevated compared to the median ODC expression of 7.89 (0.0- 45.8)
in non-tumorous lung tissue. ODC expression levels were not associated with
any clinicopathological parameters. Using an ODC/-actin ratio of 10 as a
cut-off, tumorous ODC expression is a significant prognostic factor in
NSCLC. The ODC ratio between tumorous and non-tumorous expression
was even more prognostic. Moreover, Cox’s proportional hazards model
analysis showed ODC expression to be an independent prognostic factor.
Conclusions: In this study ODC is shown to have a prognostic potential in
NSCLC. Low levels of tumorous ODC expression are associated with a more
aggressive tumor biology. Also a increase of ODC mRNA expression during
carcinogenesis seems to have a favorable prognostic effect. Measuring the
ODC expression in NSCLC patients could help in further chemotherapy
decisions. Our results suggest that further investigation of ODC mRNA
expression in NSCLC may be warranted.
A41
The prognostic role of Bcl-2 mRNA expression in curatively
resected non-small cell lung cancer (NSCLC)
Brabender Jan1, Peter V. Danenberg2, Paul M. Schneider3, Daniel
Vallbo¨hmer1, Arnulf H. Ho¨lscher1, Ralf Metzger1, Peter P. Grimminger2.
1University of Cologne, Cologne, Germany, 2University of Southern California,
Los Angeles, CA, 3University Clinic Zu¨rich, Zu¨rich, Switzerland
Background: The effect of the apoptosis related gene Bcl-2 in the patho-
genesis in NSCLC remains poorly investigated. Hence the aim of this study
was to explore the potential role of Bcl-2 mRNA expression as a prognostic
biomarker in patients with curatively resected NSCLC.
Methods: 91 tumor and matching normal tissue samples from patients with
NSCLC were analyzed using a quantitative real-time RT-PCR method. The
relative Bcl-2 mRNA expression was measured using -actin as a reference
gene. 45 of the 91 patients had stage I tumors (49%), 19 had stage II (21%)
and 27 had stage IIIa (30%). Squamous cell carcinoma was found in 43
patients (47%), adenocarcinoma in 33 (36%) and in large cell carcinoma in
15 (17%) of the patients.
Results: Bcl-2 mRNA expression was detected in 83 (91%) of the investi-
gated tumor samples and in 74 (81%) of the normal lung tissue. The median
gene expression was 0.147 in tumor tissue and 0.144 in matching normal
lung tissue (pn.s., Wilcoxon test). No associations were seen between the
tumorous Bcl-2 mRNA expression levels and clinical or histopathologic
parameters such as gender, tumor size, TNM stadium and grading, but with
tumor histology and smoking. With a follow up period of 63–105 months, the
median survival time was 57.0 months. Bcl-2 mRNA expression was
significantly associated with patients prognosis (p0.013, Log Rank test).
Multivariate regression analysis revealed Bcl-2 expression status and tumor
stage as independent prognostic factor.
Conclusions: Low Bcl-2 expression in NSCLC suggests a more aggressive
cancer biology and has a potential as a biomarker for this disease. Our data
suggests that Bcl-2 mRNA expression plays a crucial role in the biological
behavior of NSCLCs. Quantitation of Bcl-2 expression improves estimation
of prognosis and appears to identify patients who will benefit from intensive
adjuvant therapy.
A42
Circulating cell free RNA level and clinical response to the
chemotherapy in patients with lung cancer
Choonhee Son1, Tae-Won Jang2. 1Dong-A University Hospital, Busan,
Republic of Korea, 2Kosin University Hospitala, Busan, Republic of Korea
Introduction: It is well known that circulating cell free RNA level(cRNA)
rises in patients with many kinds of cancer. Recently, several studies showed
cRNA might be a surrogate marker for the clinical outcome, suggests
circulating RNA level may correlate with tumor burden. And experimental
study with cancer cell line showed the changes of cRNA are predictive for
the response to the chemotherapy.
Objectives: We tried to find out whether cRNA can be used as a biomarker
for clinical response to chemotherapy in patients with thoracic malignancy.
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Methods: Twenty-three patients with lung cancer (NSCLC n17, SCLC
n4, unclassifiable carcinoma n1, mesothelioma n1) were divided into
two groups according to the response of chemotherapy (Partial response
group n12, group I; non response group n11, group II). Blood samples
were collected 2 times before and after chemotherapy. The RNA was isolated
from 1mL serum with the RNA spin Mini RNA Isolation Kit (GE Health-
care, USA). A real-time quantitative RT-PCR assay (QRT-PCR, TaqMan
format) was used for transcript quantification of the glyceride 3-phosphate
dehydrgenase (GAPDH) gene.
Results: Pre (group I: 41.06 vs. group II: 41.23; p0.85) and post (group I:
39.77 vs. group II: 40.90; p0.09) chemotherapy RNA concentration ex-
pressed as Ct GAPDH level were not different between two groups. More-
over, rising or falling tendencies of cRNA after chemotherapy were not
different between two groups (p0.68).
Conclusion: We could not find any correlation between cRNA and clinical
response to chemotherapy in patients with lung cancer. There would be two
possible explanations. First, blood sampling time after chemotherapy was not
appropriate for the reflection of the changes of cRNA. Second, our study
patients had heterogeneous tumor characteristics that may be a cause of
failure to prove cRNA as a surrogate for the response to chemotherapy.
A43
Tumor microRNA biomarkers associated with de novo chemo-
resistance in small cell lung cancer
Glen J. Weiss1, Aarati R. Ranade2, David Cherba3, Shravan Sridhar2, Patrick
Richardson3, Anoor Paripati1, Brad Bowles1, Craig Webb3. 1Scottsdale
Clinical Research Institute/TGen, Scottsdale, AZ, 2The Translational
Genomics Research Institute (TGen), Phoenix, AZ, 3Van Andel Research
Institute, Grand Rapids, MI
Background: Standard treatment for small cell lung cancer (SCLC) is
platinum-based chemotherapy. Up to 30% of SCLC patients are de novo
platinum-resistant, without alternative therapeutic options for first-line ther-
apy (Schmittel et al Ann Oncol 2007; Lara et al. JCO 2009). We sought to
identify tumor microRNA (miRNA) biomarkers associated with de novo
chemoresistance (measured as disease progression [PD] at first radiologic
response assessment) in SCLC that may identify these patients for future
clinical trial stratification.
Methods: Diagnostic tumor samples were obtained after prior approval of
the local Institutional Review Board (IRB) from patients diagnosed between
2001 to 2007 and receiving care and follow-up at Scottsdale Healthcare
(Scottsdale, Arizona). All patients subsequently received systemic chemo-
therapy. Baseline clinical characteristics were available including age at
diagnosis, gender, limited- or extensive-stage disease, smoking history, and
the presence of baseline co-morbidities (hyperlipidemia, history of myocar-
dial infarction or cerebrovascular accident, congestive heart failure, periph-
eral vascular disease, hypertension, diabetes, deep vein thrombosis, pulmo-
nary embolism, chronic obstructive pulmonary disease [COPD], or
emphysema). miRNA profiling was performed on the GenoExplorer mi-
croRNA Expression System (Sanger miRNA Registry, version 13.0 March
2009). Array data was normalized to RNU6 and 5S-rRNA and miRNA
analysis was performed using XenoBase version v3.4.2009.0922, a data
integration and discovery tool developed at the Van Andel Research Insti-
tute. This tool integrated the clinical data, miRNA probe data and interaction
data from the Sanger miRNA Registry. Expression level of the top 16
miRNA candidates for PD were validated by qRT-PCR and normalized to
RNU6 and 5S-rRNA. Fisher’s exact test was used to identify any significant
(p0.05) associations between baseline co-morbidities and chemoresistance.
Results: Total RNA was extracted from 34 FFPE SCLC tumor specimens of
which, 34 samples had sufficient total RNA yield to perform miRNA
microarray profiling while 28 samples had sufficient total RNA for perform-
ing qRT-PCR. For the 34 patients, median age was 69.1 years (range
42.5–82.5). There were 17 men and 17 women. The most prevalent docu-
mented baseline co-morbidities were hypertension (47%) and COPD/emphy-
sema (32%). Stage was available for 33 patients, of which, 12.1% were
limited-stage and 87.9% extensive-stage at diagnosis. All 34 patients re-
ceived systemic chemotherapy, a platinum-based regimen was the confirmed
treatment for 28 patients. Response evaluation by CT imaging was available
for 21 patients. There were 2 complete responses, 13 partial responses, 2 with
stable disease, and 4 with PD. Of the top 16 miRNA biomarker candidates
for PD by miRNA array analysis, three miRNAs were validated by qRT-
PCR, including miR-92a-2* (p0.010), miR-147 (p0.018), and miR-
574-5p (p0.039). There were no significant associations between baseline
co-morbidities and chemoresistance.
Conclusions: In this study, at least 3 tumor miRNAs appear to be signifi-
cantly associated with de novo chemoresistance. No baseline co-morbidities
were significantly associated with chemoresistance. Preclinical investigation
of the biological relevance of these miRNAs is ongoing. Additional valida-
tion of these potential biomarkers warrants further exploration in an inde-
pendent cohort of SCLC patients.
Acknowledgments: This work was supported by the American Cancer
Society-Sylvia Chase Pilot Grant, IBIS Foundation of Arizona, and TGen
Foundation.
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A44
MicroRNA biomarkers associated with vandetanib, sunitinib,
and/or erlotinib resistance
Glen J. Weiss1, Kristen M. Nelson2, David K. Edwards, V2, Scott P.
Boisvert2, Chao Sima2. 1Scottsdale Clinical Research Institute/TGen,
Scottsdale, AZ, 2The Translational Genomics Research Institute (TGen),
Phoenix, AZ
Background: Tyrosine kinase inhibitors (TKIs) are increasingly being tested
in non-small cell lung cancer (NSCLC). We sought to identify in vitro
microRNA (miRNAs) biomarkers associated with resistance to vandetanib
(V), sunitinib (S), and/or erlotinib in NSCLC lines.
Methods: V and S sensitivity was determined in 7 NSCLC lines (A549,
H358, H460, H520, H1703, H2122, and HCC827); E sensitivity was deter-
mined in same 7 cell lines, as well as, HCC4006 and H2073. Drug IC50s
were determined using an Alamar Blue proliferation assay at 72 hours. We
assessed expression of 7 miRNA candidates by qRT-PCR, derived in a
similar manner to work by our group using HCC827 cells with acquired
resistance to E after repeat exposure to E (Nelson et al. AACR 2009). Data
were normalized to the reference RNU6 and fold changes were computed
against the selected sensitive cell line for each drug. A two-sided z-test was
used to compute the p-values for the fold changes. To see whether a miRNA
can determine resistance across cell lines, a score is calculated as follows:
first, its fold changes were ternarized: significant increase (1; fold change
1 AND p-value 0.05), significant decrease (-1; fold change 1 AND
p-value 0.05), non-significant fold change (0). These values were then
compared with the characteristics of the cell lines: 1/-1 on a resistant/
sensitive cell line will be counted as one plus point and otherwise as one
minus point. A non-significant fold change will not be counted regardless of
the sensitivity of the cell line. Finally the score is computed as the total points
divided by the number of cell lines (reference cell line was not used in
computing the scores). The “TKI resistance score” of “1” or “-1” suggests a
perfect miRNA resistance indicator for the cell lines tested, while if the score
is close to zero, it implies either too many insignificant values or too many
inconsistencies.
Results: For V, HCC827 (IC500.4uM) was classified as sensitive. For S,
H1703 (IC500.9uM) was classified as sensitive. For E, HCC827
(IC500.76uM) and HCC4006 (IC500.02uM) were classified as sensitive.
The remaining lines were resistant for V, S, and E with IC50s ranging from
2.5 to 14.4uM, 4.5 to 9.5uM, and 10 to 50uM; respectively. All 7 miRNAs
were successfully measured in the NSCLC lines. Applying the TKI resis-
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tance score, miR-21 had the best result for S with a score of 0.67. miR-424
had the best result for V and E 0.67 and 0.75 individually, and 0.71
across both groups together.
Conclusions: There are varying in vitro sensitivities across TKIs for a
currently FDA approved TKI (E) or TKIs current being tested in NSCLC
clinical trials (V and S). NSCLC lines have similar sensitivity and resistance
to V and E, although V appears to be more potent in vitro, as reflected by
lower IC50s. There are miRNAs associated with TKI resistance. miR-424
may be useful to explore as a biomarker for both V and E resistance, while
miR-21 may be more appropriate to explore as a biomarker for S resistance.
If validated in clinical samples, these miRNA biomarkers may assist in
treatment stratification for NSCLC clinical trials.
A45
Initial evaluation of the health economic impact of a
prognostic 15-gene expression-based signature in early-stage
NSCLC patient management
Er Chen1, Christine Buerki2, Fadia Saad2, Marianne Laouri1. 1Quorum
Consulting Inc., San Francisco, CA, 2Med BioGene Inc., Vancouver, BC,
Canada
Introduction: LungExpress Dx™ is a 15-gene expression-based prognostic
signature in early-stage (stage I and II) non-small-cell lung cancer (NSCLC)
for identifying, more selectively than clinicopathological criteria, patients
with significantly different prognoses, and may provide additional clinical
value beyond standard measures of risk. This high / low risk stratification is
independent of such clinicopathological criteria, including stage, histology,
gender and age, and may assist in guiding the post-surgical treatment of
early- stage NSCLC patients. An initial evaluation of the health economic
impact of the 15-gene signature was conducted by comparing it to the current
clinical practice in early-stage NSCLC patient management.
Methodology: We developed a Markov model with two mutually exclusive
health states; alive, and dead, spanning a lifetime horizon. The patient outcome
data and risk stratification were based on a recent validation study of the
prognostic performance of the 15-gene signature. The efficacy of adjuvant
chemotherapy was derived from published clinical trials, and costs were ob-
tained from the literature or through micro-costing. Survival benefits and costs
were discounted at a rate of 3% per year. One-way sensitivity analysis was
performed to account for the uncertainty in some model parameters.
Results: Nearly 52% of patients were reassigned to a new risk category when
the 15-gene signature was applied instead of the clinicopathological criteria.
Overall, application of the 15-gene signature led to an increase of 0.89 life years
while being at least cost neutral. The model results were sensitive to the risk
reduction associated with adjuvant chemotherapy, the costs of adjuvant chemo-
therapy and treatment failure, as well as the cost of the test.
Conclusions: Based on this initial analysis, integrating the 15-gene signature
into current clinical practice to assist in guiding treatment decisions appears to be
a cost-effective strategy for the management of early-stage NSCLC patients.
Session B
Basic Research, Cancer Stem Cells,
Immunology, Noncoding RNAs, Tumor
Microenvironment
B1
Examination of the cancer stem cell hypothesis in human lung
tumors
Kerstin W. Sinkevicius, Carla F. Kim. Children’s Hospital Boston, Boston,
MA
We hypothesize that a population of cells possessing stem cell characteristics
called cancer stem cells (CSCs) drive lung tumor growth and metastasis. This
hypothesis is particularly important to investigate because CSCs may have
distinct biological mechanisms that render them more resistant to chemo-
therapy than other cancer cells. If lung tumors contain a CSC population,
treatments that specifically eliminate the CSC population may provide more
effective, novel means of therapy. To investigate the CSC hypothesis in
human lung tumors, we first established an orthotopic transplantation assay
to propagate tumors from primary human lung non-small cell lung cancer
(NSCLC) cells. Nude and more severely immunodeficient NOG (NOD/
SCID-IL2RY-null) mice developed secondary tumors 12 and 3 months,
respectively, after transplantation of 100,000 cells into the lungs. Next, we
used this assay to compare the ability of different human NSCLC cell
populations to serially propagate tumors in the lungs of recipient mice. We
are also determining if lung cancer cell invasion and metastasis requires the
activity of chemokine receptors, proteins known to function in the dissem-
ination and homing of normal stem cells. Together, these studies will
determine if and how stem cell biology approaches can be applied to
understand lung cancer biology, insight that is crucial for therapeutic ad-
vances for lung cancer patients.
B2
Polo-like kinase-1 regulation by cyclooxygenase-2 in non-small
cell lung cancer
Young Whan Kim1, Kyu-Hwa Lee1, Jae-Jun Yim1, Chul-Gyu Yoo1, Choon-
Taek Lee1, Sung Goo Han1, Young-Soo Shim1, Sherven Sharma2, Steven M.
Dubinett2, Seok-Chul Yang1. 1Seoul National University College of Medi-
cine, Seoul, Seoul, Republic of Korea, 2University of California Los Angeles,
David Geffen School of Medicine, Los Angeles, CA
Background: Lung cancer is the most common cause of cancer-related
mortality in men and women in the United States, accounting for 30% of all
such deaths per year. Despite focused research in conventional therapies and
considerable advances in the understanding of the molecular carcinogenesis
of lung cancer, the 5-year survival rate for all lung cancer patients remains
less than 15%. Elevated expression of cyclooxygenase-2 (COX-2) and
Polo-like kinase-1 (PLK-1) is observed in a wide variety of cancers. Aug-
mented expression of COX-2 and enhanced production of prostaglandin E2
(PGE2) are associated with increased tumor cell survival and malignancy;
COX-2 has been implicated in the control of human non-small cell lung
carcinoma (NSCLC) cell growth. PLKI-1 is a key player in the mitotic
regulation of both normal and malignant transformed cells. PLK-1 siRNA
induced the cell death of lung cancer cells and the systemic administration of
PLK-1 siRNA/atelocollagen complex inhibited the growth of lung cancer in
a liver metastatic murine model. There is a strong correlation between their
interactions in prostate carcinoma. But there are few studies about these two
targets for cancer prevention and treatment. The goal of this study is to
evaluate the possible association between COX-2 and PLK-1 in NSCLC.
Methods: In this study, we investigated the pattern of expression of COX-2
and PLK-1 expression in human lung cancer cell lines such as A549 and
NCI-H157 cells and COX-2 gene modified A549 cells (COX-2 vector,
COX-2 sense, and COX-2 anti-sense A549 cells) after treatment with IL-1,
COX-2 inhibitor, and PLK-1 siRNA.
Results: Expression of PLK-1 was decreased in A549 COX-2 sense cells,
and was increased in A549 COX-2 anti-sense cells. Knock out of PLK-1
expression by PLK-1 siRNA augmented COX-2 expression in A549 and
NCI-H157 cells. When A549 and NCI-H157 cells were treated with COX-2
inhibitor on a dose dependent manner, PLK-1 and COX-2 were reduced.
However, when the expression of COX-2 was induced by IL-1, the
production of PLK-1 decreased.
Conclusions: These results demonstrate that COX-2 and PLK-1 have a
strong relationship, possibly being regulated and inhibited by each other in
NSCLC, and suggest that these proteins have a reverse relationship in
NSCLC. These proteins may be interesting targets for new molecular
therapies in NSCLC.
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B3
Silver nanoparticles induce antitumor activity in lung cancer:
In vitro and in vivo studies
Hee Sun Park1, Sunhyae Jang1, Hye Rim Cha1, Jeung Eun Lee1, Ju Ock
Kim1, Tae Won Jang2, Choon-Hee Son3, Young June Jeon4, Sun Young
Kim1. 1Chungnam National University Medical School, Daejeon, Republic
of Korea, 2Kosin University College of Medicine, Busan, Republic of Korea,
3Dong-A University, Busan, Republic of Korea, 4Keimyung University
School of Medicine, Daegu, Republic of Korea
The use of nanotechnology in medicine, specifically as a drug, is set to spread
rapidly. Silver has been known since ancient times and has long been used
as disinfectant. Nanoparticles are attractive for their important and unique
features, such as their surface to mass ratio that is much larger than that of
other particles, their quantum properties and their ability to absorb and carry
other compounds. We investigate the antitumor activity of the silver nano-
particles (SNPs) in various human lung cancer cell lines and in a xenograft
animal model (Lewis lung carcinoma cells into C57BL/6 mice). These cell
lines were treated with various concentrations of SNPs for different intervals
(24, 48 and 72 hours). Cytotoxicity was assessed by the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide] assay. We found
that SNPs decreased cell viability and activated the caspase-dependent
pathway, determined by increased levels of poly (ADP-ribose) polymerase
(PARP)-1 cleavage product. Among these cell lines, H520, human lung
squamous carcinoma cell line, was the most sensitive. FACS analysis also
shows that SNPs induced cell death of H520 lung cancer cell line. Antitumor
effects of SNPs clinically were investigated in a xenograft animal model. The
solid tumor growth was significantly inhibited in SNPs-inhaled mice group.
In this investigation, we revealed, for the first time, that SNPs showed
antitumor activity on both in vitro and in vivo.
B4
LKB1-dependent proteasomal degradation of STRAD in
non-small cell lung cancer
Carrie M. Eggers, Wei Zhou, Adam I. Marcus. Emory University, Atlanta, GA
LKB1 is a serine/threonine kinase that is mutated in approximately 30% of
non-small cell lung cancer primary tumors. It regulates cell polarity and
growth, and is a lung cancer tumor suppressor. We have previously shown
that LKB1 loss disrupts lung cancer cell polarity through the canonical cdc42
cell polarity pathway, potentially leading to aberrant cell migration. LKB1
associates with its co-factor STRAD, a pseudokinase that enhances LKB1
activity and is required for LKB1 cytoplasmic localization; however, the
mechanism of how these two proteins interact to regulate cell polarity is not
fully elucidated. Here we show that STRAD protein levels are LKB1-
dependent, such that loss of LKB1 in mutant or depleted cell lines results in
a concomitant decrease in STRAD protein levels without any effects on
STRAD transcription. Conversely, when LKB1 is re-expressed, normal
STRAD levels are restored independent of LKB1 kinase activity. Further
analysis revealed that STRAD is rapidly degraded through the proteasome
and proteasome inhibition in the absence of LKB1 restored STRAD levels,
similar to LKB1 re-expression. Overall, these results suggest a pathway
whereby LKB1 protects STRAD from proteasomal degradation and loss of
LKB1 causes a rapid degradation of STRAD via the proteasome.
B5
Alveolar hypoxia enhancees tumor progression in murine lung
cancer and results in altered chemoprevention sensitivity
York E. Miller1, Robert L. Keith1, Vijaya Karoor2. 1Denver Veterans Affairs
Medical Center, Denver, CO, 2University of Colorado Cancer Center,
Aurora, CO
Background: Emphysema and chronic obstructive pulmonary disease
(COPD) have been repeatedly demonstrated to be associated with increased
risk for lung cancer, even after adjustment for smoking. The mechanism is
unknown, but chronic inflammation or oxygen radical formation have been
postulated to play a role. We hypothesized that the alveolar hypoxia which
occurs in poorly ventilated regions of lung (which are perfused by mixed
venous, rather than arterial blood) may cause increased risk for lung cancer.
Methods: FVB/N mice were either exposed to chronic hypobaric hypoxia
(equivalent to 18,000 ft elevation) or to Denver altitude (5280 ft) for 2 weeks.
Gene expression analysis and cytokine protein expression was determined on
lungs exposed to hypoxia and normoxia. For carcinogenesis experiments,
mice were exposed to hypoxia or normoxia one week after treatment with
either single dose urethane or single dose 3-methylcholanthrene (MCA)
followed by weekly injections of butlyated hydroxytoluene (BHT). Mice
were sacrificed and tumors enumerated and measured at varying times after
carcinogen treatment. Lungs and tumors were analyzed for protein expres-
sion by immunoblotting and immunohistochemistry.
Results: Gene expression analysis revealed that hypoxia upregulated mR-
NAs for a number of growth factors and oncogenes also upregulated in lung
tumors. Cytokine blot analysis revealed upregulation of a number of angio-
genic peptides. Mice exposed to hypoxia did not have an increase in tumor
multiplicity, but tumor volume showed a time dependent increase in hypoxic
mice at 15, 21, and 30 weeks of exposure (p  0.001), with tumor volumes
in the hypoxic mice increased from 3–5 fold. Continuous, rather than
intermittent, hypoxia was required for this tumor promoting effect. Immu-
noblotting demonstrated that HIF-2, but not HIF-1, is upregulated in tumors
of hypoxic mice. VEGFA and C, VEGR2, FGF2, myc, phospho-ERK,
phosphor-AKT, c-IAP1, surviving and Bcl-2 are all upregulated in tumors
from hypoxic animals. Based on this, we performed chemoprevention ex-
periments with a combined VEGFR2/EGFR inhibitor in normoxia and
hypoxia. While the inhibitor was effective under both conditions, the che-
mopreventive effect was greater in hypoxia.
Conclusions: Alveolar hypoxia promotes tumor growth in two murine lung
carcinogenesis models. HIF-2, but not HIF-1, is increased in these tumors,
concomitant with changes in signaling molecules and angiogenic factors.
Hypoxia may be responsible for some of the increased incidence of lung
cancer in patients with emphysema and COPD. Increased expression of
specific angiogenic factors may suggest specific targeted therapeutics that
might be more effective in lung cancer patients with COPD.
B6
LKB1 regulates a novel CRTC1:CREB:NR4A2 pathway in
lung cancer
Takefumi Komiya1, Amy Coxon2, Yoonsoo Park2, Wei-dong Chen2, Maria
Zajac-Kaye3, Paul Meltzer2, Tatiana Karpova2, Frederic J. Kaye3. 1Howard
University Hospital, Washington, DC, 2National Cancer Institute, Bethesda,
MD, 3University of Florida, Gainesville, FL
Activation of the CREB co-activator CRTC1 (also known as Mect1/Torc1)
by a t(11;19) chromosomal rearrangement underlies the etiology of malig-
nant salivary gland tumors. Since LKB1 is a target for mutational inactiva-
tion in 20–30% of non-small cell lung cancer and was recently shown to
regulate hepatic CRTC2/CREB transcriptional activity in mice, we hypoth-
esized that loss of LKB1 might serve as an alternate, nontranslocation
mechanism to activate CRTC/CREB cancer gene pathways in these lung
tumors. Although CRTC1 is preferentially expressed in adult brain tissues,
we observed elevated levels of steady-state CRTC1 protein in thoracic tumor
cell lines using custom generated antipeptide antisera. In addition, we
demonstrated that somatic loss of LKB1 is associated with underphospho-
rylation of endogenous CRTC1 detected by mobility shift on immunoblot-
ting, with enhanced Crtc1 nuclear localization, and with enhanced expression
of the CRTC prototypic target gene, NR4A2/Nurr1. Inhibition of NR4A2
using a hairpin RNAi plasmid was associated with growth suppression of
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tumor cell lines with activated Crtc1 due to either loss of LKB1 or expression
of the translocated CRTC1 fusion oncogene, but showed little effect on
growth of LKB1-wildtype lung tumor cell lines. These data i) strengthen the
role of dysregulated CRTC as a bona fide cancer gene, ii) present a new
element to the complex LKB1 tumorigenic axis, iii) suggest that CRTC
genes may be aberrantly activated in a wider range of common adult
malignancies, and iv) suggest that the orphan nuclear receptor NR4A2/Nurr1
may serve as a therapeutic molecular target in an important subset of human
lung cancer.
B7
Autophagy induces cytoprotection in cisplatin-treated lung
cancer cells
Sei Hoon Yang, Hye Yeon Jang, Hyang Jeong Jo, Kang Kyoo Lee, Sun Rock
Moon, Hak Ryul Kim, Eun Taik Jeong. Wonk Wang University Hospitial,
Iksan, Jeonbuk, Republic of Korea
Purpose: Most of lung cancer patients had received the systemic chemo-
therapy because they had diagnosed the advanced stage at presentation.
Cisplatin-based chemotherapy is main regimen for advanced lung cancer.
But serious adverse reaction (SAE) had occurred after chemotherapy. This is
main reason for chemotherapy withdrawal. If we will use the reduced dose
of cisplatin, cisplatin-based the chemotherapy will be continued. To figure
out whether the effect of low dose of cisplatin will be synergistically enhance
by autophagy inhibition, even though the reduced dose of cisplatin less effect
for treatment response, We investigated that role of autophagy by 3-methy-
ladenine, class III PI3 kinase inhibitor in cisplatin-treated lung cancer cells.
Methods: Lung cancer cells were incubated with normal media and treated
the 5 M (LD20) and 20 M (LD50) of cisplatin according to time
dependent. We examined the sensitivity to low or high doses of cisplatin
treatment using the MTT cell viability assay and compared apoptosis and
autophagy by nuclear staining, apoptotic or autophagic-related proteins or
autophagic vacuoles. autophagy is also displayed the development of acidic
vascular organelles by acridine orange and the fluorescent expression of
GFP-LC3 protein in the GFP-LC3 transfected cells.
Results: Low dose of cisplatin-treated lung cancer cells is relatively less
sensitive to cell death rather than high dose treated cells in a time-dependent
manners. We did not find out the nuclear fragmentation in lower dose even
though detected its in high dose. PARP cleavages also were not detected in
low dose of cisplatin exception 24H. We observed that massive vacuolization
in the cytoplasm were seen at lower dose treated cells. Acridine orange
stain-positive cells also were increased according to time dependent. We
figured out that the autophagosome-incorporated LC3 II protein expression
more increased in low dose treated cells (24H to 48H) in spite of no detection
of LC3 II in high-dose treated cells. The expression of GFP-LC3 were
increased in 5 M treated cells by time-dependent manner. When 3-methy-
ladenine, class III PI3kinase inhibitor, was pretreated in 5 M cisplatin-
treated lung cancer cells, cell survival significantly were decreased.
Conclusion: Autophagy induces cytoprotection in lower dose of cisplatin-
treated lung cancer cells.
B8
Dual roles for the LKB1-STRAD tumor suppressor pathway
in the lung cancer cell polarity and motility programs
Erik R. Kline, Katherine Hales, Adam I. Marcus. Emory Winship Cancer
Institute, Atlanta, GA
The serine/threonine kinase LKB1 is mutated in 30% of non-small cell lung
cancers, and is the third most frequently mutated gene in lung adenocarci-
noma. LKB1 regulates energy metabolism and cell polarity through its
association with its co-factor STRAD. We previously showed that when a
lung cancer cell first polarizes, LKB1 migrates to the leading edge coordi-
nating polarity via a canonical cell polarity protein, the small Rho GTPase
cdc42 and its binding partner PAK. Here, we investigate the LKB1-STRAD
pathway during the transition from polarity to cell motility. Using confocal
immunofluorescence microscopy, we show that when a cancer cell becomes
motile, STRAD relocalizes to associate with vimentin intermediate fila-
ments in a motility-dependent manner. To dissect the mechanistic basis of
this observation, we tested the hypothesis that STRAD regulates vimentin
function to oversee cancer cell motility. We show that STRAD co-localizes
with phosphorylated Ser56 vimentin at the tips of immature vimentin
filaments and fully decorates mature vimentin filaments in an LKB1-inde-
pendent manner. STRAD loss results in aberrant lamellipodia formation,
uncoordinated movement, vimentin bundling, and decreased vimentin Ser56
phosphorylation. Conversely, STRAD, but not LKB1 overexpression, dis-
assembles the vimentin network with no apparent effect on cell survival.
These findings suggest a cell polarity-motility program whereby LKB1-
STRAD initiates cell polarity through cdc42-PAK, then STRAD re-
localizes to the vimentin cytoskeleton to oversee vimentin dynamics in an
LKB1-independent fashion. These results link the LKB1-STRAD tumor
suppressor pathway to the lung cancer cell polarity and motility programs,
and explain how defects in LKB1-STRAD alter lung cancer invasion.
B9
The EphA3 receptor suppresses tumorigenicity in non-small
cell lung cancer through mTOR pathway
Guanglei Zhuang, Luping Lin, Dana Brantley-Sieders, Takefumi Kikuchi,
David Carbone, Jin Chen. Vanderbilt-Ingram Cancer Center, Nashville, TN
Somatic mutations of Eph receptors in lung cancer have been recently
identified in multiple systematic mutational screens. However, the oncogenic
potential of Eph receptors and mutants has not been extensively evaluated
and precisely defined. In this study, we applied an integrative approach to
identify EphA3 receptor tyrosine kinase as a potent tumor suppressor in
non-small cell lung cancer (NSCLC). By analyzing SNP array-based genetic
maps with gene expression signatures, we found that EphA3 resided in a
frequently deleted focal locus on chromosome 3p. EphA3 was frequently
downregulated in lung cancer at both transcriptional and protein levels.
Functionally, reduction of EphA3 promoted cell migration by altering
cytosketon organization, while ectopic EphA3 expression inhibited cell
migration in vitro and tumor growth in vivo. EphA3 suppressed tumorige-
nicity in a kinase activity-dependent manner by regulating the mTOR
signaling pathway. More importantly, somatic mutations of EphA3 discov-
ered in lung cancer patients significantly decreased EphA3 kinase activity.
These findings identify a novel EphA3 signaling pathway with tumor-
suppressor activity in NSCLC, and predict that therapeutic intervention to
diminish mTOR function will improve the survival of patients with EphA3
deletion or mutation.
B10
Human non-small cell lung is significantly infiltrated with
regulatory T cells
Adam Yagui-Beltra´n1, Magnus Johansson2, Biao He1, Lisa M. Coussens2,
David M. Jablons1. 1Department of Surgery and 2Department of Pathology,
University of California San Francisco, San Francisco, CA
Introduction and Objective: Five-year survival for non-small cell lung
cancer (NSCLC) remains static at 15% despite advances in therapeutic
modalities. Studies have shown that chronic inflammation promotes carci-
nogenesis by aberrantly exploiting physiological tissue homeostatic pro-
cesses. Moreover, increased macrophage infiltration in malignancies of the
breast, ovaries and the lung, for example, has been associated with poor
clinical outcome, perhaps indicating a functional pro-tumor role(s) of spe-
cific infiltrating leukocytes in tissue-specific microenvironments. We aim to
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1) determine the relevant leukocytes in lung cancer and 2) identify the
molecular and cellular mechanisms governing their functional significance.
Methods: We will exploit adapted ex vivo 3-dimensional (3D)-organotypic
systems from originated from NSCLCs from our surgeries at UCSF, com-
bined with multiplex immunohistochemical, flow cytometric and fluores-
cence-activated cell sorting (FACS) techniques to 1) immunophenotype
tumor infiltrating leukocytes and 2) define the molecular and cellular mech-
anisms behind their functional significance in the carcinogenesis and pro-
gression of NSCLC. The data yielding from our results, we hope, will be the
basis for future translational studies.
Results: 1) Significant increased infiltration of CD45 leukocytes in human
NSCLC compared to bordering “normal” lung parenchyma. 2) Tumor
infiltrating leukocytes are majorly composed of CD4CD25 regulatory T
cells (Tregs), which in physiological circumstances are involved in the
prevention of autoimmunity, but which seems to be play a pro-tumor role in
lung cancer.
Conclusion and Future Perspectives: Recent studies by other groups and
our preliminary observations lead us to hypothesize that microenvironmental
antitumor immunosuppression is carried out by specific subpopulations of
adaptive leukocytes. Thus, identifying the culprit immune cells, and the
mechanisms that allow them to interplay with malignantly initiated lung
epithelial cells and immune populations involved in cancer “killing” (such as
CD8 T cells) leading to full-blown tumors becomes paramount. The
information gained will serve as a platform to future studies aiming to design
new agents that target the pro-cancer leukocytes within the various pulmo-
nary microenvironments, which in turn could be taken to preclinical and
clinical studies to assess their therapeutic power as either as potentiators of
available cytotoxic or targeted agents or as novel single agents against lung
cancer.
The authors were supported by grants from the National Institutes of
Health (CA132566, CA130980), a Dept of Defense Award for Mesothelioma
(W81XWH-09-1-0342), an Era of Hope ScholarAward (W81XWH-06-1-
0416), Bonnie J. Addario Lung Cancer Foundation, Kazan, McClain,
Abrams, Fernandez, Lyons, Greenwood, Harley & Oberman Foundation
Inc., and The Eileen D. Ludwig Endowed Chair Fund for Thoracic Oncology
Research.
B11
VEGF and the epigenetic regulation of its receptors in non-
small cell lung cancer
Martin Barr, Steven Gray, Kathy Gately, Graham Pidgeon, Kenneth
O’Byrne. St. James’s Hospital, Dublin, Ireland
Introduction: VEGF is a potent angiogenic cytokine that is overexpressed in
non-small cell lung cancer (NSCLC). In this study, we examined the role of
VEGF in non-small cell lung cancer cells and the epigenetic mechanisms
regulating expression of its receptors.
Methods: A549 (adenocarcinoma) and SKMES1 (squamous cell) NSCLC
cells were screened for the VEGF receptors VEGFR1 (Flt-1), VEGFR2
(KDR), Neuropilin-1 (NP1) and Neuropilin-2 (NP2). The effect of VEGF
(100ng/ml) on cell proliferation was examined using the BrdU assay. Cell
cycle was assessed by propidium iodide staining following VEGF blockade
(1mg/ml). Phosphorylation of the downstream signalling proteins, Akt/PKB
(PI3K) and Erk1/2 (MAPK) was examined by confocal microscopy. VEGF
receptor expression in response to the histone deacetylase inhibitor, TSA
(Trichostatin A), was assessed, in addition to its effect on proliferation and
apoptosis of NSCLC cells. Cells were treated with TSA and VEGF levels
were measured in conditioned media by ELISA. The ChIP assay was used to
study the association between histone proteins and DNA while the effect of
TSA on acetylation of histones H3 and H4 was examined by Western
blotting. The cell survival effects of VEGF on A549 and SKMES1 cells
following NP1 and NP2 gene silencing (100nM siRNA) and KDR blockade
using neutralizing antibodies, were examined using the MTT assay.
Results: VEGF increased proliferation of NSCLC cells while VEGF block-
ade using VEGF antibodies induced growth arrest in the G0/G1 phase of the
cell cycle. VEGF induced phosphorylation of the cell signal proteins Akt and
Erk1/2. TSA, which itself induced cell death, upregulated the expression of
VEGFR1 and VEGFR2 and downregulated NP1 and NP2. De novo protein
synthesis was required for downregulation of the Neuropilin receptors by
TSA but not for VEGFR1 and VEGFR2. Increased acetylation of histones
H3 and H4 by TSA was observed in both cell lines. VEGF secretion by
NSCLC cells was decreased in response to TSA. Addition of VEGF was
however unable to rescue cells from TSA-induced cell death. Silencing of
NP1 and NP2 receptors and neutralization of KDR reduced survival of A549
and SKMES1 cells. VEGF was unable to rescue siNP1 and siNP2-treated
NSCLC cells.
Conclusion: This study confirms that VEGF is a growth factor for NSCLC
acting, at least in part, through NP1 and NP2. While TSA upregulated
VEGFR1 and VEGFR2 and downregulated the Neuropilin receptors, in
particular NP1, VEGF was unable to rescue cells from TSA-induced cell
death and in siNP1- and siNP2-treated NSCLC cells. These findings impli-
cate the NP receptors as critical survival factors for NSCLC cells.
Methylation Profiling, Epigenetics, Genomics
B12
EYA4 is a novel lung tumor suppressor candidate at the lung
cancer susceptibility locus 6q23-25
Ian M. Wilson1, Emily A. Vucic1, Raj Chari1, Yu-An Zhang2, Daniel T.
Starczynowski1, Timon P.H. Buys1, Aly Karsan1, John Yee3, Calum
MacAulay1, Stephen L. Lam1, Adi F. Gazdar2, Wan L. Lam1. 1British
Columbia Cancer Research Center, Vancouver, BC, Canada, 2University of
Texas Southwestern Medical Center, Dallas, Texas, 3Vancouver General
Hospital, Vancouver, BC, Canada
Background: Since not all smokers will go on to develop lung cancer,
genetic modifiers of non-small cell lung cancer (NSCLC) risk have long been
suspected. Genes associated with nicotinic acetylcholine receptors on chro-
mosome 15 have been identified by multiple groups, and are being further
investigated. Other recent work examining familial lung cancers has identi-
fied a region associated with lung cancer susceptibility located at 6q23-25.
Although gene candidates from this region have been pursued, none have yet
been confirmed as the focal point of the region. The identification of novel
tumor suppressor genes (TSGs) within this region would provide targets for
therapeutics and screening, as well as insights into the germ line and somatic
alterations responsible for lung cancer susceptibility.
Objective: Our primary goal is to identify novel TSGs in the lung cancer
susceptibility locus using a two-hit integrated screen that highlights genes
somatically silenced by both DNA hypermethylation and deletion.
Methods: Copy number status was determined for invasive non-small cell
lung cancers (NSCLC) and carcinoma in situ (CIS) by aCGH using a
whole-genome array. DNA methylation status was determined for tumor and
matched normal DNA using the Illumina Infinium assay. Gene expression
data were generated for these samples using an Agilent 44k expression
microarray, or downloaded from Gene Expression Ominbus. Integrated
analysis of DNA copy number and methylation data in each tumor detected
two-hit regions of alteration. The frequency of two-hit alteration was calcu-
lated, and those probes altered in 15% of samples were investigated
further. This included further analysis of mRNA expression, validation of
DNA hypermethylation by qMS-PCR, evaluation of DNA methylation
control by 5’-aza treatment of cancer cells, evaluation of candidates as
prognostic factors, and candidate gene functional analysis by shRNA-
mediated knock-down.
Results: Our analysis identified somatic hypermethylation and deletion of
the gene EYA4 which is located within the susceptibility locus (6q23–25).
This gene is frequently lost, hypermethylated and silenced in NSCLC
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samples. We also demonstrate allelic loss and under-expression of this gene
in pre-invasive CIS samples, indicating that EYA4 inactivation is a very
early event in tumorigenesis and is maintained through tumor evolution. In
addition to these findings, examination of patient survival data shows that
EYA4 under-expression is significantly associated with poor prognosis.
Finally, we have identified a role for this gene in the apoptotic program by
showing that normal cells with targeted knock down of EYA4 expression
have a significant reduction in apoptosis following serum starvation. Our
data indicated that EYA4 is an important gene in NSCLC that may be
involved in modifying lung cancer risk.
B13
Genome-wide combination profiling of DNA copy number and
methylation for deciphering biomarkers in non-small cell lung
cancer patients
Ji-Woong Son1, Kang-Jin Jeong2, Soon-Young Park2, Chang-Gyo Park2,
Hoi-Young Lee2, Jae-Ku Kang2. 1Konyang University Hospital, Daejeon,
Republic of Korea, 2College of Medicine, Konyang University, Daejeon,
Republic of Korea
Lung cancer is the leading cause of cancer death in the world. Early detection
of lung cancer has the highest potential for saving lives. As yet, no routine
screening method that enables early detection exists, and this is a key factor
in the high mortality rate of this disease. Copy number changes and DNA
methylation alterations are good indicators of carcinogenesis and cancer
prognosis. Recently, a number of microarray studies have been based on
copy number and DNA methylation alterations in order to find clinical
biomarkers of carcinogenesis. In this study, we attempted to combine profiles
of DNA copy number and methylation patterns on 20 paired cancerous and
noncancerous tissue samples from non-small cell lung cancer (NSCLC)
patients and we detected several clinically important genes which showed
genetic and epigenetic relationships. On array comparative genomic hybrid-
ization (CGH), squamous cell carcinoma (SCC) patients showed higher
frequency of gains and losses than adenocarcinoma (AC) patients. Statisti-
cally significant differences were observed across the histologic subtypes for
gains at 1p31.1, 3q26.1, and 3q26.31–3q29, and as well as losses at 1p21.1,
2q33.3, 2q37.3, 3p12.3, 4q35.2, and 13q34 in SCCs, and losses at 12q24.33
occurred in ACs (p0.05). Both ACs and SCCs were commonly observed
chromosomal gains regions at 1q44, 3q24, and 3q26.33, and losses regions
at 2p11.2, 2q37.3, 3p21.1, 7p15.2, 11q12.2, 14q32.33, 16p13.3, and 21q22.3
with highly recurrent. In an analysis of DNA methylation at 1413 autosomal
CpG loci associated with 773 cancer-related genes, we identified 6, 9 and 3,
7 loci showing significantly higher and lower DNA methylation levels in
tumor tissue than adjacent non-tumor lung tissues from ACs and SCCs,
respectively. Of these, two showed common significant hypermethylation in
tumor tissue form ACs and SCCs: HOXA9 and MYOD1. Subsequently we
searched regions exhibiting concomitant hypermethylation and genomic loss
(hemizygous or homozygous) in both ACs and SCCs. Because genomic
changes match epigenetic alterations in the cellular genome, the combined
variation between genomic and epigenomic status could affect the expression
level of genes in these regions in a direct or indirect manner. One clone
representing 7p15.2 (candidate gene such as HOXA9 and HOXA11) and
target ID representing HOXA9 E252 R were commonly detected. Quan-
titative real time PCR demonstrated combined analysis detected potential
candidate HOXA9 gene that were down expressed in most of NSCLC
patients. Moreover, the expression of HOXA9 in A549 was rescued, and the
invasion of A549 was significantly inhibited by treatment with the demeth-
ylation agent 5-aza-2’-deoxycytidine. Taken together, our results show that
combined profiling analysis techniques is useful tool for identification of
biomarkers in lung cancer, and that HOXA9 might represent potential
candidate gene for pathogenesis and diagnosis of NSCLC patients in Korea.
Model Systems: In vivo and in vitro
B14
Differential induction of redox imbalance by urethane in
susceptible and resistant mice models of lung adenocarcinoma
Mauricio S. Caetano1, Carlos Gil Ferreira1, Samuel S. Valenc¸a2, Cinthya
Sternberg1. 1National Institute of Cancer of Brazil (INCA), Rio De Janeiro,
Brazil, 2Institute of Biomedical Sciences, UFRJ, Rio De Janeiro, Brazil
The mechanisms involved in the initiation of lung carcinogenesis are not yet
well understood. Oxidative stress is suggested to play a significant role in this
process and in the present study our purpose was to investigate the role of
redox imbalance induced by urethane exposure, a known adenocarcinoma
inducer, using resistant and susceptible mice models of lung cancer. Female
C57/B6 and A/J 8–12 weeks-old mice were treated with weekly intra-
peritoneal injections of 1mg/g of animal weight of urethane in 0.1 mL of
saline for 4 weeks. The control mice were saline-injected under the same
weekly regimen. Bronchoalveolar lavage (BAL) and total lung tissue were
collected at different time points of the experiment of both control and
urethane-injected mice from both mice strains. Lung tissue was either
processed histologically or stored as a homogenate for further biochemical
measurements. Measurements performed at resistant C57/B6 mice treated
with urethane have shown a decreased catalase activity that correlated to
accumulation of carbonylated proteins 2 weeks after the end of urethane
treatment. Such parameters are regarded as a sign of oxidative stress.
However, from third week on, these parameters were back to control levels.
The modulation of oxidative state of C57/B6 lung was not accompanied by
histological modifications. Surprisingly, we did not observe the same results
in the susceptible A/J mice. Instead, catalase activity increased mildly 2
weeks after the end of urethane treatment, and a further increase was
observed at the fourth week after the end of the urethane regimen. Although
there was no accumulation of carbonylated proteins in A/J urethane-treated
lungs, histological examination of the tissue revealed inflammatory infiltrate
as well as increased cellularity accompanied by thickening of lung septum.
In the present study, we have shown that urethane modulates redox compo-
nents of the lung and this effect seems to be strain dependent. It is known that
urethane-treated A/J mice will develop lung adenocarcinoma within 16–20
weeks after the first injection and that only a very small percentage of
C57/B6 will develop lung cancer under the same conditions. Therefore, we
put forward the idea that the ability of C57/B6 mice to upregulate a proper
stress response to urethane at an initial stage might help lung cells to cope
with urethane toxicity and act as a protective mechanism against carcino-
genesis. On the other hand, the apparent lack of response observed in A/J
mice might mitigate the establishment of a chronic nocive environment that
would contribute to lung tissue damage and subsequent carcinogenesis.
B15
The role of Foxm1 in lung cancer development: Transgenic
gain of function and gene knock-out strategies
I-Ching Wang, Tanya V. Kalin, Yufang Zhang, Jonathan Snyder, Jeffrey A.
Whitsett, Vladimir V. Kalinichenko. Cincinnati Children’s Hospital Medi-
cal Center, Cincinnati, OH
The Forkhead Box M1 (FoxM1) transcription factor is induced in a majority
of human non-small cell lung cancers, and its expression is associated with
poor prognosis. We and others had shown that FoxM1 transcriptionally
regulates a variety of genes essential for cell cycle progression, inflamma-
tion, angiogenesis, and tumor cell invasiveness. Published studies demon-
strated that deletion of N-terminal region of FoxM1 (FoxM1-N) prevented
FoxM1 protein degradation, increased FoxM1 transcriptional activity and
accelerated cellular proliferation in vitro. In present study we determine
whether expression of FoxM1-N mutant will affect cell proliferation and
cancer formation in vivo. To express constitutive activated FoxM1 in the
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lung, we created a new tetO7-FoxM1-N transgenic mouse line. The tetO7-
FoxM1-N mice were breed with either SPC-rtTA or CCSP-rtTA transgenic
mice to induce expression of FoxM1-AN mutant in alveolar type II
epithelial and Clara cells, respectively. Our results showed that Doxycycline
(Dox) treatment induced FoxM1-N transgene in lung epithelial cells caus-
ing increased epithelial proliferation and epithelial hyperplasia. Focal Clara
cell hyperplasia was found in both SPC-rtTA/tetO7-FoxM1-N and CCSP-
rtTA/tetO7-FoxM1-N double transgenic lungs after Dox treatment for 1
month. Alveolar type II cells were isolated and used for quantitative RT-
PCR. Transgenic overexpression of FoxM1-N mutant increased mRNA
levels of multiple cell cycle regulatory genes, including cyclin B1, Plk-1,
c-myc and DNA Topoisomerase II-alpha (Top2a). Thus, constitutive activa-
tion of FoxM1 is sufficient to induce proliferation of respiratory epithelial
cells, causing epithelial hyperplasia in vivo.
We also provided evidence that Foxm1 expression in respiratory epithelial
cells is required for lung tumorigenesis. Using Dox-inducible CRE/loxP
system, we conditionally deleted Foxm1 floxed gene from lung type II
epithelial cells of SPC-rtTA/tetO-CRE/FoxM1fl/fl mice. Foxm1 deletion
prior to tumor initiation caused a striking reduction in the number and size
of lung adenomas induced by either urethane or 3-methylcholanthrene
(MCA)/butylated hydroxytoluene (BHT) treatment. Moreover, conditional
deletion of Foxm1 in pre-existed lung tumors of tumor bearing mice
dramatically reduced tumor growth and this was associated with diminished
DNA Topoisomerase-2 and cyclin B1 mRNA. In vitro experiment demon-
strated that FoxM1 siRNA transfected human adenocarcinoma A549 cells
displayed decreased Top2a mRNA and protein levels. Chromatin immuno-
precipitation (ChIP) and promoter dual luciferase assay demonstrated that
Foxm1 is directly bound to and transactivates mouse TOP2a promoter,
indicating that TOP2a is a direct target of Foxm1. Moreover, we also
detected reduced expression of mitotic regulatory gene Kinesin family
member KIF-14 and NIMA-related kinase 2 (NEK2) in Foxm1-deficient
cells. Our studies demonstrate that the Foxm1 transcription factor is required
for proliferation of tumor cells during formation of lung tumors.
B16
Selective requirement for Akt1 in mutant K-ras-mediated lung
tumor initiation and progression in mice
M. Christine Hollander, Colleen R. Maier, R. Ilona Linnoila, Phillip A.
Dennis. National Cancer Institute, Bethesda, MD
Tobacco use is the leading etiological factor in lung cancer, and tumors
frequently carry mutations in the K-ras oncogene. Mutant K-ras induces lung
tumors in mice that are dependent on PI3K activation, which in turn activates
pro-survival q Akt pathways. Akt inhibitors in clinical development as
cancer therapeutics are not isoform specific, and have uncertain efficacy and
toxicity. Mouse models of mutant K-ras-mediated lung tumorigenesis were
used to validate specific Akt isoforms as potential therapeutic targets.
Genetic deletion of either Akt1, Akt2 or Akt3 were used in two mouse
models for lung tumorigenesis. In the first, the tobacco carcinogen NNK
induces lung tumors with mutations in K-ras. In the second, a mutant K-ras
transgene (K-rasLA2) is activated by a spontaneous recombination event. Of
the 3 Akt isoforms, only Akt1 is required for both lung tumor initiation and
progression by mutant K-ras in mice. Akt1 deletion decreased lung tumor
multiplicity by 95% in the NNK model and by 60–70% in a mutant K-rasLA2
model. In the K-rasLA2 model, average lung tumor size normally increases
with age and is associated with tumor progression. This increase in size was
nearly absent in mice deficient for Akt1, and signaling to Akt and down-
stream of Akt was greatly diminished in tumors lacking Akt1. Knockdown of
Akt1 in human lung tumor cells with mutant K-ras prevented tumor growth
in xenografts. These data validate Akt1 as a specific target for potential
therapeutic intervention in human lung cancer.
B17
In vivo characterization of the role of Erbb3 in mutant EGFR-
induced lung tumorigenesis
Katerina A. Politi1, Pang-Dian Fan1, David W. Threadgill2, Harold Varmus1.
1Memorial Sloan-Kettering Cancer Center, New York, NY, 2North Carolina
State University, Raleigh, NC
Mutations in the EGFR gene are observed in 10–20% of lung adenocarci-
nomas in the United States and Europe. The two most commonly observed
mutations—a point mutation in exon 21 that leads to substitution of a leucine
for an arginine at position 858 and small in-frame deletions in exon 19 that
eliminate an LRA motif in the protein—are associated with sensitivity to the
tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. Seventy-five percent
of tumors bearing these mutations respond to treatment with TKIs. Despite
this high response rate, complete responses are rarely observed and drug
resistance inevitably emerges. Moreover, it remains unclear why 25% of
patients with EGFR-mutant tumors do not respond to treatment.
To address these issues and elucidate the mechanisms of mutant EGFR-
induced transformation of lung epithelial cells we generated tetracycline-
inducible transgenic mice that express either of these two mutants specifi-
cally in the lung epithelium. Upon transgene induction the mice develop lung
adenocarcinomas with bronchioloalveolar carcinoma features that respond to
treatment with erlotinib. Specifically, we tested how the phenotype and
clinical behavior of EGFR mutant lung tumors are influenced by the presence
of other EGFR family members. In lung adenocarcinoma cell lines with
EGFR mutations, activation of the PI3K pathway has been shown to be
mediated by the EGFR heterodimerization partner ERBB3 and is inhibited
by the tyrosine kinase inhibitor gefitinib. Given these findings in vitro, we
asked whether ERBB3 is required for tumorigenesis by mutant EGFR in vivo
by conditionally deleting Erbb3 in the lung epithelium in mutant EGFR-
expressing transgenic mice. To delete Erbb3 specifically in the lung epithe-
lium in the same cells in which we express mutant EGFR, we used TetO-cre
transgenic mice. Experimental animals carry two Tet-inducible transgenes
(TetO-mutant EGFR, TetO-cre), the tetracycline regulator expressed specif-
ically in the lung (CCSP-rtTA), and the floxed Erbb3 allele. Surprisingly,
deletion of Erbb3 does not affect lung adenocarcinoma formation. Moreover,
activation of signaling pathways downstream of mutant EGFR, including the
PI3K pathways, is unaltered in tumors arising in the absence of Erbb3. These
results suggest that Erbb3 is not required for tumorigenesis by mutant EGFR.
Current experiments are underway to establish the mechanism by which
tumors develop in the absence of this receptor.
B18
Blockade of Myc-induced apoptosis by Mcl-1 allows the
development of advanced lung adenocarcinomas
Thaddeus D. Allen1, Chang Qi Zhu2, Kirk D. Jones3, Naoki Yanagawa2,
Ming-Sound Tsao2, J. Michael Bishop1. 1G.W. Hooper Research Founda-
tion, University of California San Francisco, San Francisco, CA, 2Ontario
Cancer Institute/Princess Margaret Hospital, University of Toronto, To-
ronto, Ontario, Canada, 3University of California San Francisco, San
Francisco, CA
MYC is frequently over-expressed in human lung cancer, but how MYC
interacts with other genes that are deregulated is poorly understood. We
over-expressed MYC in the pulmonary epithelium of mice and discovered a
Myc-induced apoptotic program that hindered tumor initiation. In due
course, however, the animals developed both adenomas and adenocarcino-
mas that over-expressed Myc and harbored mutant alleles of Kras. Mutation
of Kras was therefore a genetic event that cooperated with MYC in the
formation of lung tumors. We hypothesized that survival signals downstream of
activated Ras could confer resistance to Myc-induced apoptosis. Contrary to this
supposition, mutant Ras alone could not completely abrogate Myc-induced
apoptosis. Tumor progression required an additional anti-apoptotic event. One
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candidate event was the increased expression of Mcl-1, which we found in a
subset of MYC-transgenic tumors. We examined human lung adenocarcinomas
and found a positive correlation between high MCL-1 and Myc expression and
MCL-1 only conferred poor prognosis to human lung adenocarcinomas when
Myc was co-expressed. Consistently, Mcl-1 was able to block the anti-tumor
effect of MYC activation in mouse tumors but did not have a significant effect on
tumor progression when MYC was not highly expressed. Our results suggest that
Myc-induced apoptosis is an impediment to lung tumorigenesis that is circum-
vented by independent steps during tumorigenesis. The over-expression of
MCL-1 is one adaptation that offsets Myc-induced apoptosis allowing for the
formation of aggressive lung adenocarcinomas.
B19
Human achaete-scute homolog-1 (hASH1) modulates tobacco-
specific nitrosamine (NNK)-induced lung tumorigenesis in
mice
Xiaoyang Wang, Sandra M. Jensen-Taubman, Kathleen Keefe, Ilona R.
Linnoila. National Cancer Institute, Bethesda, MD
Achaete-scute homolog-1 (ASCL1 or hASH1 in humans; ascl1 or Mash1 in
mice) is a proneural, basic helix-loop-helix transcription factor which is
pivotal for neuroendocrine (NE) cell differentiation in normal and neoplastic
lung. In mice hASH1 also greatly enhances SV40 large T antigen –induced
lung carcinogenesis and causes NE differentiation in the tumors. On the other
hand, constitutive expression of hASH1 in non-NE mouse airway progenitor
(Clara) cells results in bronchiolization of alveoli (BOA), a potentially
premalignant lesion mediated by matrilysin-1 (MMP7). In the current study
we examined NNK-induced lung tumorigenesis in the CC10-hASH1 trans-
genic (TG) mice. Mice were given 3 doses of NNK intraperitoneally at
monthly intervals and sacrificed at 24 and 52 weeks from the first injection.
As expected, this resulted in type II cell adenomas characteristic of NNK
treatment. However, tumor formation was delayed in TG mice when com-
pared with that of their wild-type (WT) littermates, which served as controls.
We postulated that this may be due to increased levels of the DNA repair gene
O-6-methylguanine-DNA methyltransferase (MGMT). We have previously
shown that MGM is upregulated in vitro byMMP7 in human airway cells. In the
current study, we were able to demonstrate, that the expression of both MMP7
and MGMT was increased in the lungs of TG mice, compared to that of the WT
controls. MGMT was further increased after NNK exposure, while tumors
remained negative. In vitro studies using human airway epithelial cells (BEAS-
2b) and peripheral airway carcinoma cells (H441) corroborated these findings.
We conclude that constitutive expression of hASH1 in metabolically active
non-NE epithelial cells may lead to induction of MMP7 and MGMT which may
initially protect from adduct formation and carcinogenesis. However, MGMT is
subsequently silenced by methylation associated with the NNK-exposure, and
tumorigenesis will occur. Our study provides further proof that the function of
hASH1 is not limited only to NE cells.
B20
Synergistic lung tumorigenesis by cigarette smoke carcinogen
and inflammation
Y.P. Peter Di. University of Pittsburgh, Pittsburgh, PA
Lung cancer is the leading cause of cancer mortality among men and women.
The estimated deaths of lung cancer are equivalent to total death numbers
combined from colon, breast, pancreatic, and prostate cancers (2nd to 5th
ranked cancer types in mortality rate). Despite significant medical advance-
ment in treating cancers, lung cancer remains a deadly disease. Tobacco
smoke is the main cause of lung cancer since the exposure and use of tobacco
smoke accounts for about 90% of lung cancer incidences. However, genetic
susceptibility and environmental factors also contribute significantly to the
pathogenesis of lung cancer because only a selected group of smokers
actually develop lung cancer. An effective treatment of lung cancer is still
not available not only because of a deficiency in early detection of lung
cancer but also the lack of viable tools to test anticancer drugs. This is largely
due to limited numbers of lung tumors that could be generated in animal
models. To address this deficiency in lung cancer animal models and to test
our hypothesis that inflammatory microenvironment enhances lung tumori-
genesis, we developed a unique exposure paradigm to induce lung tumor
occurrence in a mouse model. Our novel approach used a mouse model with
a combined exposure of tobacco smoke carcinogen nitrosamine and chronic
inflammation that was induced by recurrent introduction of low level endo-
toxin. There was a synergistic increase in lung tumor incidence by more than
five folds when compared with the carcinogen exposed mouse group without
inflammation. In the mouse group with dramatically increased lung tumors,
we observed a distinct cytokine expression profile that resulted in a threefold
increase of total alveolar macrophages. These increased macrophages dis-
played an alternative activation toward tolerant M2 phenotype. An increased
K-ras mutation frequency was also identified in lung tumor samples using
laser capture microscopy. In addition, inflammation accelerated the tobacco
smoke carcinogen-induced lung tumorigenesis and a set of genes were
identified to be involved in this process. We will present how our tumori-
genesis model was generated and the potential use of this model for testing
of chemoprevention and anti-cancer treatment.
Novel and Targeted Therapy, Drug Design
B21
Overcoming pharmacokinetic resistance to erlotinib: Rationale
and preliminary findings from a phase II study
Lynsay L. Waller, Antonius A. Miller, Nathan P. Streer, Thomas P. McCoy,
W Jeffrey Petty. Wake Forest University Comprehensive Cancer Center,
Winston-Salem, NC
Background: Clinical benefit from erlotinib is associated with dose-depen-
dent toxicities including rash and diarrhea. Patients who have never smoked
exhibit high plasma drug levels and experience high response rates and
prolonged progression free survival with erlotinib. Active smokers are
unlikely to respond to erlotinib at the dose of 150 mg daily and require a dose
of 300 mg daily to normalize drug exposure. Significant inter-patient vari-
ability in erlotinib metabolism exists. Attempts to perform intra-patient dose
escalation of erlotintib are challenging due to the frequent progression of
cancer prior to achieving each patient’s maximal tolerated dose (MTD). To
establish an effective strategy for intra-patient dose escalation, a phase II
study has been designed in which four cycles of dose dense chemotherapy
are administered followed by rapid dose-escalation of erlotinib.
Methods: Patients with metastatic NSCLC received docetaxel 75 mg/m2 and
cisplatin 75 mg/m2 on day1 on a q 2 week cycle for a total of 4 cycles. All
patients were given pegfilgrastim growth factor support on day 2. Patients
then received erlotinib with initial doses based on current smoking status,
150 mg daily for non-smokers and 300 mg daily for smokers. Erlotinib doses
were escalated by 75 mg every 2 weeks until development of grade 2
non-hematologic toxicity. In the event of grade 2 toxicity, erlotinib was
continued at the same dose. In the event of grade 3 toxicity, doses were
held until resolution and restarted after decreasing the dose by 75 mg daily.
Results: To date, 25 patients have been enrolled. Two patients progressed
while receiving erlotinib prior to achieving MTD. No grade 4 or grade 5
toxicities related to dose-intense erlotinib were observed. No cases of
interstitial lung disease or significant hepatic toxicity related to dose-intense
erlotinib were observed. Reasons preventing further dose escalation included
grade 2 rash (23.5%), grade 2 diarrhea (23.5%), grade 3 rash (17.6%), grade
3 diarrhea (17.6%), grade 3 dehydration (5.9%), and progressive disease
(11.8%). The median MTD achieved for smokers was higher than for
non-smokers, 300 mg vs. 225 mg. P 0.03. There was no difference in the
median MTD between men and women. Erlotinib dose ranges for smokers
Journal of Thoracic Oncology • Volume 5, Number 6, Supplement 3, June 2010 Abstracts
Copyright © 2010 by the International Association for the Study of Lung Cancer S247
were 300–525 mg vs. 150–225 mg for non-smokers. Pharmacogenomic and
EGFR mutation testing will be performed at study closure.
Conclusion: A high degree of inter-patient variability exists in erlotinib
MTD. Active smokers tolerate a significantly higher dose of erlotinib than
non-smokers. The dose-escalation strategy used in this study appears to be
safe and effective for individualizing erlotinib dose.
B22
17-allylamino-demethoxygeldanamycin (17AAG) to inhibit growth
in adenocarcinoma in lung cancer with nonphosphorylated
mesenchymal-epithelial transition factor (MET)
Min-Woong Kang1, Kangwon Jang2, Seokkee Lee1, Shin Kwang Kang1, Jae
Hyun Yu1, Myung Hoon Na1, Jeong Eun Lee3, Sun Yung Kim3, Kyu Sang
Song4, Choong-Sik Lee4, Seung Pyung Lim1. Departments of 1Thoracic and
Cardiovascular Surgery, 3Internal Medicine, and 4Pathology, Chungnam
National University Hospital, Daejeon, Republic of Korea, and 2Infection
Signaling Network Research Center, Molecular Research Center, Chungnam
National University, Daejeon, Republic of Korea
Patients with EGFR mutations that substitute methionine for threonine at
position 790 (T790M) are associated with approximately half the cases of
acquired resistance to EGFR kinase inhibitors, gefitinib and erlotinib. Re-
sistance to these agents invariably develops, and current treatment strategies
have limited efficacy in this setting. 17-allylamino-demethoxygeldanamycin
(17AAG) inhibits the chaperoning action of heat-shock protein 90 (Hsp90)
and promotes proteasomal degradation of multiple oncogenic signaling
molecules such as EGFR, Akt, and MET, a receptor for hepatocyte growth
factor that has been implicated in growth, invasion, and metastasis of many
tumors including NSCLC. In order to identify the MET expression and
phosphorylation and the effect of 17AAG in EGFR mutation cell lines, we
detected the phosphorylated form of MET in both cell lines by Western blot
assay and evaluated cell proliferation after exposing 17AAG to the PC9 cells
and H1650 cells by MTT assay. In the Western blot analysis, there were no
phosphorylated MET in the H1650 cell lines, but, there were detected phosphor-
ylated MET genes, in the PC9 cell lines. In H1650 cell lines without phspho-
rylated MET, the proliferation was inhibited by dose dependently at 24 h by
MTT assay. However, PC9 cell line group that has phosphorylated MET, the
proliferation was not inhibited by 17AAG at 24h by MTT assay. These results
demonstrated that 17AAG can be effective in inhibiting cell proliferation in
adenocarcinoma cells with EGFR mutation and non phosphorylated MET.
B23
Silibinin induces apoptosis by downregulating survivin
through inhibition of hypoxia-inducible factor-1 in non-small
cell lung cancer cells
Hye Ok Kim, Hye Kyoung Choi, Eun Sil Ha, Kyoung Joo Lee, Gyu Young
Hur, Ki Hwan Jung, Sung Yong Lee, Sang Yeub Lee, Je-Hyeong Kim, Chol
Shin, Jae Jeong Shim, Kwang Ho In, Kyung Ho Kang, Se Hwa Yoo. Korea
University Medical Center, Seoul, Republic of Korea
Background: Silibinin is a nontoxic flavonoid extracted from milk thistle
and known to exhibit anticancer properties. Recent studies have shown that
treatment with silibinin induced apoptosis of cancer cells by down-regulation
of survivin and inhibition of hypoxia induced factor(HIF)-1 expression. In
this study, we investigate the relationship between survivin and HIF-1 to
anticancer effect of silibinin in non small cell lung cancer.
Materials and Methods: We investigated the effects of silibinin (50, 100
and 200 M for 24hrs) on cancer apoptosis in A549 lung adenocarcinoma
cells under normoxic and hypoxic conditions. Cultured A549 cells were
treated with different concentration of silibinin, and the degree of cell
survival and apoptosis was analyzed. The expression of survivin and HIF-1
was detected by real-time reverse transcription-polymerase chain reaction
and Western blotting.
Results: Silibinin treatment inhibits growth and increased the death of A549
cells in dose and time dependent pattern. Survivin and HIF-1 were expressed
in A549 cells under normal and hypoxic conditions, with significant increase
under hypoxic conditions. Silibinin treatment induces apoptosis by inhibition of
survivin under normoxic condition. Under hypoxic condition, silibinin also
induces apoptotic cell death by inhibition of HIF-1 and survivin.
Conclusion: Our results demonstrate that survivin and HIF-1 are expressed
in A549 cells and silibinin induces apoptosis of lung cancer cells by
inhibition of HIF-1 and down-regulation of survivin expression. Therefore,
targeting of apoptosis pathway by treatment with silibinin appears to be
effective, and may be useful method of treatment in lung cancer.
B24
Re-treatment of gefitinib in patients with non-small cell lung
cancer (NSCLC) who previously responded to gefitinib: A
single-arm, open label phase II study
In-Jae Oh1, Su-Young Chi1, Hee-Jung Ban1, Byung-Kab Yoon1, Kyu-Sik
Kim1, Manaljav Tesden-Ish2, Young-Chul Kim1, Min-Ki Lee3. 1Chonnam
National University Medical School, Gwangju, Republic of Korea, 2Center
for Biomedical Human Resources, Chonnam National University, Gwangju,
Republic of Korea, 3Pusan National University Medical School, Pusan,
Republic of Korea
Background: The lack of an established therapeutic option for the non-small
cell lung cancer (NSCLC) patients who have progressive disease after
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)
failure leave physicians with great challenges on how best to manage this
growing group of patients. From recent several reports, there is a potential
rationale to reintroduce EGFR-TKI after the failure of previous EGFR-TKI
treatment. We hypothesize that reintroduction of the gefitinib will lead to
significant clinical and radiological improvements or disease stabilization in
certain percentage of patients with progressive disease.
Patients and Methods: This is a single arm, open label, prospective, phase
II trial of gefitinib retreatment for the advanced or metastatic (IIIb and IV)
NSCLC patients who previously responded to gefitinib. Initial responses to
gefitinib of 18 recruited patients were partial remission (PR) in 7 cases
(38.9%) and stable disease (SD) in 11 cases (61.1%). Before retreatment with
gefitinib, progressive disease (PD) should be observed with at least one
cytotoxic treatment following initial gefitinib failure. Patients received ge-
fitinib 250mg orally once daily.
Results: After retreatment with gefitinib, 15 cases were eligible for response
evaluation. PR was observed in 4 cases (26.7%) and stable disease in 6 cases
(40.0%), while 2 cases (13.3%) showed PD (66.7 % disease control rate,
DCR). Among 6 patients who showed PR with initial gefitinib treatment, 2
patients showed PR and 3 patients showed SD (DCR 83.3%). Among 9
patients who showed SD with intitial gefitinib treatment, 2 patients showed
PR and 3 patients showed SD (DCR 55.6%).
Conclusion: In conclusion, significant proportion of NSCLC patients who
progressed after prior gefitinib treatment showed another PR or disease
control with gefitinib retreatment.
B25
Radiotherapy of lung cancer-targeting ephrin receptors
Piotr R. Ruchala, Ewa D. Micewicz, William H. McBride. University of
California Los Angeles, Los Angeles, CA
Lung cancer treatment usually utilizes some form of radiotherapy. We sought
to improve the efficacy of such treatment by exploiting the targeted delivery
of a model radiosensitizer (nicotinamide) to malignant tissues. The molecular
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target(s) we have chosen is ephrin receptors (Eph) which are overexpressed
in many types of cancer, including lung cancer.
Molecular targeting was achieved utilizing a small peptide derived from
the C-terminal portion of azurin that belongs to copper-containing redox
proteins called cupredoxins, and is capable of binding to ephrin receptors .
We recently screened a sub-library of peptides derived from the C-terminal
region of azurin and found several small compounds capable of binding
selected ephrin receptors: EphA2, EphB2 and EphB4. One such peptide,
termed AzV-36, was chosen for our studies and subsequently conjugated
with nicotinic acid via amide bond. The resulting peptide is linear, 15
residues long, contains 3 D- and several unusual amino acids, and may be
easily manufactured in large quantities. Because of its composition, it may
possess increased resistance to enzymatic cleavage.
The AzV-36-Nic conjugate was tested in vivo for its ability to radiosen-
sitize Lewis lung carcinoma (LCC) in an artificial metastasis model. Briefly,
C57BL/6 mice (8 weeks old) were intravenously injected with 5I´105 cells of
syngeneic LLC. Various treatments were initiated 4 days later, after cancer
engraftment. In general, each animal received intraperitoneally a total of 500
mg (10 mg/kg) of peptide in 4 daily doses 60 min before local thoracic
irradiation (4 Gy). Animals were sacrificed on the 14th day of the experiment
and lung tumor nodules were counted.
Studies revealed that nicotinamide targeted to ephrin receptor bearing
tumor cells (AzV-36-Nic) increased the efficacy of radiotherapy, with tumor
colonies being 3–10 fold lower than with radiation alone, depending on the
experimental schedule. In contrast, equimolar amounts of unconjugated
peptide (AzV-36) or nicotinamide alone, improved radiation efficacy only
1.3 and 1.2 fold, respectively.
In conclusion, targeted delivery of radio- or photosensitizers to ephrin
receptors may be a suitable approach in the treatment of lung cancer to
significantly improve radiotherapeutic efficacy.
B26
Results from a phase 1 study of the safety of oral TRC102, a
novel inhibitor of base-excision repair, to potentiate the
therapeutic effects of pemetrexed in patients with advanced
refractory cancer
Jonathan Goldman1, Michael S. Gordon2, Lee S. Rosen1, David S. Mendel-
son2, Ramesh K. Ramanathan3, Bonne J. Adams4, Delia Alvarez4, Lili Liu5,
Yan Xu5, Stan L. Gerson5, Charles P. Theuer4, Bryan R. Leigh4, Glen J.
Weiss3. 1Premiere Oncology, Santa Monica, CA, 2Premiere Oncology of
Arizona, Scottsdale, AZ, 3Scottsdale Clinical Research Institute/TGen,
Scottsdale, AZ, 4TRACON Pharmaceuticals Inc., San Diego, CA, 5University
Hospitals Ireland Cancer Center and Case Comprehensive Cancer Center,
Case Western Reserve University, Cleveland, OH
Background: TRC102 (methoxyamine hydrochloride) is a small molecule
inhibitor of base-excision repair (BER) that is highly water soluble and
nearly 100% bioavailable after oral administration. Preclinically, TRC102
potentiates the cytotoxicity of alkylator and antimetabolite chemotherapy and
reverses chemotherapy resistance by rapidly and covalently binding to
chemotherapy-induced apurinic/pyrimidinic (AP) sites. TRC102-bound
DNA is no longer a substrate for BER enzymes and is instead cleaved by
topoisomerase II resulting in double-strand breaks that trigger apoptosis. In
animal toxicology studies, the dose-limiting toxicity (DLT) of TRC102 was
extravascular hemolysis at doses 20-fold higher than those required for efficacy.
Methods: This phase 1 trial evaluated the safety, PK, and PD of oral TRC102
combined with intravenous pemetrexed in patients with advanced refractory
cancer. Patients were required to have ECOG PS  1 and adequate organ
function. TRC102 was escalated in cohorts of 3–6 evaluable patients in com-
bination with standard-dose pemetrexed. All patients received TRC102 alone on
Days 1–4 of a 2-week cycle followed by the combination of TRC102 (D1–4)
and 500 mg/m2 pemetrexed (D1) every 3 weeks thereafter.
Results: 22 patients were treated with a total of 83 cycles of TRC102 at 15
mg/m2 (n4), 30 mg/m2 (n7), 60 mg/m2 (n5) and 100 mg/m2 (n6). 20
of the 22 patients were evaluable for safety. Four patients experienced DLT
of Grade 3 anemia, including 1 of 6 patients at 30 mg/m2 TRC102 and 3 of
6 patients at 100 mg/m2. No other DLTs were reported. Other adverse events
considered possibly related to treatment included Grade 3/4 neutropenia
without fever, Grade 3 thrombocytopenia, Grade 1/2 fatigue, and Grade 1/2
asthenia. Clinical PK analyses indicated that TRC102 plasma concentrations
required for in vivo activity were achieved with daily oral administration at all
dose levels studied (Cmax 50 ng/mL, t1⁄2 24 hr). PD studies confirmed that
TRC102 binds pemetrexed-induced AP sites in these patients. One patient with
squamous cell carcinoma of the tonsillar fossa recurrent in the right lung and
right hilum had RECIST-defined partial response after 2 cycles of 30 mg/m2
TRC102  pemetrexed that is ongoing in Cycle 12. Stable disease for 9 cycles
was observed in a patient with metastatic squamous cell lung cancer at 30 mg/m2
TRC102  pemetrexed as 3rd line therapy. Two additional patients at 30
mg/m2, 2 patients at 60 mg/m2, and 3 patients at 100 mg/m2 also had stable
disease for at least 3 cycles.
Conclusion: Daily oral TRC102 for 4 days is well-tolerated at doses that
may potentiate the clinical activity of pemetrexed. The maximum tolerated
dose of TRC102 
 4 days was exceeded at 100 mg/m2 due to Grade 3
anemia. Phase 2 studies are planned with 60 mg/m2 TRC102 plus pem-
etrexed in non-small cell lung cancer.
B27
Preclinical characterization of a novel hypoxia-activated
irreversible pan-HER inhibitor which induces complete
responses in the H1975 xenograft model
Adam V. Patterson1, Fernando Don˜ate2, Stephen Jamieson1, Aaron Thomp-
son1, G.Leon Lu1, Ho Lee1, Annie Hsu1, Maria Abbattista1, Michelle
Puryer1, Jagdish Jaswail1, Alison Pruijn1, Andrej Maroz1, Robert F. Ander-
son1, Wouter F. van Leeuwen1, Sophie P. Syddall1, Sunali Mehta1, Amir
Ashoorzadeh1, Ralph Stevenson1, William A. Denny1, William R. Wilson1,
Jeff Smaill1. 1The University of Auckland, Auckland, New Zealand, 2Pro-
acta, Inc, San Diego, CA
Small molecule reversible inhibitors of HER1 (gefitinib, erlotinib) are now in
clinical use in lung cancer. These inhibitors are dosed at MTD which suggest
that they may not be used at an optimal biological dose and may benefit from
an improved therapeutic index. Furthermore, mutations in HER-1, such as
the T790M mutation, eventually arise and confer resistance. Several irre-
versible pan-HER inhibitors (HKI-272, BIBW-2992, PF299) are under
development in an attempt to improve upon the first generation HER-1
inhibitors. These compounds have been designed to circumvent erlotinib
resistance arising from the HER-1 T790M mutation. However, the efficacy
of these irreversible inhibitors in the T790M erlotinib resistance patients has
recently been questioned because of the lack of activity in preclinical models
(J Clin Invest. 2009;119:3000–10).
We have developed a number of hypoxia-activated irreversible pan-HER
inhibitors from a series of nitromethylaryl quaternary (NMQ) prodrugs.
These prodrugs contain a hypoxia activated trigger linked via quaternization
to the tertiary amine-bearing Michael acceptor of the irreversible inhibitor,
thereby masking activity. Furthermore, the presence of the positive charge
appears to limit the internalization of the prodrug into cells providing an
additional mechanism of deactivation. One-electron reduction provides se-
lective release under hypoxia. This approach allows for an improvement in
the therapeutic index of the kinase inhibitor bearing pro-drug and provides
targeting to hypoxic regions of tumors. This class of compounds are desig-
nated hypoxia-selective multikinase inhibitors (HSMKIs). A similar ap-
proach is under investigation for other multikinase inhibitors.
SN32807 is the lead prodrug of the irreversible pan-HER inhibitor series.
SN32793 is the multikinase inhibitor to which the trigger is attached to form
SN32807. In growth delay studies, SN32807 (88 mg/kg; q3dx8) displayed
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marked activity against the SKOV3 and H1975 tumor xenografts, inducing
regression in both models with no recovery of growth up to 20 days after the
final dose (day 21). By comparison, SN32793, the irreversible pan-HER
inhibitor could only be dosed at 1/3 the MTD of SN32807 (19 mg/kg; q3dx8)
and resulted in significantly less pronounced anti-tumor activity with rapid
growth following cessation of treatment. Remarkably, SN32807 induced
complete responses in mice with well established (500 mm3) H1975 tumors
with a median time to RTV4 (tumor quadrupling time) of 45 days (P0.0005 vs
controls; log-rank test; control RTV4  13 days). By comparison, BIBW2992
(20 mg/kg, p.o. daily) had limited growth delay effect against these large tumors
and failed to induce stasis or tumor regressions as evidenced by a median time
to RTV4 of 17.5 days (P0.0005 vs SN32807; log-rank test). At 50 mg/kg (57%
of MTD), SN32807 still controlled these large H1975 tumours as evidenced by
a median time to RTV4 of 31 days (P0.0005 vs Control; log-rank test); activity
that was significantly greater than achievable with BIBW2992 (P0.001 vs
BIBW). Collectively the data indicates that SN32807 represents an advantage
over existing HER-family inhibitors demonstrating activity against erlotinib and
BIBW2992 resistant tumor xenograft models.
B28
Enhanced growth inhibition by combined methylation/HDAC
inhibitors in lung tumor cells with silenced CDKN2A
Donna Voeller1, Min Chen1, Victor E. Marguez2, Patricia Steeg1, Frederic J.
Kaye1, Giuseppe Giaccone1, Maria Zajac-Kaye1. 1NCI, Bethesda, MD,
2NCI, Frederick, MD
Aberrant hypermethylation at regulatory CpG sites within the CDKN2A
tumor suppressor gene is associated with gene silencing and has been
proposed as a target for reactivation using both DNA methylation and histone
deacetylation inhibitors in patients with cancer. This study investigates the
importance of selecting lung tumor samples with silenced as compared to
deleted CDKN2A loci when assessing the efficacy of the new DNA meth-
yltransferase inhibitor, zebularine, used alone or in combination with the
HDAC inhibitor, depsipeptide. We analyzed 19 human non-small cell lung
cancer cell lines with defined CDKN2A status to determine the effect of
zebularine alone or zebularine in combination with depsipeptide on tumor
cell growth using MTS assay. Reactivation of silenced p16 expression in
lung cancer line was observed following zebularine treatment. We demon-
strated that zebularine treatment resulted in inhibition of cell growth in 11 out
of 12 lung cancer cell lines with silenced CDKN2A, but no cell growth
inhibition was detected in the 7 cell lines tested with deleted CDKN2A. In
addition, we found that the combination of 30 M zebularine and 6 nM
depsipeptide resulted in a synergistic inhibition of cell growth in tumor
samples with silenced CDKN2A but not in tumor samples with deleted
CDKN2A. Our results suggests that tumor cell lines with methylated
CDKN2A are more sensitive to zebularine treatment than cell lines with
deleted CDKN2A and the combination of zebularine with depsipeptide
results in a synergistic effect on cell growth inhibition which is also closely
associated with the presence of silenced CDKN2A. Thus, combination of
DNA methyltransferase and HDAC inhibitors may be a potential treatment
for lung cancer patients with silenced CDKN2A status, and careful selection
of patients will be required to optimize the benefit of this regiment.
B29
Selective pressure for the EGFR T790M resistance mutation
may be different for different EGFR tyrosine kinase inhibitors
Juliann Chmielecki1, Maria C. Pietanza2, Mark Kris2, Vincent Miller2,
William Pao3. 1Weill Graduate School of Medical Sciences of Cornell
University, New York, NY, 2Memorial Sloan-Kettering Cancer Center, New
York, NY, 3Vanderbilt-Ingram Cancer Center, Nashville, TN
Mutations within the kinase domain of EGFR confer increased sensitivity of
non-small cell lung carcinomas to the tyrosine kinase inhibitors (TKIs),
gefitinib and erlotinib. Unfortunately, all patients whose disease responds
initially to these therapies eventually develop acquired resistance. In 50%
of cases, resistance is due to a second site mutation within EGFR, T790M.
More potent ‘2nd generation’ EGFR inhibitors theoretically able to overcome
T790M-mediated resistance have displayed limited clinical success. In pre-
clinical models of acquired resistance, many of these TKIs (HKI-272,
BIBW-2992, PF00299804) actually select for the emergence of EGFR
T790M-harboring clones.
XL-647 (Symphony Evolution, Inc., Rockville, MD) is a second-genera-
tion reversible EGFR inhibitor clinically effective against EGFR mutant lung
cancer in early trials. Patients on different dosing schedules who progressed
after an initial response were re-biopsied to look for the presence of
secondary mutations within EGFR. Surprisingly, only 1 of 6 patients har-
bored T790M, and at least 2 of them subsequently derived clinical benefit
from single-agent erlotinib. To investigate this observation in vitro, we
modeled resistance to XL-647 using PC-9 cells (lung adenocarcinoma,
EGFR del E746-A750). Cells were grown with increasing concentrations of
XL-647 using established protocols. After 160 days in culture, resistant
cells (PC-9 XL-R) were derived that proliferated in concentrations of drug
50-fold higher than the IC50 of the parental cells. In parallel, we also
derived resistant cells using erlotinib (PC-9 E-R) and BIBW-2992 (PC-9
BI-R). Sequence analysis of EGFR in PC-9 E-R and BI-R cells revealed the
secondary T790M mutation in addition to the exon 19 deletion in both lines.
However, no secondary EGFR mutations were observed in XL-R cells. XL-R
cells were intermediately sensitive to erlotinib, while E-R and BI-R (both
containing T790M) were completely resistant.These pre-clinical and early clin-
ical data indicate that the propensity to develop T790M-mediated resistance may
differ among distinct EGFR TKIs. Mechanisms underlying these observations
are currently being further explored.
COI: William Pao, consulting Symphony Evolution.
Funding: NCI grants R01-CA121210 (W. Pao), P01-CA129243 (M. Kris),
Vanderbilt’s Specialized Program of Research Excellence in Lung Cancer
grant (CA90949), and the VICC Cancer Center Core grant (P30-CA68485).
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B30
Molecular heterogeneity of osteopontin isoforms in non-small
cell lung cancer
Jessica Donington1, Chandra Goparaju1, Justin Blasberg2, Ryan Harrington1,
Nathalie Hirsch1, Harvey Pass1. 1New York University School of Medicine,
New York, NY, 2St. Luke’s Roosevelt Medical Center, New York, NY
Purpose: Osteopontin (OPN) is ubiquitous protein expressed in a wide range
of normal and pathologic contexts. OPN expression increases the malignant
potential of non-small cell lung cancer (NSCLC) and elevated OPN levels in
tumors and plasma are associated with poor prognosis in NSCLC. Three
distinct OPN mRNA isoforms are expressed in humans (OPNa, OPNb, and
OPNc) but reports of OPN expression in clinical NSCLC samples or tumor
model systems have not reported which isoforms are expressed. Epithelial to
mesenchymal transition (EMT) is thought to be essential for metastasis of
solid tumors. We hypothesize that the individual OPN isoforms have differ-
ential impact on the invasive and metastatic potential of NSCLC and
associated downstream gene targets.
Methods: mRNA expression of OPN isoforms was evaluated in 43 NSCLC
tumors and matched normal lung. Functional impact of the individual OPN
isoforms was evaluated by transfecting cDNA plasmids specific to each
isoform and controls into four NSCLC cell lines, H153 and H358 (low native
OPN expression) and A549 and H460 (high native OPN expression) and
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compared behavior of a pooled population of cells in scratch closure, cell
proliferation as measured by Cell-Titre-Blue™, soft-agar colony formation,
and Matrigel™ invasion assays. mRNA was extracted from the cell lines
with overexpression of individual OPN isoforms and controls and analyzed
using Affymetrix Gene ChipTMU133 Plus2 platform. Gene array results
were compared against a panel of common markers for EMT to correlate
results of the functional assays with pathways of interest.
Results: OPN was overexpressed in the NSCLC tumor compared to the
matched normal lung in 39 (90.7%) of the pairs. OPNa was the dominant
isoform in all samples. We noted a significant increase in the activity in all
four cell lines with overexpression of OPNa in scratch closure and prolifer-
ation assays at 24 hours. OPNa overexpression resulted in significant in-
crease the size and number of colonies in soft-agar at 21 days and significant
increase in invasion through Matrigel™ compared to controls in all four cell
lines. Overexpression of the OPNb resulted in less significant modulation of
function in all assays compared to OPNa. OPNc overexpression had no
impact on scratch closure activity, but significantly decreased activity in
proliferation, soft agar colony formation, and Matrigel™ invasion assays
compared to controls in all four cell lines.
OPNa overexpression resulted in a relative increase in expression of
MMP-2, Snail-1,Snail-2, TGFb receptor-1, MMP-9, N-cadherin, ILK, vi-
mentin, SOX-8, and SOX-9 and a relative decrease in the expression of
cytokeratin 18, and 20, desmoplakin, and e-cadherin compared to controls,
all consistent with EMT activation. Overexpression of OPNc resulted in a
relative increase in expression of MMP-2, MMP-9 and Snail-1, but a
decrease in expression of Snail 2, TGFb-receptor 1, N-cadherin, ILK,
vimetin, Sox8, Sox 9 and fibronectin. Overall, OPNc overexpression resulted
in less consistent picture for EMT activation. Relative differences in expres-
sion of EMT markers between OPNa and OPNc and controls were validated
by RT-PCR in all four NSCLC cell lines.
Conclusion: OPNa conferred a more malignant phenotype with increased
migration, proliferation, anchorage independent growth and invasion in
NSCLC. Importantly, OPNa is the isoform preferentially up-regulated in
NSCLC tumor specimens. In contrast OPNc which lacks exon 4, confers an
opposite effect when overexpressed in NSCLC. Gene array data indicate that
OPNa specific activation of EMT pathways may be responsible for the
phenotypic differences. These data implicate OPNa and particularly exon 4
in the pathogenesis and metastatic behavior of NSCLC. These data may lead
to therapeutic strategies which selectively inhibit OPN isoforms and alter the
metastatic potential of NSCLC.
B31
EGFR genotype does not affect clinical outcomes of the
Korean patients with advanced pulmonary adenocarcinoma in
first-line cytotoxic chemotherapy
Hee Joung Kim1, Sung Ken Yu2, Kwan-Ho Lee2, Wan-Seop Kim3, Kye
Young Lee1. Departments of 1Internal Medicine and 3Pathology, School of
Medicine, Konkuk University, Seoul, Republic of Korea; 2College of Medi-
cine, Yeungnam University, Daegu, Republic of Korea
Introduction: EGFR mutation is the most important predictive marker for
EGFR-TKI, and tailored therapy based on EGFR genotyping in the front-line
treatment of advanced NSCLC patients becomes increasingly important.
EGFR mutations are more frequent in female, non-smokers, adenocarcinoma
and Asian people. However, few clinical studies have addressed whether
EGFR genotyping before the initiation of treatment affect clinical outcomes
of the first-line cytotoxic chemotherapy and the subsequent EGFR-TKI
treatment. This study was undertaken to investigate the effects of EGFR
mutations on treatment response to the first-line chemotherapy in the Korean
patients with advanced pulmonary adenocarcinoma.
Methods: One hundred and forty-four stage III or IV pulmonary adenocar-
cinoma patients were included at two centers in Korea. DNA from biopsy or
cytology specimen was determined for EGFR mutation by pyrosequence-
based typing in the initial staging period. All patients received at least two
cycles of the first-line platinum-based doublet chemotherapy. EGFR-TKI
was used as second or third-line treatment in patients after failure to
cytotoxic chemotherapy. We evaluated objective response rate (ORR) and
progression-free survival to the first-line chemotherapy and 1-year survival
rate between the groups with EGFR-mutant and EGFR wild-type.
Results: EGFR mutations were presented in 47 patients (32.6%): exon 19
deletion mutations 65.5 %, exon 21 L858R point mutation 25.5 %, and others
8.5 %. There was no significant statistical difference in objective response
rate (ORR) (40.4%, 95% CI [26.4–54.5] vs. 37.1%, 95% CI [27.5–46.7] ,
p0.70) and disease control rate (DCR) (83.0%, 95% CI [76.9–89.1] vs.
78.4%, 95% CI [71.2–84.8], p0.52) and median progression-free survival
(PFS) (6.6 months, range 2.0–15.3 vs. 4.8 months, range 1.7–15.4) between
patients with EGFR-mutant and wild-type. However, the patients with EGFR
mutations showed better 1-yr survival rate (YSR) (85.7%, 95% CI [74.1–
97.3] vs. 54.2%, 95% CI [41.5–67.0], p0.002) and longer median PFS
(7.7	 5.6 months vs. 4.1	 3.9, p0.007) to EGFR-TKI than those patients
with EGFR wild-type.
Conclusions: First-line platinum-based combination chemotherapy admin-
istered in advanced pulmonary adenocarcinoma showed similar ORR, DCR
and PFS regardless of EGFR mutation status. However, patients with EGFR
mutation who received cytotoxic chemotherapy had superior 1-YSR and
longer PFS to EGFR-TKI than those with wild-type EGFR. These results
suggest that EGFR genotype does not affect clinical outcomes of the first-line
cytotoxic chemotherapy before the subsequent EGFR-TKI treatment.
B32
Validation of a prognostic gene signature for early-stage non-
small cell lung cancer in an independent cohort
Sandy D. Der, Melania Pintilie, Chang-Qi Zhu, Dan Strumpf, Igor Jurisca,
Frances Shepherd, Ming-Sound Tsao. University Health Network, Ontario
Cancer Institute/Princess Margaret Hospital, Toronto, ON, Canada
Background: Adjuvant chemotherapy given to patients with early stage
non-small cell lung cancer (NSCLC) results in prolonged survival. An
accurate prognostic test potentially could provide guidance with respect to
the need for and benefit from post-operative treatment. Recently, we devel-
oped an mRNA-based classifier based on 15 genes from molecular analysis
of tumor samples from the NCIC CTG JBR.10 trial that was both prognostic
and predictive for survival benefit from chemotherapy.
Methods:We undertook this study to validate the prognostic performance of
this 15-gene signature using an independent cohort of 183 frozen tumor
samples from patients with early stage NSCLC (Stage I/II) treated at Princess
Margaret Hospital/University Health Network (2000–2005). Microarray-
based profiling was performed on these samples and patients were segregated
into high and low risk groups using the expression values of the 15-gene
signature. The signature was tested using a Cox proportional hazards model
while controlling for clinical factors, age, sex, and histology.
Results: The survival of these two risk groups was significantly different
(n183, HR 2.21, 95% CI: 1.28–3.81, p-value 0.0045). Subset analysis
using this signature to segregate patients into good and poor prognosis
subgroups within Stage I (n129, HR 2.30, 95% CI 1.15–4.59, p-value 
0.019) and Stage II (n54, HR 2.075, 95% CI 0.83–5.17, p-value  0.12)
indicated that although only Stage I achieved statistical significance, the
magnitude of the difference for Stage II was similar to Stage I. It is possible
that the relatively low numbers of Stage II patients may have been a factor
resulting in the high p-value.
Conclusion: In addition to in silico validation of this 15 gene prognostic
classifier in 4 large, public NSCLC expression datasets, we have determined
validation of its performance in this independent cohort. Additional ongoing
validation studies include the development of a qPCR-based assay to be
tested on both frozen tissue and FFPE samples from this cohort.
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B33
High-throughput protein biomarker discovery and translation
into clinical diagnostics for oncology using the SomaLogic
SOMAmer-based assay
Rachel Ostroff. Jennifer Bertino, Chris Bock, Edward Brody, Tracy Keeney,
Stephan Kramer, Bridget Lollo, Alex Stewart, Jeff Walker, Stephen Wil-
liams, Dom Zichi. SomaLogic, Inc., Boulder, CO
This abstract was presented as a short talk in Concurrent Session 6: Other
Biomarkers. A full abstract is printed in the Proffered Presentations section
(PR12).
B34
Validation of the prognostic value of a nonangiogenic and
angio-genic growth pattern classification in patients operated
for a non-small cell lung cancer (NSCLC)
Peyman Sardari Nia1, Yanina Dockx1, Anouschka Cogen1, Patrick Lauwers1,
Jeroen Hendriks1, Paul Germonpre´1, Jelena Stojsic2, Dragan Subotic2, Eric
Van Marck1, Paul Van Schil1. 1Antwerp University Hospital, Edegem,
Belgium, 2Institute for Lung Diseases, Clinical Center of Serbia, Belgrade,
Serbia
Objectives: An essential prerequisite of nonangiogenic growth appears to be
the ability of the tumour to preserve the parenchymal structures of the host
tissue. This morphological feature is visible on a routine haematoxylin-eosin
tissue section (HE). Based on this feature, we have proposed a classification
of NSCLC into three different growth patterns, based on the interaction
between the tumour and the normal lung parenchyma. Type 1 is preservation
of lung tissue and use of its microenvironment for further growth [alveolar
growth pattern (nonangiogenic)]. Type 2 gives destruction of lung tissue with
formation of a new microenvironment for continued expansion [destructive
growth pattern (angiogenic)] and type 3 preserves the normal lung tissue with
formation of a new microenvironment [papillary growth pattern (intermedi-
ate)]. We have previously shown that these growth patterns have an inde-
pendent prognostic value and represent distinct biologic subtypes with
differences in angiogenic and proliferative characteristics. The attractiveness
of the growth pattern hypothesis lies in the fact that it integrates several
distinct molecular mechanisms into a single feature and is therefore a
possible candidate for a biologic classification of NSCLC. The aim of the
current study is to validate the prognostic value of this growth pattern
classification in a large group of patients operated on for a NSCLC.
Methods: Clinicopathological factors of 432 patients having complete re-
section for primary NSCLC were retrospectively reviewed. Patients dying
within 30 days after operation were excluded. None of the patients received
systemic chemotherapy or radiotherapy before the operation. According to
pathologic TNM classification 118 (27.3%) patients were in stage IA, 176
(40.7%) in stage IB, 15 (3.5%) in stage IIA, 72 (16.7%) in stage IIB, 27
(6.3%) in stage IIIA and 24 (5.6%) in stage IIIB. The HE-stained tissue
sections from all the tumor blocks of these patients were analyzed indepen-
dently from the clinical data. Tumors were classified into three growth
patterns: destructive (angiogenic), papillary (intermediate) and alveolar (non-
angiogenic). The median followup for the whole group was 50 months
(range: 2–192). A multiple Cox regression model was used to test the
prognostic value of growth patterns together with other relevant clinicopath-
ological factors for overall survival (OS), disease-specific survival (DSS) and
disease-free survival (DFS).
Results: According to the growth pattern classification, 307 (71.1%) had a
destructive, 60 (13.9%) a papillary and 65 (15.0%) an alveolar growth
pattern. Multiple Cox regression analysis showed that growth pattern
(p0.020), N-status (p0.001), age (p0.001) and type of operation
(p0.022) were independent prognostic factors for OS whereas growth
pattern (p0.001), N-status (p0.001) and type of operation (p0.007)
were independent prognostic factors for DSS. Growth pattern (p0.001) and
N-status (p0.001) were independent prognostic factors for DFS. Alveolar
(nonangiogenic) growth pattern was a consistent independent predictor of
poor prognosis for OS (hazard ratio (HR)1.521, 95% confidence interval
(CI)1.074–2.155, p0.018), for DSS (HR1.932,CI1.315–2.840,
p0.001) and for DFS (HR2.112, CI1.419–3.144, p0.001).
Conclusion: The proposed classification has an independent prognostic
value for overall survival, disease-specific survival, and disease-free sur-
vival, providing a possible explanation for survival differences of patients in
the same disease stage.
B35
Combined analysis of EGFR and IGF1R gene copy number
reveals no mutual correlation, but does show a prognostic
implication of high IGF1R copy number in resected NSCLC
Murry W. Wynes1, Rafal Dziadziuszko2, James Ranger-Moore3, Shalini
Singh3, Nir Peled1, Barbara Szostakiewicz2, Katarzyna Dziadziuszko2, Jacek
Jassem2, Fred R. Hirsch1. 1University of Colorado Denver, Aurora, CO,
2Medical University of Gdansk, Gdansk, Poland, 3Ventana Medical Systems,
Inc., Tucson, AZ
Background: EGFR and IGF1R are tyrosine kinase receptors thought to
play a fundamental role in cancer pathogenesis and progression. Both are
capable of activating similar downstream pathways, which results in prolif-
eration, survival and invasion. IGF1R is highly expressed in many malig-
nancies and activation of IGF1R signaling is one potential mechanism of
EGFR TKI resistance. EGFR is over-expressed or amplified in many human
cancers, including NSCLC, however the prognostic value of EGFR expres-
sion and gene copy number is controversial. The aim of this study was to
evaluate the correlation of both EGFR and IGF1R gene copy number and
their prognostic implication in surgically treated NSCLC patients (pts).
Methods: EGFR and IGF1R gene copy numbers were evaluated on a tissue
microarray containing triplicate cores from 189 pts (median follow-up 5.3
yrs and 5-yr survival probability 38%) using experimental SISH probes,
Ventana Medical Systems, Inc. (Tucson, AZ). Evaluable results, at least one
core with valid EGFR and IGF1R scores, were obtained for 147 pts.: median
age 64 years (37–85); 117 (80%) males; 141 (96%) ever smokers; 86 (59%)
squamous cell carcinomas; and 38 (26%) adenocarcinomas. The pathological
stages were I: 52 (35%), II: 37 (25%) and III: 49 (33%), IV: 6 (4%) and
unknown: 3 (2%). A certified pathologist counted signals (1 for individual
signal and the size of clusters were estimated) in 50 nuclei for each core and
the mean number of EGFR and IGF1R copies/nucleus/core were determined.
We have seen exceptionally high correlation between the core with the
highest copy number and the average of the triplicate cores (r0.97) and
used the core with the highest score for analysis.
Results: Median copy number for EGFR was 2.7 (1.2–27.9) and for IGF1R
was 2.5 (1.3–7.2). Regarding EGFR there were 20 samples with average
genes/nucleus 4 and of those 11 samples with clusters, whereas for IGF1R
there were 9 tumors with average genes/nucleus  4 and none with clusters.
Using the median as a cut-off, there was no statistical differences related to
patient pathoclinical characteristics for EGFR alone, however for IGF1R
alone, squamous cell carcinomas displayed higher gene copy number (me-
dian 2.67 (1.28–7.24) vs. 2.28 (1.27–4.44), respectively; p0.04. When the
markers were analyzed together there was relatively equal distribution
between the four possible permutations and no correlation between the
markers (r0.03, p0.71). Survival analysis revealed no differences in PFS
or OS with EGFR alone (log-rank p0.74 and p0.65, respectively),
however with IGF1R alone PFS and OS survival associated with increased
gene copy number (log-rank p0.07 and p0.06, respectively), which was
supported by multivariate Cox regression model analysis examining gene
copy number as a continuous variable (PFS- HR 0.63, p0.003, OS- HR
0.59, p0.001). In the combined marker Kaplan-Meier analysis, both im-
proved PFS and OS associated with those patients that were EGFR/
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IGF1R compared to those that were EGFR/IGF1R- (PFS p0.05, OS
p0.04). However, multivariate Cox regression models did not support these
findings (PFS- HR 1.029, p0.57, OS- HR 1.035, p0.51).
Conclusions: Increased gene copy number, for both EGFR and IGF1R, is
frequent in localized NSCLC. Increased IGF1R gene copy number was
associated with squamous cell histology and with prolonged PFS and OS.
While no correlation was found between EGFR and IGF1R copy numbers,
Kaplan-Meier survival probability analyses suggested that there was in-
creased PFS and OS for those patients whose tumors were EGFR/IGF1R
versus those with EGFR/IGF1R-, however, more detailed multivariate
analyses showed minimal association. Due to the number of therapeutics that
target both of these growth factor receptors, future studies should determine
the predictive value for combined EGFR/IGF1R gene copy status.
B36
In-lung adenocarcinoma maspin nuclear expression is
associated with high expression of surfactant A and in stage I,
improved survival at long-term follow-up
Fulvio Lonardo1, Seema Sethi1, Ayman Soubani1, Harvey Pass2. 1Wayne
State University KCI, Detroit, MI, 2New York University, New York, NY
Background: Expression of maspin (Ma), a mammary serin protease inhib-
itor tumor suppressor, has been paradoxically linked to both improved and
reduced prognosis in cancers, including non small cell lung cancer
(NSCLC).We have described that chemical transformation of bronchial
epithelial cells results in a selective reduction of nuclear (N) vs. cytoplasmic
Ma levels. We and others have demonstrated that N vs. combined nuclear
and cytoplasmic (NC) Ma expression, in resected lung adenocarcinoma, is
associated with favorable morphological features, including lower grade and
proliferative rate and negative p53 expression, and in stage I, improved
survival. These results warrant the hypothesis that the biological activity of
Ma may be influenced by its cellular localization. However, the reported data
on the role of Ma in NSCLC biology, including its effect on prognosis,
remain contradictory.
Design: We tested the effect of Ma cellular localization on survival in 67
resected adenocarcinoma, including 35 stage I, 10 stage II, 18 stage III, 4
stage IV, by extending the mean follow-up, from our previous study, from 41
to 130 months, the longest to date. In order to test the hypothesis that Ma
cellular localization may be linked to cell differentiation, we further studied
the relation of N vs. NC Ma to surfactant A and TTF-1 expression.
Expression of all molecules was analyzed by immunohistochemistry. Pa-
tients’ survival status was determined from the medical records and the
Metropolitan Detroit Cancer Surveillance System.
Results: 1) Nuclear versus combined NC Ma is an indicator of improved
survival in resected stage I adenocarcinoma (mean follow-up 162 months;
p0.021) but not in more advanced stages. 2) Nuclear vs. combined NC Ma
is associated (p0.030) with higher levels of surfactant A ( 50%) but not
with expression of TTF-1 in tumor cells.
Conclusion: These results, along with previous in vitro and in vivo data in
cancers of the lung and other organs, warrant the following working hypoth-
eses: 1. Cellular localization plays a crucial role in the biology of Ma; and 2.
The tumor suppressor activity of Ma depends from its nuclear localization
and may be exerted by influencing molecular pathways that control cell
differentiation.
B37
Inherited genetic variations associated with lung cancer
survival in a population-based study
Angeline S. Andrew1, Sam Tanyos1, Rebecca Mason1, Tracy Onega1,
Margaret R. Karagas1, Eric J. Duell2. 1Dartmouth Medical School, Lebanon,
NH, 2Catalan Institute of Oncology, Barcelona, Spain
Lung cancer is the most common type of cancer and the leading cause of
cancer deaths for women and men. Prognosis varies within groups of
histopathologically staged and graded tumors, indicating the need for more
specific sub-grouping. The objective of this project was to test the hypothesis
that polymorphisms in the DNA repair and apoptosis related genes modify
lung cancer survival in the New England Lung Cancer Study. This popula-
tion-based case-control study interviewed 277 incident lung cancer cases
diagnosed 2005–2007 in New Hampshire and Vermont, U.S. Genomic DNA
was isolated from peripheral blood for genotyping. Survival status was
assessed by NDI and SSDI searches. Treatment data were obtained from the
cancer registry. Survival time was analyzed in relation to genotype by Cox
regression with adjustment for stage, histology, smoking, age, gender, and
tumor size. We observed shorter survival time among cases who had variant
genotypes for ERCC2 compared to the common form (intron 17 SNP HR 1.8
(95%CI 1.1–2.9), particularly those receiving chemotherapy treatment.
Among those receiving chemotherapy, variant genotype for Fas (5’ SNP)
also were associated with shorter survival, HR 2.6 (95%CI1.0–6.7))
compared to the common form. In contrast, the apoptotic gene BAT3 (exon
15 SNP) was associated with longer survival among chemotherapy recipients
(variant vs. common HR 0.3 (95%CI 0.1–0.9). These population-based lung
cancer data suggest differential survival time associated with DNA repair and
apoptosis genotypes that is modified by chemotherapy treatment.
B38
Development and testing of an mRNA expression signature
correlated with the presence of EGFR mutations in non-small
cell lung cancer
Pierre Saintigny1, Li Zhang2, Luc Girard6, You H. Fan1, J. Jack Lee3, Roy S.
Herbst1, Edward S. Kim1, Kevin Coombes3, George Blumenschein1, Anne
Tsao1, David C. Lam7, William L. Gerald8, David G. Beer9, Xi Ming Tang1,
Scott M. Lippman1, Li Mao1,10, Waun Ki Hong5, Ignacio Wistuba4, John
Minna6, John V. Heymach1. Departments of 1Thoracic/Head and Neck
Medical Oncology, 2Bioinformatics and Computational Biology, 3Biostatis-
tics and Applied Mathematics, 4Pathology and 5Division of Cancer Medi-
cine, UT M. D. Anderson Cancer Center, Houston, TX, 6The Hamon Center
for Therapeutic Oncology Research and Departments of Internal Medicine
and Pharmacology, UT Southwestern Medical Center, Dallas, TX, 7Univer-
sity of Hong-Kong, HKSAR, 8Memorial Sloan-Kettering Cancer Center, New
York, NY, 9University of Michigan, Ann Arbor, MI, 10University of Maryland
Dental School, Baltimore, MD
Background and Aim: Oncogenically mutated epidermal growth factor
receptor (EGFR) is a validated therapeutic target for non-small cell lung
cancer (NSCLC) and activation of the EGFR signaling pathway by somati-
cally acquired EGFR mutations is known to play a critical role in lung cancer
development. Using multiple tumor datasets, our aims were to develop an
EGFR mutation mRNA expression signature from human lung adenocarci-
nomas to aid in developing personalized medicine for targeting EGFR in
NSCLC, to characterize the downstream events of EGFR signaling associ-
ated with EGFR mutation, and to determine if mRNA signatures associated
with EGFR mutations in NSCLC lines were maintained in tumor specimens.
Materials and Methods: We performed lung adenocarcinoma (N  195)
mRNA expression profiling using several microarray platforms and deter-
mined the presence of tumor EGFR mutations in by sequencing tumor
cDNAs or DNAs and also performed similar studies on 53 NSCLC cell lines.
The tumor sets were from University of Hong Kong, University of
Michigan Comprehensive Cancer Center, Memorial Sloan Kettering Cancer
Center, and The University of Texas M. D. Anderson Cancer Center
(BATTLE I trial). In addition, gefitinib and erlotinib drug response pheno-
types were performed on the NSCLC lines by in vitro testing. Training and
testing sets and cross validation were used to test and evaluate the mRNA
signature model.
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Results: We developed a 93 gene signature that was consistently associated
with EGFR mutation in multiple different datasets including validation in the
BATTLE I tumor set of chemotherapy refractory advanced stage NSCLCs.
In addition, the EGFR mutation signature of NSCLC lines and tumors were
preserved. In leave-one-out cross validation tests using the training set, the
misclassification rate was found to be 23%. Prediction accuracy of the
signature was further evaluated in 2 independent data sets using receiver
operating characteristic curves. The area under the curve was 0.95 (p-
value2.2e-06) for the NSCLC cell lines set of 53 samples, and 0.67
(p-value0.014) for 100 human tissue samples collected from our recent
BATTLE (ES Kim, ASCO 2009) clinical trial in chemotherapy-refractory
NSCLC patients. We also found that the signature was correlated with drug
sensitivity to erlotinib (R-0.52, p-value3.3e-04) and gefitinib (R-0.59,
p-value3.2e-05) in the NSCLC cell lines. Furthermore, the signature was
found to be associated with survival in the Director’s Challenge dataset of
442 adenocarcinomas. Using gene set enrichment analysis (GSEA) we found
gene sets associated with endocytosis and vesicle recycling to be upregulated
in EGFR mutant tumors, while mitoticrelated genes were downregulated.
Conclusion: We have identified an EGFR mutation signature developed
from human adenocarcinomas from previously-untreated NSCLC patients
that was significantly associated with EGFR mutations in an independent
cohort of chemotherapy-refractory NSCLC patients. This signature also
provided prognostic information in resected lung adenocarcinomas. In addi-
tion, the gene signature identified in clinical samples was also associated
with EGFR TKI response in NSCLC cell lines and identifies genes whose
expression are altered in EGFR mutated tumors including those involved in
endocytosis and mitosis. These data suggest that an EGFR mutation signa-
ture may provide predictive value and biological insights into EGFR inhib-
itor-responsive in lung adenocarcinomas.
Grant Support: Department of Defense PROSPECT W81XWH-07-1-
03060 and BATTLE W81XWH-06-1-0303 awards, and University of Texas
SPORE in Lung Cancer P50CA070907.
B39
Oncogenomic profiling of adenocarcinomas: A pilot study
Michele L. Cote, Ann G. Schwartz, Shirish Gadgeel, Ayman O. Soubani,
Ramsi Hammad. Wayne State University and Karmanos Cancer Institute,
Detroit, MI
Genomic mutations found in lung carcinomas can be potential therapeutic
targets. Recent data has shown that EGFR tyrosine kinase inhibitors and
ALK kinase inhibitors can produce dramatic responses in patients with
tumors that have EGFR mutations and EML4-ALK translocations, respec-
tively. Somatic mutations in adenocarcinomas of the lung are being rapidly
identified, with mutational profiles often correlating with clinical features
and smoking history. There are likely novel mutations yet to be identified
that may serve as future therapeutic targets, or may help distinguish between
sub-types of lung cancer. We are therefore conducting an analysis of genetic
mutations in tumor specimens from previous population-based studies of
lung cancer utilizing the OncoCarta Assay v1.0 (Sequenom). Analysis is
conducted on tumor DNA extracted from formalin fixed paraffin embedded
tissue and the assay examines 238 mutations in 19 common oncogenes
including EGFR and KRAS mutations.
We are reporting results on tumors from 14 women with either bronchiolo-
alveolar adenocarcinoma (BAC, n10) or adenocarcinoma (AC, n4).
Eight of the samples were from never smokers (57.1%) and half were
diagnosed with local stage disease (n7). One case was African American.
We identified 9 mutations in tumors from 7 individuals. Forty percent of
BAC tumors harbored at least one mutation, and 75% of AC tumors harbored
at least one mutation. Mutation frequency was split evenly between lung
cancers diagnosed in the local stage (50%) versus later stage disease (50%).
Mutations were found in 62.5% of the non-smokers (5 of 8) and 33.3% of the
ever-smokers (2 of 6). Two white non-smoking subjects had the EGFR exon
21 mutation (L858R), and a third African American non-smoking subject
had a L747 S752 deletion. Four KRAS mutations were also identified. Two
BAC tumors from individuals with smoking histories carried the G12C and
G12D mutations, respectively. Two non-smoking individuals (1 AC, 1 BAC)
had KRAS mutations and each harbored an additional mutation (KRAS
G12A / PDGFR-alpha D842V and KRAS G12D / PIK3CA E545K, respec-
tively). Data from at least 14 additional samples will be presented, including
tumors from African Americans and from those with and without COPD.
B40
Foxp3 expression in tumor-associated lymphocytes and
epithelial cells is associated with smoking status but not with
survival of lung cancer patients
Regan M. Memmott1, David J. Liewehr1, Seth M. Steinberg1, Stephen M.
Hewitt1, Pierre P. Massion2, Phillip A. Dennis1. 1National Cancer Institute,
Bethesda, MD, 2Vanderbilt University School of Medicine, Nashville, TN
Lung cancer continues to be the leading cause of cancer-related death in the
United States, and the identification of prognostic markers could impact the
design of clinical trials. Tobacco use is associated with 85% of lung cancer
cases. Preclinical studies demonstrate that administration of the tobacco-
specific carcinogen NNK increases lung-associated Foxp3 regulatory T
cells (Treg) prior to the development of lung tumors in A/J mice, and
depletion of Treg prevents lung tumorigenesis in multiple mouse models.
Treg are a subset of CD4 T cells that express the transcription factor Foxp3
and prevent autoimmunity by suppressing autoreactive T cells, but also may
limit the development of an effective immune response against cancer.
Foxp3 may also be expressed in cancer cells of epithelial origin, but the role
of tumor cell expression of Foxp3 is unclear. To investigate the association
between Foxp3 expression in T cells and epithelial cells in lung cancer
specimens with clinical outcomes, immunohistochemical analysis was per-
formed on tissue microarrays containing 85 paired cores (different areas of
the same specimen) using antibodies that recognize Foxp3 or the T cell
marker, CD3. The number of tumor-associated Treg was determined by
scoring entire cores. Treg that were positive for both nuclear Foxp3 and
membranous CD3 were detected in 93% of the samples. However, these
samples varied substantially in the number of tumor-associated Treg, with
25% of samples containing less than 30 Treg and 25% of samples containing
greater than 110 Treg. Variability in the number of tumor-associated
Foxp3 Treg was also observed between cores from the same sample, for
example, 36% of paired cores varied by 2 fold. For Foxp3 expression in
tumor epithelium, samples were considered positive if 25% of the epithe-
lial cells stained for Foxp3, and staining intensity was scored as weak or
strong. Foxp3 expression in tumor epithelium occurred in 59% of the
samples analyzed, with 36% of samples staining weakly and 23% staining
strongly for Foxp3. Epithelial staining of Foxp3 did not vary between paired
cores and was localized to both the nuclear and cytoplasmic compartments of
these cells. Tumor-associated Foxp3 Treg moderately correlated with
patient pack-years (r0.37, p0.023), but was not associated with survival.
Interestingly, Foxp3 expression in tumor epithelium was inversely associated
with smoking status (p0.029), but was also not associated with survival in
lung cancer patients. Collectively, these results show that Foxp3 is com-
monly expressed in lymphocytes and epithelial cells in lung cancer speci-
mens. They also confirm prior studies that relate smoking and exposure to
tobacco-carcinogens with increased lung- and tumor-associated Treg. The
inverse relationship between smoking and tumor epithelial Foxp3 expression
has not been previously reported, but is consistent with other studies that
show that Foxp3 can function as a tumor suppressor in epithelial cells. The
high degree of variability for tumor-associated Treg suggests that TMA cores
may not be reliable to evaluate components of the tumor microenvironment,
and/or that a larger number of samples or larger sections of tumors may be
needed to establish prognostic significance.
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B41
Organotypic cultures allow evaluation of molecular effects of
intergrinav binding antibody CNTO95 in intact NSCLC tissue
explants
Ilona Schonn1, Frank Diehl2, Christine Hein1, Jana Kru¨ger1, Jasmin Oehl-
mann1, Cordula Rosenbrock1, Monika Spo¨rl1, Kevin Sullivan1, Hartmut
Juhl1, Kerstin David1. 1Indivumed GmbH, Hamburg, Germany; 2Inostics
GmbH, Hamburg, Germany
Background: A preclinical drug test model that is based on short term
cultivated cancer tissues has been used to determine molecular effects of
intact IgG1 antibody CNTO95, CNTO95 is directed against integrinv which
is expressed in non-small cell lung cancer (NSCLC) cells. It is suspected to
mediate drug resistance of taxanes.
Materials And Methods: 400 m tissue slices prepared from freshly
resected NSCLC tumors were treated with CNTO95, docetaxel, paclitaxel,
and a combination of both, antibody and taxane, for 48 h. The compounds
were kindly provided by Centocor Inc., PA. Functional drug effects were
compared regarding viability and apoptosis (as determined by ATP and
caspase 3/7 assays). In addition, immunohistochemical staining against six
key proteins (caspase 3, Bcl-2, Ki67, p27Kip1, p-FAK, p-paxillin) was
performed, as well as mutation analysis of BRAF, KRAS, p53 and EGFR.
Results: NSCLC tumors showed a heterogeneous response to single agent
treatment with docetaxel and paclitaxel as well as to combination-therapy
with CNTO95. Two cases out of 10 showed an additive response after
treatment with a combination of CNTO95 and docetaxel or paclitaxel (i.e.
caspase induction, Ki67 down-regulation), both owning a mutation in KRAS
or p53 respectively. Treatment with CNTO95 alone did not affect cancer
tissue.
Conclusions: We were able to evaluate a fully humanized monoclonal
antibody and its interaction with taxane derivatives docetaxel and pacli-
taxel regarding their impact on tumor cells. This study underlines the
value of organotypic tissue models to determine drug function providing
a complex model that fully reflects the structure and reactivity of an intact
human tumor.
Small Cell Lung Cancer, Mesothelioma,
Thymoma, and Other Thoracic Cancers
B42
Effectiveness of plasma proGRP as a biomarker for lung
cancer
Min-Ki Lee1, Hee-Jung Ban2, Byung-Kab Yoon2, In-Jae Oh2, Kyu-Sik
Kim2, Young-Chul Kim2, Manaljav Tesden-Ish3. 1Pusan National Univer-
sity Medical School, Pusan, Republic of Korea, 2Chonnam National Univer-
sity Medical School, Gwangju, Republic of Korea, 3Center for Biomedical
Human Resources, Chonnam National University, Gwangju, Republic of
Korea
Background: Lung cancers are aggressive neoplasm of rapid growth and
high mortality, but there are few non-invasive biomarkers for helping early
histological diagnosis until now. Progastrin-releasing peptide (proGRP) is a
recently identified biomarker of small cell lung cancer (SCLC), a disorder of
neuroendocrine tissue differentiation. We aimed this study for evaluating the
clinical effectiveness of new automated proGRP measurement system.
Methods: From January 2009, the EDTA plasma of 178 patients were
prospectively collected at their first hospital visit for two-step automated
immunoassay using the ARCHITECT® proGRP assay kit (Abbott Diagnos-
tics, USA). The age distribution showed 65.2 	 9.2 years (mean 	 standard
deviation, range 3987) and male patients comprised 77.0% (n137). The
proportion of malignancy was 87.1% - 59 squamous cell lung cancer (SQC)
40 adenocarcinoma (ADC), 37 SCLC, 12 non-small cell lung cancer
(NSCLC), 5 large cell lung cancer (LCC), 2 metastatic lung cancer (MET) -
and 12.9% was benign lung disease.
Results: The plasma levels of proGRP at the time of diagnosis were
significantly higher in malignancy (336.4 	 925.4 pg/ml) than benign lung
diseases (40.1 	 11.5 pg/ml, p0.001). There was a significant difference
between the histologic types (SCLC 1256.3 	 1605.6 pg/ml, LCC 290.9 	
349.2 pg/ml, ADC 59.2 	 77.1 pg/ml, SQC 38.7 	 12.1 pg/ml, NSCLC
35.2 	 14.4 pg/ml, benign disease 40.1 	 11.5 pg/ml, MET 25.6 	 16.5
pg/ml, p0.001). The proGRP levels of lung cancers were higher in the
cases of metastases (5159 	 1247.1 pg/ml) than others (159.6 	 404.0
pg/ml, p0.02). In SCLC patients, there was a significant difference between
limited stage (533.0 	 759.6 pg/ml) and extensive disease (1940.1 	 1947.7
pg/ml, p0.01).
Conclusion: The proGRP level measured by automated ARCHITECT®
proGRP assay kit can be used as a diagnostic biomarker for lung cancers
from neuroendocrine origin, especially for SCLC. And the level may repre-
sent the extent of the lung cancers.
B43
Oncogenic NFE2L2 mutations in squamous cell carcinomas
from lung, head/neck, esophagus, and skin
Sug Hyung Lee, Yoo Ri Kim, Nam Jin Yoo. The Catholic University of
Korea, Seoul, Republic of Korea
NRF2 encodes a transcription factor that induces expression of cytoprotec-
tive proteins upon oxidative stress. An earlier study discovered oncogenic
NRF2 mutations in lung and head/neck cancers that inactivate KEAP1-
mediated degradation of NRF2. The aim of this study was to identify
NFE2L2 mutations not only in lung and head/neck cancers, but also in other
human cancers. For this, we analyzed 1,145 cancer tissues from carcinomas
from esophagus, skin, uterine cervix, lung, larynx, breast, colon, stomach,
liver, prostate, urinary bladder, ovary, uterine cervix and kidney, and me-
ningiomas, multiple myelomas and acute leukemias by single-strand confor-
mation polymorphism (SSCP) assay. We detected NRF2 mutations in esoph-
agus (8/70; 11.4%), skin (1/17; 6.3%), lung (10/125; 8.0%) and larynx (3/23;
13.0%) cancers. Of note, all of the 22 mutations except one in a lung
adenocarcinoma were found in squamous cell carcinomas (SCC) (95.5%).
The mutations were observed within and near DLG and ETGE motifs that are
important in NRF2 and KEAP1 interaction. All of the esophageal SCC and
skin SCC with the NRF2 mutations showed increased NRF2 expression in
the nuclei. However, none of the SCC from esophagus and skin harbored
KEAP1 mutation. Our study demonstrated here that NRF2 mutation occurs
not only in lung and head/neck cancers, but also in esophageal and skin
cancers. Our data suggest that the NRF2 mutation play a role in the
development of SCC and a feature of SCC.
B44
Matching phenotype-genotype interactions identifies mTOR as
a druggable molecule in malignant pleural mesothelioma
targeted therapeutic approach
Simona Inghilleri1, Ymera Pignochino2, Michele Zorzetto1, Patrizia Mor-
bini1, Ernesto Pozzi1, Giulia M. Stella1. 1University of Pavia and Fondazi-
one IRCCS Policlinico San Matteo, Pavia, Italy, 2IRCC-Institute for Cancer
Research and Treatment, Candiolo, Italy
This abstract was presented as a short talk in Concurrent Session 2: Other
Thoracic Cancers (Mesothelioma, Thymic, Neuroendocrine). A full abstract
is printed in the Proffered Presentations section (PR5).
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B45
A small cell lung cancer tissue microarray shows that 1-
integrin expression in diagnostic samples has prognostic
relevance
Malcolm H. Lawson1, Natalie Cummings2, Doris M. Rassl2, William Ho-
wat1, James D. Brenton1, Gillian Murphy1, Robert C. Rintoul2. 1Cancer
Research UK Cambridge Research Institute, Cambridge, United Kingdom,
2Papworth Hospital NHS Foundation Trust, Papworth Everard, Cam-
bridgeshire, United Kingdom
Background: In order to determine the prognostic and/or predictive rele-
vance of potential biomarkers in small cell lung cancer (SCLC) a dedicated
SCLC tissue microarray (TMA) was constructed using diagnostic biopsy
samples collected by a variety of methods including endobronchial biopsies,
transbronchial needle aspiration and CT guided cutting needle biopsy. The
TMA was used to evaluate the role of 1-integrin expression in SCLC.
1-integrin has previously been implicated in chemoresistance in SCLC
through activation of PI3 kinase signaling mediated through adhesion to
matrix proteins in an in vitro cell culture system1. Furthermore, a study of 75
Japanese patients found high expression to be a poor prognostic factor2.
Methods: The TMA was built from 203 formalin fixed, paraffin embedded
diagnostic biopsy samples from patients diagnosed at Papworth Hospital
(Cambridge, UK) between 1998 and 2005. 189 cases had cores of tissue on
the completed TMA. There was some attrition due to the small size of
individual biopsies. The TMA was stained for 1-integrin using a mouse
monoclonal antibody (Novocastra, Newcastle, UK) and staining was scored
for extent and intensity by two observers working together who were blinded
to all clinical data.
Results: Data on the clinical character-istics and outcomes of the patient
cohort were generally complete and were consistent with published data.
Median survival was 13.52 months (9.8–17.2 months) for limited stage and
5.53 months (3.9–7.2 months) for extensive stage disease. Contrary to
previous studies age was not an independent prognostic factor in multivari-
able survival analysis, but was significantly correlated with performance
score (rs0.32, p0.0005) and associated with first line treatment modality
(219.62, p0.0005). Median time from documented relapse following
chemotherapy to death in this cohort was 3.3 months. Staining the TMA for
1-integrin expression revealed 151 cases with cores that had evaluable
tumor tissue. There was no difference in survival between the group that
were included on the TMA and those that were not. In 91% (138/151) of
cases more than 50% of tumor cells stained for 1-integrin. Expression at
low intensity compared to high intensity was a good prognostic factor in Cox
Regression analysis (HR of death 0.60, 95% confidence interval 0.39–0.92,
p0.019).
Conclusion: This result, which is consistent with in vitro data and a previous
small histology based study, confirms that 1-integrin expression is a
prognostic factor for overall survival in SCLC. Construction of a SCLC
TMA was technically challenging due to the small size of the biopsies
concerned and we believe this is the first dedicated SCLC TMA for
biomarker validation. The result demonstrates that use of a TMA is a feasible
and useful way to validate in vitro findings. This approach offers a novel way
of bridging the translational gap in a disease where fresh tissue is not easily
available.
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B46
Analysis of expression array data to identify biomarkers
specific for small cell lung cancer
M. F. Bari1, David Snead4, Jonathan Moore2, Daniel Zehnder1, Helen
Brown3. 1Clinical Science Research Institute, 2Systems Biology Centre, and
3Biological Sciences, University of Warwick, United Kingdom, 4University
Hospitals Coventry and Warwickshire, United Kingdom
In the management of lung cancer the most important initial step is identi-
fying whether the tumor is small cell lung cancer (SCLC) or one of the
variants of non small cell carcinoma (NSCLC). SCLC present as central
tumors, are not usually amenable to curative surgical resection and treated
primarily by chemotherapy. Tumor typing is routinely made on tissue
samples. Pathologists in most cases perform this role with confidence but on
occasions a number of diagnostic difficulties arise, even with well prepared
samples containing adequate material. In such circumstances the distinction
of SCLC from squamous carcinoma (SCC) and adenocarcinoma (AC) can be
facilitated by a number of reliable immunocytochemical markers, however
distinction from other pulmonary neuroendocrine tumors notably atypical
carcinoid (AC), and large cell neuroendocrine carcinoma (LCNEC) cannot
be reinforced by any ancillary stains. In order to address this issue, we have
conducted a meta analysis of all published expression array data on SCLC
using log ratio of means (ROM) to measure the strength of a particular gene
in a particular study (Hu et al., 2009) and stratified genes according to the
following criteria: number of studies recorded, strength in individual studies
and triangulation of gene loci against known regions of genomic aberration,
in order to identify putative biomarkers likely to be useful for diagnosis.
Analysis of data derived from clinical samples and cell lines, and affymetrix
and two color microarray experiments were separated and processed inde-
pendently; enabling genes list from these different sample and array types to
be compared. Genes were also compared between lung cancer types, includ-
ing adenocarcinoma, squamous carcinoma, large cell neuroendocrine carci-
noma and large cell carcinoma not otherwise specified. 11 expression array
studies and 1 Suppression subtractive hybridization study were used in this
analysis. (Anbazhagan et al., 1999; Bangur et al., 2002; Bhattacharjee et al.,
2001; Difilippantonio et al., 2003; Garber et al., 2001; Sugita et al., 2002;
Virtanen et al., 2002; Pedersen et al., 2003; Jones et al., 2004; Kim et al.,
2006; Taniwaki et al., 2006; Rohrbeck et al., 2008;) The resulting genes list
ranked over 500 in order of importance for SCLC according to the above
criteria. The top 20 over expressed genes being ASCL1, TOP2A, STMN1,
INSM1, DDC, SOX4, SCG2, TUBB, NRCAM, DEK, CENPF, CDC7,
CDKN2C, CDC25B, GRP, ISL1, KIF5C, FOXG1, TPD52, DCX. The top 20
under expressed genes being CAV2, CCND1, ANXA1, ANXA8, ANXA11,
CES1, CTSH, CTSL1, DUSP6, FOLR1, FHL1, RNASE1, TGM2, VIPR1,
CD44, CAPN2, TGFBR2, IL13RA1, ARHGDIB, KRT19. We also tried to
find genes that are upregulated in SCLC and downregulated in other types,
to find the genes specific for SCLC in two or more studies, top 10 of them
are: KIT, MYB, DCX, INSM1, ISL1, STMN1, CKB, MAPT, CTNND2 and
TUSC3. This study has demonstrated feasibility in merging complex data
from multiple studies to rationalize a list of biomarkers likely to be useful in
the diagnosis and management of SCLC. Additional studies are required to
investigate the utility of these biomarkers in routine practice.
B47
Low-dose actinomycin D decreases Mcl-1 expression and acts
synergistically with ABT-737 against SCLC cell lines
Haishan Xu1, Malika Humphries1, Geoffrey Wolfe Krystal2. 1McGuire VA
Medical Center, Richmond, VA, 2Virginia Commonwealth University, Rich-
mond, VA
SCLC is initially a highly chemotherapy-responsive disease but relapse and
progressive development of chemotherapy resistance is the rule. Overexpres-
sion of pro-survival members of the Bcl-2 family, including Bcl-2, Bcl-XL
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and Mcl-1 are thought to play a role in the pathogenesis and chemotherapy
resistance of SCLC. ABT-737, a BH3-mimetic drug which blocks the
function of Bcl-2 and Bcl-XL, has shown single agent activity in preclinical
models of SCLC and enhances the activity of a variety of cytotoxic agents.
Low levels of Mcl-1 expression and high levels of Noxa expression have
been characterized as markers of sensitivity to ABT-737 by several labora-
tories, including our own. We have also noted that Noxa-mediated down-
regulation of Mcl-1 expression is absent in 4/4 SCLC cell lines examined,
suggesting that maintenance of Mcl-1 expression in the face of stimuli that
induce Noxa is important for the pathogenesis of SCLC. Because of the short
half-life of Mcl-1 mRNA and protein, transcriptional inhibition by CDK-9
inhibitors has been shown to decrease Mcl-1 expression. In order to find
additional clinically useful methods for decreasing Mcl-1 expression, we
studied the activity of actinomycin D, a general transcriptional inhibitor used
in the treatment of Wilms tumor, sarcomas, germ cell and trophoblastic
tumors. Actinomycin D decreased Mcl-1 expression in a dose-dependent
fashion in the low ng/ml range, 3 logs lower than that required for general
transcriptional inhibition. While exposure to actinomycin resulted in a cell
line-dependent increase in Noxa expression, Noxa was not required for the
decrease in Mcl-1 expression, as it occurred in the H209 cell line, which does
not express Noxa, as well as the H69, WBA and H526 cell lines which do.
Concentrations of actinomycin D from 0.4–4 ng/ml showed single agent
activity across a panel of SCLC cell lines in 72 hr MTT viability assays.
When combined with low micromolar doses of ABT-737, near complete loss
of viability was seen with combination indices in the 0.5 range, indicating
synergy by Chou-Talalay analysis, without a significant effect on MRC-5
pulmonary fibroblasts. In addition to loss of Mcl-1 expression and enhanced
Noxa expression, correlates of apoptosis induced by the combination in-
cluded marked Bid cleavage. Exposure to 4 ng/ml actinomycin was only
required for the first 24 hrs of the combined incubation but the presence of
ABT-737 was required for the full 72 hrs to see maximum loss of viability.
This actinomycin exposure mimics a clinically achievable AUC of 100
ng.hr/ml after bolus administration, suggesting the feasibility of combination
studies utilizing bolus actinomycin D administration.
B48
Epigenetically modified autologous tumor cell vaccines:
Potential personalized immunotherapies targeting cancer-testis
antigens in thoracic malignancies
Julie A. Hong1, Mary Zhang1, Nachimuthu Chinnasamy2, Yuweii Zhang1,
Tricia F. Kunst1, Ana Hancox1, Leandro Mercedes1, King Kwong1, Steven
A. Rosenberg1, Richard A. Morgan2, David S. Schrump1. 1Thoracic Oncol-
ogy and 2Immunotherapy Sections, Surgery Branch, Center for Cancer
Research, National Cancer Institute, National Institutes of Health, Bethesda,
MD
Background: Cancer-testis antigens (CTA) are highly diverse immunogenic
proteins encoded by germ cell restricted genes, which are heterogeneously
activated via epigenetic mechanisms in human cancers. One potential strat-
egy to target CTAs in thoracic malignancies involves utilization of epige-
netically modified autologous tumor lines to immunize patients against
multiple CTAs that can be upregulated in primary cancers by systemic
administration of chromatin remodeling agents. The present study was
undertaken to assess the feasibility of this approach as a prelude to a phase
I clinical trial.
Methods: Primary tumor tissues were harvested by various techniques from
40 patients with thoracic malignancies and processed for cell culture.
Quantitative RT-PCR, western blot, and immunohistochemistry (IHC) tech-
niques were used to assess BORIS, MAGE-A1, MAGE-A3, NY-ESO-1, and
CT-45 cancer testis-X chromosome (CT-X) gene expression in cell lines
cultured in normal media with or without the DNA demethylating agent,
decitabine (DAC), the histone deacetylase inhibitor, Depsipeptide (DP), or
sequential DAC/DP. Cytokine release assays were used to assess recognition
of tumor cells before and after drug exposure by CD8 allogeneic peripheral
blood lymphocytes (PBL) transduced with retroviral vectors encoding HLA-
A0201-specific T cell receptors (TCR) recognizing peptide epitopes of
NY-ESO-1 and MAGE-A3.
Results: Primary tumor lines were successfully generated and continuously
propagated from 16 of 40 individuals (40%), including 5 NSCLC, 1 SCLC,
2 esophageal cancer, 6 malignant pleural mesothelioma, and 2 sarcoma
patients. Quantitative RT-PCR and IHC analysis revealed heterogeneous,
time- and dose-dependent CT-X gene induction patterns in these cell lines
following treatment with DAC, DP, or sequential DAC/DP under exposure
conditions greatly exceeding those achievable in clinical settings. Induction
levels of CT-X gene expression frequently approximated or exceeded those
observed in control testes.DAC, or sequential DAC/DP exposure facilitated
recognition of tumor targets by NY-ESO-1 as well as MAGE-A3 specific
cytolytic T lymphocytes.
Conclusion: Generation of autologous epigenetically-modified cancer lines
from primary thoracic malignancies is feasible. These data support phase I
evaluation of epigenetically- modified autologous tumor cell vaccination as
a means to broadly immunize thoracic oncology patients against a variety of
potentially relevant CTAs that can be targeted using gene induction and
adoptive cell transfer regimens.
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